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ABSTRACT 
 
COMMUNITY PHARMACISTS AND SUBSTANCE USE DISORDERS: 
ATTITUDES KNOWLEDGE AND PRACTICES 
 
 
 
By 
Deepika Rao 
December 2018 
 
Thesis supervised by Dr. Vincent Giannetti 
Background: Substance use disorder (SUD) is a serious health concern affecting a large 
proportion of the US population. Community pharmacists are well-positioned to prevent, 
screen, and provide appropriate treatment for SUD. Stigma towards these patients and 
SUD results in reduced quality of care as well as poor treatment outcomes. It is 
imperative that pharmacists have the appropriate knowledge of and attitude towards 
prevention, harm reduction, and treatment to develop therapeutic relationships and 
improve their delivery of pharmacy services. 
Objective: To assess knowledge, practices (with an emphasis upon screening), stigma 
and general attitudes of community pharmacists towards SUD and evaluate the 
relationship between these factors. 
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Methods: A systematic literature review was conducted prior to beginning the study that 
identified gaps in the literature. Based on the results of the review, a questionnaire was 
developed assessing the following: demographic information, practice and educational 
characteristics, knowledge about SUD medications, practices of pharmacists (especially 
screening), stigma towards SUD patients and attitude towards harm reduction strategies 
and treatment for SUD and a general open-ended question. Online survey methodology 
was used to distribute the questionnaire on Qualtrics© (Provo, Utah) software among a 
sample of community pharmacists (n =960) from the Duquesne University alumni 
network and Giant Eagle Pharmacy chain via an email link. Data was collected over a 
period of four months. The data was analyzed using SPSS Statistics 24 (Armonk, NY). 
Descriptive data, mean differences and correlations were performed and regression 
models were designed to predict knowledge, practice, screening and stigma. Content 
analysis with axial analysis was carried out for the protocols obtained from the open-
ended question. 
Results: The response rate was 134 (13.9%) and on average pharmacists were 38.3 years 
old, mostly female and Caucasian, and the majority had PharmD (vs B.S.) degrees. 
Respondents primarily reported working in suburban areas for 15 years and about 37 
hours/week on average in pharmacies that filled about 2000 prescriptions/week. Just over 
half of the sample reported receiving previous SUD specific education and continuous 
education (CE) in SUD and/or naloxone. The majority reported not having any personal 
experience with SUD. On average, pharmacists answered 69% of the knowledge 
questions correctly, performed about half of the possible clinical services, reported rarely 
performing MTM or clinical services, regarded screening as an important practice, had 
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stigmatizing attitudes towards SUD patients and slightly negative attitudes towards harm 
reduction strategies and SUD treatment. Having lower stigma was significantly related to 
performing MTM and clinical services. Higher screening scores was positively correlated 
to higher practice, but lower stigma scores. A combination of predictors was found to be 
significant for knowledge, practice, screening and stigma. Number of years worked and 
CE in naloxone were significant predictors of knowledge. Low stigma significantly 
predicted a higher likelihood of performing clinical services for SUD. Stigma and 
number of years worked also predicted screening as an important practice. Screening and 
never/rarely performing MTM services predicted high stigma among pharmacists. Scale 
of the opioid epidemic, overprescribing and prescriber accountability were some of the 
most frequently occurring categories in the protocols. 
Conclusion: The study was a comprehensive survey of knowledge, attitudes and 
practices of community pharmacists in SUD. Their knowledge of medications, current 
practices, their perception of the relevance of screening, assessment of stigma, and their 
general attitudes toward SUD were explored. Significant relationships and associations 
were found among these factors and descriptive data. These results could help improve 
research in the area, increase the role of the pharmacist in SUD, help provide better 
health-care, and assist in improving treatment outcomes for patients. 
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Chapter 1 
INTRODUCTION 
This chapter provides an overview of the disorder, its epidemiology, etiology, prevention and 
treatment. It also discusses the role of the pharmacist and the need for this study, followed by the 
specific objectives of the study. 
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I] Diagnosis of Substance Use Disorder (SUD) 
1) Previous definition 
The Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-
5), does not use the terms substance abuse and substance dependence.1  In the Diagnostic 
and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-
TR), the distinction between abuse and dependence was based on the notion of abuse 
being a mild or early stage while dependence was characterized as the more severe 
index.2 This was based on a continuum of disease development beginning with use 
leading to abuse and finally dependence.3 ‘Abuse’ was characterized as having at least 
one of the following factors in the past year: “Recurrent substance use resulting in failure 
to fulfill obligations at work, home or school, recurrent substance use in physically 
hazardous situations, recurrent substance-related legal problems, continued substance use 
despite persistent or recurrent social/interpersonal problems caused or exacerbated by the 
substance.”3 ‘Dependence or addiction’ was defined as a continued pattern of use which 
resulted in at least three of the following characteristics in the past year:  
“Tolerance, withdrawal, substance is taken in larger amounts and 
over a longer period than intended, persistent desire or unsuccessful 
efforts to cut down or control substance use, a great deal of time is spent in 
activities related to obtaining the substance, use of the substance or 
recovering from its effects, important social, occupational, or recreational 
activities are given up or reduced because of substance use, substance use 
is continued despite knowledge of persistent or recurrent physical or 
psychological problems caused or exacerbated by the substance.”3  
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However, in practice, abuse was more severe than the defined categories. As 
diagnosis of substance abuse previously required only one symptom, it wasn’t sufficient 
to address the severity. Therefore, mild SUD in DSM-5 requires two to three symptoms.2 
Also, dependence included ‘tolerance’ as a category which in SUD could be 
characterized as requiring more of the substance to get ‘high’ but could also be a normal 
body response to any drug.2,3  Therefore, the DSM-5 now refers to SUD in a single 
continuum with stages defined as mild, moderate, or severe to indicate the level of 
severity. This is determined by the total number of diagnostic criteria met by an 
individual. 
  
2) Current Definition 
Substance Abuse and Mental Health Services Administration (SAMHSA) defines 
SUD as “the repeated use of substances causing clinical and functional impairment, such 
as health problems, disability, and failure to meet major responsibilities at work, school, 
or home.”1 According to the DSM-5, a diagnosis of SUD is based on signs of impaired 
control, social impairment, risky use, and pharmacological criteria, totaling eleven 
categories.1 Each specific substance (other than caffeine, which cannot be diagnosed as a 
SUD) is addressed as a separate disorder [e.g., alcohol use disorder (AUD), stimulant use 
disorder, etc.], but almost all substances are diagnosed based on the same central criteria. 
According to the American Psychiatric Association, the original DSM-IV-TR categories 
have thus not only been combined, but strengthened in the DSM-5 definition.2 The eleven 
categories are “hazardous use, social/interpersonal problems related to use, neglected 
major roles to use, withdrawal, tolerance, used larger amounts/ longer, repeated attempts 
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to quit/control use, much time spent using, physical/psychological problems related to 
use, activities given up to use and finally craving.”4  
 
II] Impact of SUD 
SUD is related to numerous health as well as social problems leading to an 
increase in the risk of hospitalizations and death.5 A study by Daley et al notes that “SUD 
is frequently accompanied by numerous medical, psychiatric, psychological, spiritual, 
economic, social, family, and legal problems, creating a significant burden for affected 
individuals, their families, and society.”6 Traditionally, SUD did not hold prominence in 
terms of global health, especially when compared to infectious diseases or non-
communicable diseases such as cancer or cardiovascular disease. Health care services for 
SUD have usually been scarce, and in many countries were separated from conventional 
health care. The medical, economical and societal resources for SUD health care were 
never adequate to bear the burden of the illness.7 Recently, the misuse and abuse of 
controlled substances, especially opiates have increased tremendously adding to the 
burden of health care in the United States (US). The increase in abuse of opioids seem to 
be mostly related to changes in medication prescribing practices, variations in the 
formulation of the drugs, as well as the comparatively easy access due to the internet.8 In 
the mid-1990s, the American Pain Society pushed for the notion of pain as the fifth vital 
sign which was followed by the American Medical Association and the Joint 
Commission emphasizing that pain needs to be regularly evaluated in all patients and that 
the subjective measure of pain by the patient must be respected by the health care 
providers. There is growing concern that this led to enhanced use of prescription opioids 
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and became a major factor in the current opioid crisis.9 Apart from misuse of prescription 
opioids, abuse of other illicit drugs has also increased. Therefore, although abuse of and 
addiction to illicit drugs is not a new phenomenon, the scale, range and growth of the 
problem has resulted in it being described as an epidemic.8  
 
III] Epidemiology 
1) Opioid Use Disorder 
The recent increase in use and misuse of opioid medications has renewed interest 
in SUD. SAMHSA reports that in 2014, an estimated 1.9 million people had an opioid 
use disorder related to prescription pain relievers (indicating an increase of about 200,000 
in seven years). SAMHSA also estimated that about 586,000 had an opioid use disorder 
related to heroin in 2014.1 National estimates from the National Survey on Drug Use and 
Health stated that the number of Americans using prescription opioids for nonmedical 
purposes increased from 11.0 million in 2002 to 12.5 million in 2007. Of these 12.5 
million people, roughly 1.7 million met the DSM-IV-TR criteria for abuse or dependence 
in 2007, a number that has gone higher since.10 An estimated 25 million people initiated 
non-medical use of prescription opioids between 2002 and 2011.11 The number of deaths 
per year due to opioid overdose reached 16,651 in 2010.11 The Centers for Disease 
Control and Prevention (CDC) reported in 2009 that deaths due to opioid overdose have 
more than tripled since 1999.10 The 2007 Treatment Episodes Data Set reported that the 
number of patients admitted to SUD treatment facilities due to opiate/opioid (non-heroin) 
abuse nearly multiplied four times from 23,000 to higher than 90,000 from 1999 to 
2007.10 Mean annual direct health care costs for patients who abused opioids were more 
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than eight-fold higher than for non-abusers ($15,884 vs $1,830, P < 0.01).12 In addition, 
the high costs of opioid abuse were directly related to high prevalence of costly co-
morbidities among the patients as well as high utilization rates of medical services and 
prescription drugs by these patients.12  
  
2) Other disorders (Alcohol, Cannabis, Stimulants and Hallucinogens) 
SUD, due to misuse of other substances like alcohol and illicit drugs, is also 
common in the US. Of the 176.6 million people who consume alcohol in the US, an 
estimated 17 million have an AUD.1 According to the CDC, excessive alcohol use causes 
88,000 deaths a year in the world. Excessive alcohol use can increase an individual’s risk 
of developing serious health problems such as cardiomyopathy, stroke, and liver issues 
like hepatitis, liver cirrhosis and steatosis.13 In addition, AUD results in the typical health 
and social problems associated with intoxication behaviors and alcohol withdrawal 
symptoms. The most used drug after alcohol and tobacco is marijuana. SAMHSA reports 
that in 2014, about 22.2 million people (aged 12 and higher) reported using marijuana 
during the past month. Of those 22.2 million people, 4.2 million people ages 12 and up 
met criteria for a SUD based on marijuana use.1 The most commonly abused stimulants 
are amphetamines, methamphetamine, and cocaine. Stimulants can be synthetic (such as 
amphetamines) or plant-derived (such as cocaine). In 2014, an estimated 913,000 people 
(aged 12 and older) had a stimulant use disorder because of cocaine use, and an estimated 
476,000 people had a stimulant use disorder as a result of using other stimulants besides 
methamphetamines in the US.1 Also, like stimulants, hallucinogens can be chemically 
synthesized (lysergic acid diethylamide, or LSD) or may occur naturally (psilocybin 
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mushrooms, peyote) as well. Approximately 246,000 Americans had a hallucinogen use 
disorder in 2014.1  
 
IV] Etiology 
Historically, many theories have been proposed to define the etiology of SUD. 
These theories are categorized in three main subgroups: psychosocial, biological, and 
contextual. Although one would assume that multiple theories would help in improved 
understanding of the etiology of SUD, this diversity could also convey the lack of 
consensus around etiology of SUD.14 However, like the causes of other chronic diseases, 
SUD is multifactorial in origin. Etiological research has recognized many factors that 
affect drug use and whether or not it progresses towards a SUD. However, no single 
factor or set of factors predicts drug use by an individual entirely. It is not necessary that 
the same factor will affect all persons in the same way, nor is it essential that the factors 
responsible for initiation of drug use are of equal importance in the continuation of use or 
development of a SUD. Additionally, each case of SUD is different and there is no 
consensus on the specific factors that are involved in all cases of SUD.15 However, it is 
accepted that most cases have at least one of the following factors in some measure. 
Knowledge of these factors will help health care providers better identify, screen and 
treat patients with SUD. It is also important to design prevention and treatment efforts 
based on these risk factors. 
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1) Psychosocial Factors 
Psychosocial risk factors for SUD are comprised of personality traits and 
psychopathology. Even though there is considerable literature regarding the relationship 
between personality traits and drug use, especially in adolescents, few studies have 
examined the precise role of personality traits in the development of SUD.15 Most studies 
focus on personality traits developed in adolescents and relate it to adult behaviors. One 
study noted that the age of onset of consuming alcohol was indicated by several precursor 
personality attributes such as lesser levels of conventionality, lesser importance or lower 
expectations on academic achievement, more accepting attitudes toward 
unconventionality, and lower levels of religiosity. These personality traits typically result 
in individuals who are characteristically not concerned with hard work, are more 
rebellious, and reject authority. They usually have fewer motives for not drinking or 
believe drinking is harmless, and have greater positive expectations about the social 
benefits of drinking. They might show aggressive and antisocial behavior in childhood.15 
In another review, the authors concluded that there was a strong relationship between 
antisocial behavior and SUD, even though the relationship is not clearly understood.16 
Studies evaluating the association between adolescent personality characteristics and 
development of SUD found that many of the characteristics that signaled the onset of 
drinking alcohol also predicted misuse of other substances. The most influential 
predictors of frequent drug use are variables labeled as the ‘unconventionality variables’ 
which include rebelliousness, tolerance of deviance, and poor progress in school. These 
personality attributes that reflect lower levels of conventionality were also related to more 
positive attitudes toward drug use and finally predicted the initiation of substance use. 
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For example, the authors noted that in general, adolescents who start to use substances 
are more unconventional in their attitudes and values and have fragile ties to the 
conventional organizations of school and religion. They stated  that this weaker tie is 
displayed in more tolerant attitudes toward deviance, lesser religiosity, greater 
rebelliousness and opposition to authority, higher disobedience, lower educational 
expectations, and more favorable beliefs about substance use.15 Thus, the personality 
attributes related to development of a SUD were exactly the same as the ones that 
predicted alcohol misuse. 
 Adult deviant (such as substance use or abuse) and antisocial behavior patterns 
are often preceded by such behaviors in late childhood and early adolescence. These 
behaviors together with increasing life stresses that typically occur in adulthood may be 
risk factors for development of SUD. For example, conduct disorder has been proved to 
precede the onset of or occur concurrently with SUD.15 Therefore, it is important that 
health care providers look for such behaviors in youth to reduce the risk of them 
developing a SUD.  
Although early antisocial behaviors and deviance are risk factors for drug abuse, 
the two most common psychopathologies that have been identified frequently with SUD 
are depression and an antisocial personality. This means that risk factors might develop 
concurrent with development of a SUD as well. Studies that include both clinical and 
epidemiological samples have proposed that SUD and psychopathology maybe related. 
The authors conducted both inpatient and outpatient surveys and noted that of all the 
patients with psychiatric disorders such as antisocial behavior, attention deficit disorder 
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(ADD), anxiety disorders, phobic disorders and depression, around one-third had a 
SUD.15  
Apart from the above internalizing disorders, externalizing disorders like disruptive 
behaviors also occur in high rates in both adult and adolescent patients with SUD.15 
These personality traits and psychiatric illnesses could be as a result of SUD, independent 
of SUD or be a risk factor for SUD.16 Identifying these risk factors in their patients 
should encourage health care providers to screen these patients for SUD. 
 
2) Biological Factors 
Genetic vulnerability is the one of the most prominent biological risk factors for 
the development of SUD. Family studies are therefore important for detecting genetic 
vulnerability for SUD. Studies that have explored generations of SUD patients discovered 
that drug use or abuse is elevated among siblings of drug abusers and that there is a direct 
association between parents who use or abuse substances and their children using drugs 
or having a disorder.15 Therefore, it becomes imperative for health care providers to pay 
special attention to individuals with a family history of SUD. The high recurrence of 
SUD within generations suggests that family history is one of the most effective 
predictors of vulnerability to substance use, which in turn partly stems from genetic 
factors. A study conducted in 1994 determined that possession of the dopamine (D2A1) 
allele was significantly associated with occurrence of SUD.17 This is one of the many 
possible genetic factors that have been studied. 
However, because there are variations in the genetic makeup of families, twin 
studies may be more suitable to identify the role of genetic factors in SUD. Many twin 
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studies have provided useful insights and suggest that genetic factors explain some of the 
variance in the development of SUD and that a large proportion of the heritability of drug 
abuse in adulthood may be attributed to genetic factors that underlie the development of 
behavior problems in childhood.15 A study conducted in Virginia reported that twin 
resemblance for substance use was not only substantial, but also consistently greater in 
monozygotic than in dizygotic twins.18 However, as twins are exposed to the same 
environment while growing up, it is necessary to remove any confounding factors that 
may occur in these studies. Cross-adoption studies thus provide the optimal study 
paradigm for identifying the interaction of genetic and environmental factors in the 
development of a trait or disorder. Cross-adoption studies of children of parents with 
AUD who were raised by adoptive parents (non-alcoholic) have shown increased risk for 
alcohol abuse and dependence compared to adopted children with non-alcoholic 
biological parents.15 
Physiological influences that may aggravate an individual's susceptibility to 
develop SUD could include neurological impairment and amplified sensitivity to a drug. 
This is usually because of their biologic make-up which determines responsiveness.15 For 
example, a study noted metabolic variations in Caucasian and Asian races. In contrast to 
Caucasians, many Asians were biologically protected from becoming alcoholics. This 
was because of the polymorphism of two liver enzymes aldehyde dehydrogenase and 
alcohol dehydrogenase-2.15 On the other hand, efficient alcohol metabolism may also 
enhance the risk of alcoholism because people are likely to need a higher quantity of 
alcohol to experience the same ‘high’ and therefore ingest more. This would facilitate the 
addictive potential of alcohol and increase their risk of developing AUD.15 The authors 
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thus noted that “the inability to metabolize a drug may be a protective influence in 
continued exposure, whereas efficient metabolism may permit high levels of exposure 
conducive to the development of abuse and dependence.”15 
Gender is another important biologic risk factor for development of SUD. A study 
evaluating the differences in substance use between genders noted that men tended to use 
almost all types of substances more than women. The study also reported that men were 
more likely to have emergency department visits or overdose deaths due to substance use 
or abuse than women.19 Studies typically report that men among all age groups, have 
higher rates of development of SUD than women. However, that does not translate to a 
lower risk for women of developing a SUD as compared to men. Additionally, women 
may be more susceptible to craving and relapse, which are two important diagnostic 
criteria in the DSM-V definition of SUD.19  
 
3) Contextual factors 
In addition to the influences of genetic and biological factors (i.e. family factors 
that can be both transmitted and non-transmitted) on individual susceptibility for SUD, 
unique environmental factors may be involved in the predisposition towards SUD, which 
are difficult to measure.15 Hence, the exact mechanism through which family history 
results in an increased risk is not clearly understood. Family studies by themselves, 
cannot definitively determine these unique environmental effects. These factors are called 
contextual factors and are defined as factors external to the individual and occur because 
of the social (family or peer group) or broader environment. Moreover, the complex 
interaction among these factors contributes to the overall complexity of SUD etiology.15  
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Family factors are the most prominent contextual risk factor in the development 
of SUD. Many family factors may be associated with the development of SUD such as 
poor parental relations, family disruptions, poor childrearing, substance use or abuse 
behaviors in the family, favorable or encouraging parental attitudes to substance use, and 
lack of social interaction. Parents may confer an increased risk of SUD on their children 
by acting as negative role models. Children in these households observe parents using or 
abusing drugs as a coping mechanism. Children usually acquire their coping techniques 
through social learning and thus internalize these behaviors as adolescents.15 
Differences in development of SUD in patients belonging to different 
socioeconomic classes point towards economic backgrounds being a risk factor. Affluent 
families may provide people with resources to acquire illicit substances and this increased 
use may lead to development of a SUD. For example, a study observing teenagers from 
affluent, suburban families and low socioeconomic status adolescents from inner-city 
settings noted that suburban youth reported significantly higher levels of substance use 
than inner-city youth.20 
The peer environment also makes a considerable contribution to development of 
SUD. Generally, among older adolescents, peers have a greater effect than families 
because typically, adolescent drug use takes place due to the influence of close friends. 
However, peer influence on development of SUD may also occur in a mutually 
reinforcing pattern because drug-using adolescents also tend to gravitate towards similar 
peers. The contributing effects of peer influences are thus likely to be altered at different 
ages.15 A study analyzing peer relationships by social networking practices of the 
subjects noted that having friends in that social network, being liked but not too popular, 
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and having fewer peers who use substances were significantly related to subjects not 
having SUD.21 
The contextual factors that have an impact on development of SUD also include 
the surrounding community drug use practices and neighborhood disorganization. The 
authors noted that communities with high rates of crime, easy accessibility to drugs, and a 
general acceptance of drug use and abuse in the community are all associated with 
development of SUD among residents of these neighborhoods.15 The larger sociocultural 
environment also has important effects on drug use. The frequency and nature of 
representation of substances in the media may have significant effects on the people. 
Moreover, social and legal policies (taxes on substances, restrictions on conditions of 
purchase and use, legal status) and enforcement of these policies may have vital effects 
on rates of SUD development. It is important to note that the effect of these contextual 
factors are highly dependent on the degree of acculturation and assimilation of 
individuals and their families into the community.15 
Alternatively, the environment can also create a protective sense of self-worth, 
identity, and safety. Neighborhood and community factors may thus serve to protect 
individuals from developing SUD. For example, restrictions on tobacco use in public are 
placed because of the opinions and values of the larger community, which may in turn 
deter individuals from using substances and thus decrease the chances of developing 
SUD.15  
A thorough understanding of all risk factors, especially biologic factors will 
enable health care providers to better understand the disease model of SUD. This will 
 15
help in decreasing stigma associated with SUD and help improve attitudes towards 
patients and also increase positive attitudes towards prevention and treatment strategies. 
 
V] Prevention 
The psychosocial, biological, and contextual factors must all be considered in the 
prevention of SUD. A multidimensional assessment of risk factors is essential for 
strategically comprehensive prevention efforts.22 Prevention strategies are categorized as 
primary or secondary based on when the intervention occurs: primary is before the 
behavior occurs (substance use) and secondary is after it occurs but before the behavior 
becomes habitual (patient develops a SUD).23 Primary prevention seeks to prevent the 
onset of disease. Secondary prevention on the other hand, comprises screening for or 
identifying early stages of the disease. It also includes reversing early effects of the 
disease if possible. Tertiary prevention attempts to reduce the consequences of the 
disease as well as try for remission.22  
At every stage of prevention, ‘behavioral immunity’ (a set of behaviors that 
prevent people from succumbing to external negative influences) toward drug-seeking 
and misuse or abuse must be cultivated. This can be achieved by enhancing the goal of 
avoiding substances for both individuals and populations. It is necessary to address both 
the patient and the environment in which they live. Prevention of SUD requires a 
thorough evaluation of the stressors that affect the patient, and health care providers must 
accordingly provide patients with methods to improve self-efficacy in avoiding misuse or 
abuse of substances.22  
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1) Primary Prevention 
Primary or universal prevention efforts are essential because people belonging to 
all sections of the society are at risk for experimenting with substances. This is especially 
true among teenagers and young adults. It is therefore, necessary to provide preventive 
interventions because there can be negative consequences related to even sporadic use 
(e.g., substance overdose). Additionally, as discussed above, the etiology of SUD is 
complex. Targeting prevention to a specific sample of people that are classified as ‘high 
risk’ may lead to excessive false positive findings; thereby wasting resources. This 
approach could also lead to incorrect labeling which is highly problematic considering 
the sensitive nature of the disease. On the contrary, targeting interventions can also lead 
to omitting individuals who require preventive interventions. Moreover, a universal 
orientation is generally more cost-effective and logistically feasible because it can be 
applied to a larger population using pre-existing structures like schools or work 
organizations. It is thus less expensive to provide everyone with the intervention than to 
identify and selectively offer preventive services to those most at risk.23 
Individual and environmental intervention strategies are two types of primary 
prevention approaches. Some prevention interventions are intended to help individuals 
develop the healthy behavior while others focus on creating environments that sustain 
that healthy behavior. Research shows that the most effective prevention interventions 
tend to incorporate both approaches.24  
Many prevention approaches focus on helping people develop the knowledge, 
attitudes, and skills they need to alter their behavior. These individual-level strategies 
typically include classes on healthy behaviors. Effective classroom-based programs focus 
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on both life and social skills while also considering the external influences on substance 
use. These programs involve interactions among participants while emphasizing a social 
commitment to avoid substances. The programs also commonly include community 
components such as the socioeconomic status of people in the community, religious 
beliefs and value systems of the community to help relay the message. These programs 
are generally conveyed by peer leaders and highlight the benefit of building life skills and 
social resistance to illicit substances.24 
Environmental strategies take a broader approach than individual-level strategies. 
Professionals use environmental strategies to change the factors within the community, 
namely physical, social, or cultural factors that may lead to substance use. For example, 
prevention strategies could include targeting the laws or norms that are favorable towards 
substance use and misuse.24 
SAMHSA states that environmental strategies are most effective when 
implemented as part of a comprehensive approach. Environmental strategies include 
communication and education strategies, which strive for increased awareness. They 
create community support for prevention by influencing community norms. They may 
also use enforcement methods to deter people from substance misuse.24 
 
2) Secondary Prevention 
Although many individuals experiment with substances as part of their 
developmental life cycle, most young individuals do not regularly use illegal drugs and 
most of them do not make the transition to developing a SUD. Thus, drug use in itself 
may not be the most appropriate goal of prevention. Moreover, the effects of primary 
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prevention are usually too insignificant to have a major impact on prevalence of SUD in 
the community. Considering the limited resources and reduced budgets of most 
governments, it may be more important to focus on abuse and dependence and not merely 
the use of drugs.23 
 Randomized controlled trials have demonstrated that guiding people who misuse 
or abuse alcohol in the right direction (secondary prevention) resulted in a decrease in 
alcohol consumption and alcohol-related problems.25 Similarly, efforts to screen for and 
treat individuals who use opioids but have not developed an opioid use disorder, may 
reduce the risk of overdose, psychosocial decline, and medical complications.26  
Patients may use physicians as one of the major sources of opioid pain relievers 
(OPR) whether or not they have medical reasons for use of the drugs. An Institute of 
Medicine report suggests that among all physicians, primary care physicians may be the 
primary source of OPRs. The report specifically states that in 2007, analysis of office 
visit data resulted in pain relievers being the most frequently found drug category. In 
2008, pain relievers contributed to 10.1% of all drugs prescribed to adults.27 Interactions 
with medical professionals thus are a valuable opportunity for early identification of 
opioid use disorder and consequent secondary prevention. However, detection of an 
opioid use disorder in these patients can be very difficult because they are often reluctant 
to disclose their concerns about developing a SUD. They may fear being judged, being 
cut off from a legitimate supply, or being invalidated by the prescribers. Patients fear 
being labeled as drug seekers if prescribers assume that they are faking their pain. These 
apprehensions of patients must be considered by prescribers before relying on self-
reported data. Additional information may need to be collected regarding opioid use in 
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the patients. Urine toxicology can be used to verify a patient's self-reported opioid use 
history. However, urine toxicology of patients on long-term OPRs such as chronic pain 
patients is not a reliable strategy. Moreover, urine toxicology also cannot determine if a 
patient is misusing prescribed opioids or other illicit substances by taking extra doses or 
by an intranasal or injection route.26 Another concern is that patients may receive opioid 
prescriptions from multiple providers, a practice called ‘doctor shopping.’ Doctor 
shoppers can be identified through use of state prescription drug monitoring programs 
(PDMPs).26 Use of PDMPs could lead to more effective screening and prescribers could 
then modify their prescribing practices and provide treatment accordingly. In states that 
mandated checking the PDMP before prescribing controlled substances, PDMP 
utilization increased and this was correlated with a decline in number of opioid 
prescriptions and a severe drop in patients exhibiting doctor shopping behaviors.26 This 
proves the effectiveness of this secondary prevention strategy. 
Although primary and secondary prevention strategies have their respective 
advantages and shortcomings, these interventions do not have to be viewed as mutually 
exclusive approaches. Rather they are mutually supportive programs and do not need to 
be opposing alternatives in most cases. There are many advantages to have a combination 
approach where the disadvantages of one strategy is nullified by the other. For example, 
while universal interventions can be used to promote an ‘antidrug’ message in the larger 
society, selective interventions can be designed based on the universal message thereby 
reinforcing the message and avoiding the cost of developing a new targeted message. 
Moreover, the risk of incorrectly labeling individuals as high-risk in secondary 
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prevention programs can be avoided by delivering the same targeted message within 
universal prevention programs.23 
 
3) Harm reduction 
 Prevention programs especially primary and secondary, typically focus on risk 
reduction. Another approach to prevention is to enhance protective factors. Several 
studies have noted that protective factors can moderate the effects of risky environments, 
reduce susceptibility while increasing resilience of the patients.15 Protective factors such 
as positive relationships within families, non-deviant siblings and peers, high academic 
achievement, and some amount of conventionality such as low rebelliousness and 
obedience to broad social norms reduce the effect of risk factors in adolescents. 
Protective factors in adulthood include those that increase responsibilities such as 
employment, marriage, and childrearing.15 
Many of the protective factors can also help to reduce the effects of negative 
environmental risk factors. For example, substance use by one parent maybe offset by the 
non-use of the other. A supportive family while growing up provides an external system 
that helps to cope with stress.15 However, specific protective factors are applicable at 
certain stages of life and research needs to be conducted to determine those appropriate 
factors in every age group. Moreover, the exact mechanism of their protection needs to be 
studied. Harm reduction is based on increasing these protective factors while reducing 
harms due to SUD. 
 Harm reduction is not a goal but an approach or strategy to reduce harms of SUD. 
The aim of harm reduction is to reduce the negative consequences of drug use rather than 
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to cure SUD. It aims to decrease the adverse events typically associated with substance 
abuse, especially when quitting use is not highly probable. These strategies can however, 
be harmonious with an eventual goal of abstinence.28 Harm reduction strategies are 
directed towards altering drug using behaviors and effects (acquisition, drug use, and 
withdrawal).29 The United Nations Office on Drugs and Crime (UNODC) described the 
harms as high-risk situations, such as criminal behavior. Harms are related to the drug 
used, the amount consumed, and the method of administration. The purity of the drug or 
drugs consumed, dose consumed, duration and frequency of use, mode of administration 
are factors that affect the harms that accompany overdose or intoxication. Physical state 
(nutrition, tolerance, etc.) and psychological factors (expectations) of the individual may 
also be important factors. Drug withdrawal harms on the other hand are related to factors 
that affect the patient’s work and social functioning. Withdrawal can also be related to 
physical and psychological issues and is usually correlated with high-risk activities, and 
criminal behaviors, which in turn are harms related to drug use. Therefore, they create a 
vicious circle.29 
 General harm reduction strategies include education, brief interventions and 
counseling focused on changing high-risk behaviors as well as interventions to reduce 
injury and violence. The purpose of education is to provide accurate information about 
the consequences and risks of drug use and promote behaviors that reduce risk.29 
Education programs usually include information on biological and psychosocial risks of 
SUD, risks of overdose, infectious diseases, and comorbid disorders. Brief interventions 
might include acute therapy, cognitive behavioral therapy (prolonged), and motivational 
interviewing (MI).29 A study evaluated MI versus standard care for individuals in an 
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emergency room following an alcohol-related event. The study reported that patients who 
received MI had a significantly lesser incidence of drinking and driving, traffic 
violations, and alcohol-related injuries than patients who received standard care.30 
Counseling commonly involves strategies to change the environment such as changing 
alcohol containers (from bottles to plastic glasses), prohibiting beverages with high 
concentrations of alcohol, recruitment of individuals in the community, etc.29 
 Specific strategies also include pharmacological interventions. One aim of these 
interventions is to reduce the risk of contracting or transmitting HIV and other infectious 
diseases by substituting injected substance with non-injecting drugs.29 A meta-analysis of 
studies conducted in the United Kingdom showed that opioid substitution therapy was 
associated with reduction in new hepatitis C infections [adjusted odds ratios (AORs) = 
0.41, 95% confidence interval (CI): 0.21–0.82)].31 Drug substitution also leads to patients 
obtaining legal drugs dispensed under the care of a health professional, so the risk of 
overdose and other medical complications is minimized. Furthermore, drug substitution 
helps to reduce crime and the high-risk behaviors that patients typically exhibit since it 
reduces the urgency of acquiring the drug. Additionally, drug substitution allows health 
professionals like pharmacists to keep in contact with the patients, which aids in keeping 
them in treatment and thereby reduces relapse.29   
Needle/syringe exchange programs include strategies to prevent the sharing of 
injecting equipment and for the safe disposal of non-sterile injecting paraphernalia. These 
programs raise awareness and knowledge of the risk of contracting infectious diseases 
(e.g. HIV, HCV, etc.) through injecting drugs, provide information and assistance on the 
steps to inject safely, offer sterile injecting equipment, if possible, communicate practical 
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steps on how to disinfect needles, syringes and other equipment, increase access to safe 
disposal or deliver sessions on how to dispose of non-sterile equipment.29 The meta-
analysis also reported that implementation of both opioid substitution treatment and 
needle/syringe exchange programs together, were associated with a reduction in self‐
reported needle sharing by 48% (AOR 0.52, 95% CI: 0.32–0.83) and mean injecting 
frequency by 20.8 injections per month (95% CI: −27.3 to −14.4).31 
 Overdose prevention is another important harm reduction strategy. Naloxone, a 
short-acting opioid antagonist, overturns the respiratory depressing effects of opioids and 
prevents overdose among patients.29 A study evaluating the effectiveness of overdose 
training reported that 96% of the overdose episodes were reversed due to naloxone 
administration.32 Other drugs, such as methadone, which in contrast have similar 
properties to heroin and morphine, act as maintenance treatments but also help to reduce 
overdose. Since they are not injected, they reduce the risk of HIV and hepatitis infection, 
and criminal acts and other high risk behaviors.29 
 UNODC suggested some other overdose management strategies like “peer-to-peer 
education in first aid and cardiopulmonary resuscitation (CPR), establishing 
collaborations among peers, and encouraging peers to seek help and call an ambulance 
when an overdose is suspected.”29 Use of non-injection routes of administration over 
injection routes for substances, voluntary HIV counseling and testing for patients, 
prevention and management of infections, and wound care and maintenance are some 
other SUD specific harm reduction strategies.29 
Prevention efforts can also double up as treatment strategies. A study reported 
that substitution (e.g., methadone, buprenorphine) and antagonist (e.g., naltrexone) 
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medications in conjunction with psychosocial treatment have been shown to be effective 
not only in harm reduction but also as treatment by enabling recovery.22 
 
VI] Treatment 
 Treatment for substance use disorders are comprised of many components that 
can be broadly classified into three main categories: psychological, support based, and 
pharmacological (medication). 
 
1) Psychological treatment 
 Counseling is the primary form of psychological treatment. Counseling can be 
provided at the individual or group level. Individual counseling focuses on decreasing or 
discontinuing substance use, skill building, adherence to a recovery plan, and personal 
and professional outcomes. Group counseling is frequently used in addition to individual 
counseling to provide social reinforcement for successful recovery.33  
 Counselors provide a variety of services to patients in treatment for SUD 
including assessment, treatment planning, and counseling. Counseling typically involves 
therapies like motivational enhancement therapy, contingency management, and/or 
cognitive behavioral therapy. Motivational enhancement therapy helps people with SUD 
to build motivation and commit to precise plans to get involved in treatment and pursue 
recovery. It is generally used early in the treatment process to engage people and 
encourage them to procure further treatment. Cognitive-behavioral therapy helps patients 
to distinguish and discontinue negative lines of thinking and behavior. For example, it 
might help a person become conscious of the stressors, circumstances, and feelings that 
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lead to substance use so that the patient can avoid them or avoid substance use when they 
occur. Contingency management is intended to provide incentives to reinforce such 
positive behaviors.33 
 Some forms of counseling are tailored to specific populations. For instance, 
young people need a different set of treatment services as compared to older adults to 
guide them towards recovery. Therefore, treatments for youth frequently involve a family 
component (especially parent/guardian involvement), that may not be a part of other 
counseling programs.33 Also, specific factors like peer substance use, school 
environment, and personality may have to be considered when treating youth. Another 
example is counseling tailored for women because of gender differences in risk factors 
for SUD, as discussed previously. 
 
2) Support services 
 Recovery support services are non-clinical services that are used along with 
treatment to support individuals in their recovery period. Peers or patients who are 
already in recovery commonly provide these services. According to SAMHSA, recovery 
support can include the following:  
“Transportation to and from treatment and recovery-oriented activities, 
employment or educational supports, specialized living situations, peer-to-
peer services, mentoring, coaching, spiritual and faith-based support, 
parenting education, self-help and support groups, outreach and 
engagement, staffing drop in centers, clubhouses, respite/crisis services, or 
‘warmlines’ (peer-run listening lines staffed by people in recovery 
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themselves) and education about strategies to promote wellness and 
recovery.”33  
 While support groups do not work for everyone and are not a treatment 
requirement, they are an important component of the SUD treatment system. Alcoholics 
Anonymous or Narcotics Anonymous are 12-step facilitation programs to guide and 
support engagement in treatment. However, support groups are not considered as formal 
treatment.33 
  
3) Medication 
 Using medication to treat SUD is often referred to as medication-assisted 
treatment (MAT). In this model, medication is used along with counseling and the 
previously discussed behavioral therapies. Medications act as agonists or partial agonists 
of the receptors that lead to reduction in cravings and other withdrawal symptoms. They 
can also block the rewarding feeling that occurs after substance use, or induce negative 
symptoms when a substance is taken that deter the patients from using the substances. 
Although, MAT has been primarily used for the treatment of opioid use disorder, it can 
be used for treatment of some other SUDs.33  
MAT using methadone, buprenorphine, or extended-release injectable naltrexone 
plays a critical role in the treatment of opioid use disorders. SAMHSA reported that more 
than 300,000 people received some form of MAT for an opioid use disorder in 2011.33 
Opioid agonist therapies not only reduce the effects of opioid withdrawal and cravings 
but also increase retention in treatment. Additionally, they reduce risky behaviors that 
lead to transmission of HIV and viral hepatitis such as using opioids by injection. MAT 
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with extended-release injectable naltrexone reduces the risk of relapse to opioid use and 
helps control cravings.33 It is also particularly useful for individuals who move from a 
controlled setting like jail or residential rehabilitation where abstinence has been imposed 
to an environment where they may be at a risk for relapse. It can also be used in 
situations where maintenance with an opioid agonist is not appropriate or the agonist is 
not available.33  
 Medications can assist in the treatment of AUD as well. Acamprosate is a 
medication that reduces symptoms of prolonged withdrawal and has been demonstrated 
to help individuals with AUD. Moreover, patients who have achieved abstinence go on to 
maintain abstinence for longer periods due these medications. Naltrexone, a medication 
primarily developed to block the effects of opioids, has also been used to reduce craving 
in those with AUD. Disulfiram is another medication which changes the way the body 
metabolizes alcohol, resulting in unpleasant symptoms including flushing, and nausea if a 
person consumes alcohol after taking the medication.33 
 
4) Combined treatment 
 A patient accessing treatment may not need every one of these components, but 
each plays an important role. These systems are implanted in a broader community 
setting and the support provided by various parts of that community plays an important 
role in overall treatment. Treatment can be provided in inpatient or residential sessions. 
This happens within specialty SUD treatment facilities with a broader behavioral health 
focus, or by specialized units within hospitals. Longer-term residential treatments can be 
as long as six to twelve months and are relatively uncommon. These programs focus on 
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helping individuals change their behaviors in a highly structured setting. Shorter term 
residential treatments are much more common, and typically have a focus on 
detoxification. They provide initial intensive treatment and prepare the patient for a 
return to community-based settings. An alternative to inpatient or residential treatment is 
partial hospitalization or intensive outpatient treatment. These programs make 
participants attend very intensive and regular treatment sessions multiple times a week 
early in their treatment phase. After completing the initial partial hospitalization or 
intensive outpatient treatment, individuals often continue into regular outpatient treatment 
which meets less frequently and for fewer hours per week to help sustain their recovery.33 
Combined treatment is thus much more effective than providing only one type of 
treatment. Pharmacists can play a critical role in assisting at various points in the overall 
treatment of the patients. 
  
VII] Pharmacists and SUD 
In response to the increasing prevalence of these disorders, funding of prevention 
programs and projects designed to lessen or eliminate the threat of SUD has increased in 
the past decade. Despite these funds, adequate resources have not been invested in an 
important area that holds great potential as a prevention strategy. Improved education and 
training of the millions of people who constitute the health professions workforce will 
contribute towards decreasing the high rates of incidence and prevalence of SUD.34 
Improved education and training will lead to higher rates of screening for SUD and 
excessive substance use, increased counseling of substance users to avoid development of 
a disorder, and more patients being provided appropriate treatment for SUD to enhance 
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remission. Very little consideration has been given to training primary health care 
professionals - physicians, nurses, pharmacists, dentists, physician assistants, 
psychologists, social workers, and others - to treat the millions of individuals and their 
families affected by SUD.34 Health care professionals play a central role in the 
identification of SUD as well as facilitating an increased accessibility to treatment for 
patients.35 Pharmacists as highly accessible health care professionals, are in an 
appropriate position to help prevent and treat SUD. They should prepare themselves to 
perform these functions as a matter of professional responsibility as the prevalence of 
these disorders increase.36 Pharmacists are often the first point of contact for patients 
accessing the health care system, especially in the community setting. Pharmacists 
frequently help patients with the management of minor but self-limiting symptoms.  
Furthermore, community pharmacists deliver many preventive and primary health care 
services and treatments including medication reviews, disease management (e.g., mental 
health and lifestyle management) and routine health care such as smoking cessation and 
weight loss programs.37 With respect to SUD, community pharmacists often offer their 
expert knowledge and insight into the regulatory aspects of substance abuse treatment to 
patients. This is especially true in regard to MAT for SUD. Pharmacists, as a specialized 
service, can assess and manage the pharmacotherapy of patients with SUD and their 
comorbid conditions. For example, they can contribute in developing plans for pain 
management in patients with SUD. They are trained to acquire detailed medication 
histories from patients and to assist them in adhering to their treatment regimens. As new 
medications are developed to treat SUD, community pharmacists are well positioned to 
increase access to these novel therapies safely and efficiently.38 However, most patients 
 30
with SUD do not seek assistance or receive treatment for their disorders.  Only 14.7% of 
people with SUD received professional help in 2008.39 Hence, even though treatment 
increases the possibility of recovery, patients usually do not disclose or admit to having 
problems with substance use and so do not receive appropriate treatment. Since the 
majority of patients with SUD seek treatment primarily for other minor problems (such as 
headaches), community pharmacists can play a critical role in screening these patients 
and identifying the underlying disorder and thereby increase accessibility to treatment.35 
 
VIII] Need for the study 
Several factors are associated with treatment utilization in SUD. In addition to the 
nature and severity of the disease, the awareness of the need for treatment among patients 
and their willingness to seek help depends on the patient’s sociodemographic 
characteristics. The unmet need for treatment is usually the highest among the elderly 
population, racial-ethnic minorities, low income groups, patients without insurance, and 
rural populations.39 These unmet needs are further augmented by negative attitudes of the 
health care providers resulting in treatment interruption or avoidance. Negative attitudes 
of health professionals towards patients with SUD lead to poor communication between 
the health care professional and patient, and reduced therapeutic cooperation. It could 
also lead to attribution of SUD symptoms to other illnesses and is referred to as 
diagnostic overshadowing.35 Although attitudes of healthcare professionals towards 
substance abuse have been evaluated previously, there is a general lack of studies 
conducted specifically with community pharmacists. Health care professionals, especially 
pharmacists should have basic knowledge of prevention and treatment strategies. Primary 
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prevention such as educational efforts and secondary prevention such as screening are 
important roles for pharmacists to play. Also, positive attitudes towards harm reduction 
strategies will increase if pharmacists have knowledge of the effectiveness of these 
strategies. Moreover, an increasing number of states have initiated outpatient naloxone 
dispensing recently; however, across the nation, there is limited exposure to this unique 
practice and limited appreciation for the role of a pharmacist within this clinical setting. 
Additional awareness is needed regarding the attitudes, knowledge and practices of the 
community pharmacist and what barriers to their practice exist and how they can be 
overcome.40   
Therefore, the specific aims of the study are as follows: 
 Assess the basic knowledge of community pharmacists regarding SUD 
medications. 
 Assess the screening practices of community pharmacists for opioid drug abuse. 
 Assess stigma among community pharmacists toward SUD. 
 Assess attitudes towards needle exchange/dispensing and provision of naloxone 
for patients. 
 Identify the relationship between knowledge, attitudes and stigma with offering of 
clinical pharmacy services for patients with SUD. 
 Identify the predictors of knowledge, stigma, screening and offering of clinical 
services for SUD. 
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Chapter 2 
SYSTEMATIC LITERATURE REVIEW 
This chapter describes the systematic literature review, specifically its objectives, 
method, results and conclusion. 
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I] Introduction 
Even though considerable research has been conducted on SUD, studies with a 
focus on the community pharmacists are scarce and have limitations that need to be 
assessed. The purpose of conducting the systematic literature review was to study the 
available literature on community pharmacist and substance use disorders and identify 
gaps that need to be addressed. The specific aims of the review were: 
1. To conduct a systematic literature review to identify papers describing 
community pharmacist attitudes, knowledge and practices in treating 
substance use disorder. 
2. To provide a basis for a quantitative survey of community pharmacist 
attitudes, knowledge and practices with SUD patients. 
3. To make policy, practice and research recommendations based on identified 
gaps in the literature as well as results of the survey.  
 
II] Method 
The Preferred Reporting Items for Systematic Reviews and Meta-Analysis 
(PRISMA) guidelines were used to conduct the review.41 The search was conducted in 
PubMed, Scopus and Psych-INFO electronic databases up to December 2017. (Figure 1) 
Select key terms included “Pharmacist,” “Substance Use Disorder,” “Attitudes,” and 
pharmacy practice terms like “Medication therapy management” and “Drug Abuse 
Screening.” The exclusion criteria included reviews, RCTs or pharmacological studies, 
and non-English articles. The inclusion criteria were studies with the community 
pharmacists in the sample or as the focus of the paper, in the area of SUD; attitudes, 
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knowledge, practices (specific or general) of pharmacists and policies applicable to the 
pharmacist roles. 
The search strategy for PubMed involved three sub-searches that were then 
combined.  
 The first included (Pharmacists [MeSH] OR Pharmacist*[tiab] OR 
Pharmacist*[ot]) AND (("Substance-Related Disorders"[MeSH] OR 
"Substance-Related Disorder"[tiab] OR "Substance-Related Disorder"[ot] 
OR "Substance-Related Disorders"[tiab] OR "Substance-Related 
Disorders"[ot]) OR ("Drug Overdose"[MeSH] OR "Drug Overdose"[tiab] 
OR "Drug Overdose"[ot] OR "Substance Dependence"[tiab] OR 
"Substance Dependence"[ot] OR "Substance Dependent"[tiab] OR 
"Substance Dependent"[ot]) OR ("Opioid-Related Disorders"[MeSH] OR 
"Opioid-Related Disorder"[tiab] OR "Opioid-Related Disorder"[ot] OR 
"Opioid-Related Disorders"[tiab] OR "Opioid-Related Disorders"[ot]) OR 
("Opiate Dependence"[tiab] OR "Opiate Dependence"[ot] OR "Opiate 
Dependent"[tiab] OR "Opiate Dependent"[ot]) OR ("Prescription Drug 
Misuse"[MeSH] OR "Prescription Drug Misuse"[tiab] OR "Prescription 
Drug Misuse"[ot]) OR ("Overdose Prevention"[tiab] OR "Overdose 
Prevention"[ot]) OR ("Medication-assisted treatment"[tiab] OR 
"Medication-assisted treatment"[ot]) OR ("Opiate Substitution 
Treatment"[MeSH] OR "Opiate Substitution Treatment"[tiab] OR "Opiate 
Substitution Treatment"[ot] OR "Opioid-Related Disorders/drug 
therapy"[MeSH] OR "Opioid-Related Disorders/rehabilitation"[MeSH]) 
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OR ("Substance Abuse Detection"[MeSH] OR "Substance Abuse 
Detection"[tiab] OR "Substance Abuse Detection"[ot] OR "Drug abuse 
screening"[tiab] OR "Drug abuse screening"[ot]) OR ("Needle-Exchange 
Programs"[MeSH] OR "Needle-Exchange Program"[tiab] OR "Needle-
Exchange Program"[ot] OR "Needle-Exchange Programs"[tiab] OR 
"Needle-Exchange Programs"[ot]) OR ("Harm Reduction"[MeSH] OR 
"Harm Reduction"[tiab] OR "Harm Reduction"[ot]) OR 
“Narcotics”[mesh] OR “Narcotic Antagonists”[mesh] OR Narcotic*[tiab] 
OR Narcotic*[ot]) 
 The second involved (Pharmacists [MeSH] OR Pharmacist*[tiab] OR 
Pharmacist*[ot]) AND (("Substance-Related Disorders"[MeSH] OR 
"Substance-Related Disorder"[tiab] OR "Substance-Related Disorder"[ot] 
OR "Substance-Related Disorders"[tiab] OR "Substance-Related 
Disorders"[ot]) OR ("Drug Overdose"[MeSH] OR "Drug Overdose"[tiab] 
OR "Drug Overdose"[ot] OR "Substance Dependence"[tiab] OR 
"Substance Dependence"[ot] OR "Substance Dependent"[tiab] OR 
"Substance Dependent"[ot]) OR ("Opioid-Related Disorders"[MeSH] OR 
"Opioid-Related Disorder"[tiab] OR "Opioid-Related Disorder"[ot] OR 
"Opioid-Related Disorders"[tiab] OR "Opioid-Related Disorders"[ot]) OR 
("Opiate Dependence"[tiab] OR "Opiate Dependence"[ot] OR "Opiate 
Dependent"[tiab] OR "Opiate Dependent"[ot])) AND ((Knowledge 
[MeSH] OR Knowledge [tiab] OR Knowledge [ot]) OR (Attitude [MeSH] 
OR Attitude*[tiab] OR Attitude*[ot] OR "Attitude of Health 
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Personnel"[MeSH]) OR (Belief*[tiab] OR Belief*[ot]) OR (Social 
Stigma[MeSH] OR Stigma*[tiab] OR Stigma*[ot] OR destigma*[tiab] OR 
destigma*[ot]) OR ("Red flag"[tiab] OR "Red flag"[ot] OR "Red 
flags"[tiab] OR "Red flags"[ot])) 
 The third search was (Pharmacists [MeSH] OR Pharmacist*[tiab] OR 
Pharmacist*[ot]) AND (Acamprosate[tiab] OR  Campral[tiab] OR 
Disulfiram[tiab] OR Antabuse[tiab] OR Naltrexone[tiab] OR 
Vivitrol[tiab] OR Methadone[tiab] OR Dolophine[tiab] OR 
Buprenorphine[tiab] OR Suboxone[tiab] OR Naloxone[tiab] OR 
Narcan[tiab] OR Fentanyl[tiab] OR Morphine[tiab] OR Heroin[tiab] OR 
Codeine[tiab] OR  Oxycodone[tiab] OR  Oxycontin[tiab] OR 
Hydrocodone[tiab] OR  Vicodin[tiab] OR  Meperetin[tiab] OR 
Demerol[tiab] OR Methadone[tiab] OR Dolophine [tiab]) 
 The final search was Search 1 OR Search 2 OR Search 3. The same strategy was 
modified and used for Psych-INFO and Scopus databases. 
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Figure 1: Schematic representation of methodology used and selection criteria.  Search and selection 
criteria were conducted following the PRISMA (Preferred Reporting Items for Systematic Reviews and 
Meta-Analyses) guidelines 
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III] Results of the review 
Table 1 presents the total number of the studies included for qualitative synthesis. 
They are divided in rows according to the factors being discussed (attitudes, knowledge, 
practices or policies). The columns present the specific focus of the study like syringe 
exchange, naloxone, educational or if they are general in nature. 
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Table 1: Results of the systematic review [Number of studies (Percentage)] 
Factors Needle Exchange Naloxone 
Students / 
Educational Others 
Total 
studies 
 Number (Percentage of all 153 studies) 
Attitudes 21(13.7) 9 (5.8) 2 (1.3) 25 (16.3) 57 (37.2) 
Knowledge 0 (0.0) 0 (0.0) 0 (0.0) 1 (0.6) 1 (0.6) 
Practices 3 (1.9) 3 (1.9) 0 (0.0) 11 (7.1) 17 (11.1) 
Attitudes, 
Knowledge 0 (0.0) 1 (0.6) 3 (1.9) 2 (1.3) 6 (3.9) 
Attitudes, 
Practices 6 (3.9) 0 (0.0) 0 (0.0) 12 (7.8) 18 (11.7) 
Attitudes, 
Knowledge, 
Practices 
0 (0.0) 0 (0.0) 0 (0.0) 2 (1.3) 2 (1.3) 
Policy 1 (0.6) 10 (6.5) 5 (3.2) 36 (23.5) 52 (33.9) 
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Table 2 presents all the studies included for the qualitative synthesis. The first author, 
year of publication, location where the study was conducted, factor assessed in the study, 
primary focus of the study, study design or method of data collection, primary (relevant) 
conclusion drawn and the corresponding reference is included in the table.
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Table 2: Extraction Table: Details of the studies included for qualitative synthesis 
 
 
Number Author Year Location Factor Focus of study 
Study Design 
/ Method Primary Conclusion 
Ref
ere
nce 
1.  Adams 2016 US Practice Prescriptive authority Descriptive  
2 categories of current pharmacist prescriptive authority: 
collaborative prescribing and autonomous prescribing. 
42 
2.  Akers 2017 Washington State Policy Naloxone 
Intervention 
study 
Take-home naloxone program successfully implemented in 
community pharmacies. 
43 
3.  Alcorn  2014 US Policy Naloxone Summary - 44 
4.  Al-Shatnawi 2016 US Attitude Students Summary 
Significant proportions of student pharmacists are at high risk 
for SUD. 
45 
5.  Andrews  2013 New Jersey Policy Roles 
Intervention 
study 
Pharmacist-led pain management consult service effectively 
addressed patient's needs and modified drug-seeking 
behaviors. 
46 
6.  Babcock 2017 West Virginia Policy Naloxone Commentary - 
47 
7.  Bachyrycz 2017 New Mexico Policy Naloxone 
Secondary 
database 
Patients at risk of opioid overdose feel comfortable asking for 
naloxone kits from a pharmacist 
48 
8.  Bailey 2014 US Practice Naloxone Interview 
Pharmacists can play a role in contacting providers, provision 
of products, education of patients and providers, and 
dissemination of information. 
49 
9.  Bakhireva 2017 New Mexico Practice Naloxone 
Focus group, 
electronic 
survey 
Need for intervention focused on pharmacists' concerns. Must 
include education to multiple audiences, and address 
provider-level, system-level, and society-level barriers. 
50 
10.  Baldwin 2009 US Policy Education Commentary - 51 
11.  Baldwin 1998 US Policy Roles Summary - 52 
12.  Blake 2009 West Virginia Practice MTM 
Mailed 
survey 
Pharmacists interested in and open to receiving education and 
training for implementation of MTMS. 
53 
13.  Blumenthal 2002 US 
Attitude 
& 
Knowledg
e 
Students Focus group, interview 
Pharmacy students had divided opinions about selling 
syringes to patients. To prepare students pharmacy schools 
should increase training about HIV/AIDS and SUD. 
54 
14.  Bratberg 2015 US Policy Roles Commentary - 55 
  
42 
15.  Brooks 2001 Utah Policy Roles Mailed survey 
Pharmacists who attend SUD training programs perform more 
chemical dependency activities than other pharmacists. 
56 
16.  Burrell 2017 Pennsylvania Policy Roles Descriptive 
GIS mapping is valuable in monitoring the impact of 
overdose prevention efforts, like effect of naloxone-
distributing pharmacies on overdose rates, 
57 
17.  Butler  2010 New Zealand Attitude General  Interview 
A binary view of patients (over-users and abusers) not helpful 
in understanding the issues of SUD. 
58 
18.  Byrne 2018 Australia Practice Naloxone Covert simulation 
Most pharmacy visits did not achieve a full score, illustrating 
the need for improved awareness of how to assess and 
manage patients requesting non-prescription analgesics 
containing codeine. 
59 
19.  Carney 2016 
Ireland, 
South 
Africa, 
United 
Kingdom 
Policy Codeine 
Focus group, 
content 
analysis 
Difficulties are encountered by community pharmacists when 
supplying codeine containing preparations in negotiating 
patient awareness and compliance. Potential ways to deal with 
misuse and dependence were discussed. 
60 
20.  Carpenter 2017 US Policy Education Content analysis 
Online naloxone training materials for pharmacists included 
limited content on communication.  
61 
21.  Case 1998 Maine Attitude & Practice 
Needle/Syri
nge 
Exchange 
Telephone 
survey 
Drug paraphernalia laws and pharmacy policies may have 
prevented patients from purchasing syringes. 
62 
22.  Chaar 2013 Australia Attitude 
Opioid 
substitution 
therapy 
Interview 
Barriers were stigma and fear, the nature of an opt-in scheme, 
professionals' moral responsibilities, lack of awareness and 
knowledge, and disproportionate distribution of clients and 
lack of financial support. 
63 
23.  Chaar 2011 Australia Practice Barriers Summary - 64 
24.  Chiarello 2016 US Attitude & Practice 
Needle/Syri
nge 
Exchange  
Interview 
Increased education along with favorable law and 
organizational policies and decentralization of syringe 
provision could increase access to clean needles and decrease 
public health risks. 
65 
25.  Chiarello 2015 US Attitude General Interview 
Pharmacists engage in medical and legal gatekeeping that 
lend themselves to different identities, have different foci, 
patterns of action, and orientations. Pharmacists' decisions 
have effects on patients' access to care and contact with the 
justice system. 
66 
  
43 
26.  Clarke 2001 London Attitude 
Needle/Syri
nge 
Exchange 
Interview Strong commitment by pharmacists to provide services despite difficulties with programs.  
67 
27.  Cobaugh 2003 US Policy Roles Commentary - 68 
28.  Cobaugh 2014 US Policy Roles Descriptive 
Pharmacies should promote guidelines on opioid therapy 
(pain management agreement plans, dispensing, and waste 
disposal) and educational initiatives targeting patients and 
providers. 
69 
29.  Cochran 2015 US Attitude & Practice Roles 
Electronic 
survey 
Pharmacy-based screening and brief intervention should 
consider practice location and pharmacists' interest in 
addressing SUD issues. 
70 
30.  Cochran 2016 US Policy Screening 
Intervention 
evaluation, 
content 
analysis 
Focus of screening efforts should be on pharmacists' 
knowledge of MTM. Screening should be multidimensional to 
enable patient-centered interventions that involve additional 
disciplines. 
71 
31.  Coffin 2002 New York City Attitude 
Needle/Syri
nge 
Exchange 
Telephone 
survey 
Some pharmacists were registered for the program but did not 
support selling syringes and others were supportive, but not 
registered.  
72 
32.  Coffin 2000 New York City Attitude 
Needle/Syri
nge 
Exchange 
Telephone 
survey 
Need for tailored continuing education for pharmacists on 
HIV/Hepatitis C prevention among SUD patients and to 
address syringe disposal issues. 
73 
33.  Cooper 2010 
Los 
Angeles, 
San 
Francisco 
Attitude 
Needle/Syri
nge 
Exchange 
Telephone 
and in-person 
interview 
Non-prescription syringe sales were influenced by 
pharmacists' perception. Some negative consequences of the 
program were reported. 
74 
34.  Crawford 2014 New York Attitude 
Needle/Syri
nge 
Exchange 
Intervention 
study 
Structural interventions may be an optimal method to alter 
attitudes towards highly stigmatized populations like SUD 
patients. 
75 
35.  Davis 2017 US Policy Naloxone Descriptive 
Pharmacists are uniquely situated to reduce potential opioid 
overdose risk. Awareness and utilization of state laws will 
help. 
76 
36.  Deibert 2006 Washington state Attitude 
Needle/Syri
nge 
Exchange 
Telephone 
survey 
Structural changes like policy reform and pharmacy outreach 
may increase syringe access. Interventions should address 
pharmacy policies and pharmacist attitudes and policies. 
77 
37.  Deitz 2011  US Policy Evaluation Intervention study 
Multimedia Web-based programs could be a helpful addition 
to substance misuse prevention services. 
78 
  
44 
38.  Deyo 2015 Oregon Policy Roles Descriptive, survey 
Program improvements and health care system changes would 
enable using and responding to PDMP information while 
treating SUD. 
79 
39.  DiPaula 2015 US Policy MAT Intervention study 
Physician and pharmacist collaboration optimized care of 
buprenorphine-maintained patients. 
80 
40.  Duvivier 2017 US Policy Roles Intervention study 
Pharmacist involvement in crucial initiatives like responsible 
opioid prescribing, expanded access to MAT and naloxone, 
and education shows their impact in SUD prevention and 
treatment. 
81 
41.  Edwards 2017 US Attitude Naloxone Electronic survey 
Pharmacists had positive attitudes toward screening and 
endorsing naloxone kits and were willing to participate in the 
program. 
82 
42.  Farley 1999 Louisiana Attitude 
Needle/Syri
nge 
Exchange 
Mailed 
survey 
Pharmacists’ role in this area can be promoted through 
education and/or training and development of referral systems 
for patients. 
83 
43.  Fass 2011 Florida Attitude PDMP Mailed survey 
Majority of pharmacists were in favor of implementing a 
PDMP for controlled substances. 
84 
44.  Fedorova 2013 Russia Attitude 
Needle/Syri
nge 
Exchange 
Interview 
Training pharmacists will reduce negative attitudes. Including 
syringes in the federal list of mandatory medical products sold 
by pharmacies might increase access. 
85 
45.  Fiellin 2014 US Policy Buprenorphine Summary - 
86 
46.  Fischer 2016 North America Policy PDMP Summary - 
87 
47.  Fleming 2001 
Ireland & 
England/ 
Wales 
Attitude 
& Practice Roles 
Mailed 
survey 
Training programs, support systems, and adequate 
remuneration must be established before pharmacists can 
contribute entirely to prevention and treatment of SUD.  
88 
48.  Fleming 2014 Texas Attitude & Practice Roles 
Mailed 
survey 
Older pharmacists with a BS. Pharm degree may be more 
willing to provide counseling to patients based on their work 
experience and additional CPE related to controlled 
substances. 
89 
49.  Fleming 2013 Texas Attitude PDMP Electronic survey 
Prescriber request rates were higher than pharmacists and 
online access for providers resulted in higher request rates per 
100,000 population. 
90 
  
45 
50.  Fleming 2014 Texas Attitude PDMP Survey 
Interventions that address pharmacists’ attitude, subjective 
norms, perceived behavioral control, and perceived obligation 
may increase their intention to use PDMP data. 
91 
51.  Fonseca 2017 North America Attitude MAT Interview 
Rural community pharmacy practice has unique barriers to 
deliver MMT services which may require a coordinated, 
multi-pharmacy approach. 
92 
52.  Francoeur 2011 US Policy Roles Descriptive 
Developing medication purchasing cooperatives and 
increasing the role of methadone maintenance treatment 
programs in palliative care can help treat SUD patients. 
93 
53.  Freeman 2017 Kentucky Attitude Naloxone Electronic survey 
Pharmacists were divided in their willingness to initiate 
naloxone dispensing. Those who were confident in their 
ability to identify overdose risks were more willing. 
94 
54.  Fuller 2007 New York City 
Attitude 
& Practice 
Needle/Syri
nge 
Exchange 
Intervention 
study 
Targeting the individual and social environment through a 
multilevel community-based intervention decreased high-risk 
behavior, predominantly among African American patients. 
95 
55.  Gabay 2016 US Policy Naloxone Commentary - 96 
56.  Ghaddar 2017 Lebanon Attitude 
Needle/Syri
nge 
Exchange 
Interview 
Reducing the negative attitude towards patients and the legal 
and cultural barriers, and strengthening the pharmacists' role 
will help empower patients to use these programs. 
97 
57.  Glanz 1989 England and Wales Attitude 
Needle/Syri
nge 
Exchange 
Mailed 
survey 
Participation of community pharmacists in the prevention of 
HIV among SUD patients is a viable policy, but several 
problems need to be overcome before implementation. 
98 
58.  Gleghorn 1998 Baltimore Attitude 
Needle/Syri
nge 
Exchange 
Telephone 
survey 
To reduce patients' exposure to HIV, pharmacists should be 
educated about HIV prevention and injection drug use and be 
included in prevention programs, including legal pharmacy 
NS sales. 
99 
59.  Green 2017 
Massachu
setts and 
Rhode 
Island 
Attitude Naloxone Focus group 
To overcome stigma of naloxone receipt, improved public 
awareness of naloxone and pharmacist training regarding 
naloxone and SUD are essential. 
100 
60.  Green 2013 
Connectic
ut and 
Rhode 
Island  
Attitude PDMP Electronic survey 
Current PDMP use with the prevalent systems had inadequate 
impact on pharmacy practice. 
101 
61.  Green 2015 US Policy Naloxone Case study - 102 
  
46 
62.  Hagemeier 2015 Tennessee 
Attitude 
and 
Practice 
MTM Mailed survey 
Dissemination of treatment information, improvements SUD 
specific continuous education and in communicative self-
efficacy beliefs of pharmacists, are significantly associated 
with increased provision of treatment information by 
community pharmacists. 
103 
63.  Hagemeier 2013 
Rural 
Appalachi
a 
Attitude General Survey 
Pharmacists perceived a larger number of patients to be 
abusing opioid pain relievers as compared with their 
prescriber colleagues. 
104 
64.  Hagemeier 2014 Tennessee Attitude Communication 
Mailed 
survey 
Community pharmacists are aware of SUD prevalence and 
value their role in communicating with patients but believe 
their ability to do so effectively is hindered by a lack of 
confidence, training, and time. 
105 
65.  Hagemeier 2016 Appalachia Attitude 
Communicat
ion Focus group 
Despite the perceived importance of engaging in SUD 
communication, pharmacists reported that communication is 
uncomfortable, diverse, multifactorial, and often avoided. 
106 
66.  Hagemeier 2017 Tennessee Practice Communication 
Mailed 
survey 
Community pharmacists are less confident in their ability to 
communicate with patients about their SUD as compared to 
non-SUD patients. 
107 
67.  Hall 2011 Australia Policy Roles Commentary - 108 
68.  Harvin 2015 US Policy Roles Commentary - 109 
69.  Haug 2016 - Attitude Naloxone Content analysis 
Pharmacist training and reform of naloxone administration 
procedures are required to improve treatment outcomes and 
reduce stigma. 
110 
70.  Hemming 2016 US Policy Roles Summary - 111 
71.  Hill 2012 Glasgow Attitude Naloxone Survey There is strong support across stakeholders for the training and supply of naloxone to patients and their family/friends. 
112 
72.  Holdsworth 2015 US Policy General Descriptive A more formalized risk-based strategy focused upon ideal patient education and required follow-up was proposed. 
113 
73.  Hoppe 2014 US Policy Roles Commentary - 114 
74.  Ibragimov 2017 Tajikistan Attitude Stigma Interview 
Local sociocultural context, religious beliefs, and social 
conservatism may facilitate stigmatizing beliefs which shapes 
pharmacists’ overall attitude. 
115 
75.  Irwin 2012 United Kingdom Practice 
Patient 
interaction Interview 
The provision of training and support, especially to 
inexperienced pharmacists could further reduce the negative 
impact of patient aggression 
116 
  
47 
76.  Jackson 2016 US Policy Roles Descriptive 
Approaching patient with empathy in a nonjudgmental 
manner and by facilitating a patient’s knowledge of SUD 
pharmacists can effectively participate in treatment. 
117 
77.  Jones 2005 UK 
Attitude 
& 
Knowledg
e 
Methadone Intervention study 
Marginal change in attitude towards methadone programs; 
substance misuse and knowledge of methadone among 
pharmacists after structured educational training 
118 
78.  Jones 1998 Lothian Attitude Harm reduction 
Mailed 
survey 
Pharmacists are making a vital contribution to the 
management of SUD but believe that there is scope for 
improvements in service provision. 
119 
79.  Jones 2002 US Policy 
Needle/Syri
nge 
Exchange 
Summary - 120 
80.  Joranson 2001 Wisconsin 
Attitude 
& 
Knowledg
e 
Opioid pain 
relievers 
Mailed 
survey 
Pharmacists play a pivotal role in ensuring patient access to 
SUD medications. Also, the improper knowledge and 
negative attitudes of pharmacists could contribute to a failure 
to dispense prescription pain relievers.  
121 
81.  Kim 2014 US Policy Education Electronic survey 
The extent of pharmacy experiential education in SUD is 
limited and variable. 
122 
82.  Kimberlin 1999 Florida Policy Education Intervention study 
Pharmacists who received the intervention were more likely 
to provide information and assess for problems than 
pharmacists who didn’t receive it.  
123 
83.  Klein 2001 New York Attitude 
Needle/Syri
nge 
Exchange 
Mailed 
survey 
Most pharmacists supported the program and were willing to 
participate. 
124 
84.  Lafferty 2006 Florida 
Attitude, 
Knowledg
e & 
Practice 
General Mailed survey 
Neurobiological basis for SUD, standards of care, and pain 
management guidelines weren’t widely understood. Research 
needed to determine the educational needs of pharmacists to 
help them in detecting, preventing, and treating SUD. 
125 
85.  Lawrinson 2008 Australia 
Attitude, 
Knowledg
e & 
Practice 
MTM Telephone survey 
Pharmacists were generally positively predisposed to 
providing treatment. Embracing a shared-care approach 
between general practitioners and pharmacists might help 
provide better treatment. 
126 
86.  Leong 2015 Manitoba Practice Screening Focus group Patient – level barriers, pharmacist – level barriers and system – level barriers to effective practice were identified. 
127 
  
48 
87.  Leong 2016 Canada Attitude - Electronic survey 
Need for improved systems for managing patients at risk for 
medication misuse, diversion, and overdose like increased 
access to electronic medical records and providing additional 
continuing education. 
128 
88.  Lewis 2002 Colorado Attitude 
Needle/Syri
nge 
Exchange 
Interview 
Improved syringe disposal options, continuing education 
programs, and clarification of existing laws and regulations 
would encourage more pharmacists to sell syringes. 
129 
89.  Lim 2016 US Policy Naloxone Summary - 130 
90.  Luty 2010 UK Attitude Stigma Survey 
Behavioral discrimination occurred based on stigmatizing 
attitudes and familiarity with patients may have a de-
stigmatizing effect. 
131 
91.  Mackridge 2010 England Practice General Interview, focus group 
Expansion of services to treat SUD patients better were well 
supported by the pharmacists. 
132 
92.  Maguire 2017 Ohio Policy Education Intervention study 
A naloxone and harm reduction educational program across 
all four years of the Pharm D curriculum was implemented. 
133 
93.  Manchikanti 2007 US Policy General Summary - 
134 
94.  Matheson 2016 Scotland Attitude & Practice General 
Mailed 
survey 
Pharmacist attitudes and service engagement improved over 
time due to training. Communication with the wider SUD 
team could be further advanced. 
135 
95.  Matheson 1999 Scotland Attitude General Telephone interview 
The active backing of local health boards, professional 
authorization, further education and remuneration might 
encourage pharmacists' participation in drug misuse services. 
136 
96.  Matheson 1999 Scotland Attitude General Mailed survey 
Correcting negative attitudes could encourage pharmacists to 
provide services and enhance services in SUD treatment. 
137 
97.  Matheson 2002 Scotland Practice General Mailed survey 
Community pharmacy involvement in SUD increased largely 
in methadone dispensing and supervision. Pharmacists are 
more proactive in counseling due to greater training. 
138 
98.  McCormick 2006 
New 
Zealand Attitude General 
Mailed 
survey 
Attitudes towards various aspects of service provision to SUD 
patients are a complex concept. 
139 
99.  McLaughlin 2006 Ireland Attitude General 
Focus group, 
interview 
Most of the pharmacists were unprepared and unwilling to 
meet the challenge of caring for SUD patients, with many 
displaying negative attitudes.  
140 
100.  McVeigh 2017 Ireland Attitude & Practice 
Needle/Syri
nge 
Exchange 
Telephone 
interview 
Increase of program coverage and targeted service delivery 
within national care pathways for SUD is necessary. 
141 
  
49 
101.  Monteiro 2017 Rhode Island 
Attitude 
& 
Knowledg
e 
Students Intervention study 
Workshop focused exclusively on opioid misuse can be used 
to simulate the complex issues surrounding SUD and to 
highlight the importance of inter-professional teams. It was 
well received with high levels of satisfaction among students. 
142 
102.  Morrison 2000 New York City Practice 
Stocking 
opioids Survey 
Pharmacies in predominantly nonwhite neighborhoods do not 
stock sufficient medications to treat patients with severe pain 
adequately. 
143 
103.  Myers 1998 Canada Attitude 
Needle/Syri
nge 
Exchange 
Mailed 
survey 
While organizational, educational and policy changes may 
enable program development, individual pharmacy and 
pharmacist discretion is important. 
144 
104.  Ngyuen 2017 Pacific Northwest Policy Roles Summary 
Pharmacists contribute to SUD prevention by helping to 
detect fraudulent prescriptions, staying current with existing 
guidelines, and being aware of new safety programs. 
145 
105.  Nielsen 2016 Australia 
Attitude 
& 
Knowledg
e 
Naloxone Electronic survey 
Community pharmacists were willing to supply naloxone. 
Low levels of knowledge about naloxone pharmacology and 
administration highlight the importance of training 
pharmacists about overdose prevention. 
146 
106.  Nielsen 2007 Australia Attitude & Practice 
Buprenorphi
ne Survey 
Pharmacists' perceptions of issues related to buprenorphine 
affected attitudes towards patients and the program. They 
believed that a significant level of diversion was occurring. 
147 
107.  Norwood 2016 Indiana Attitude & Practice PDMP Survey 
Use of PDMP programs were based on number of reported 
barriers and overall concern about the prevalence of SUD in 
the community. 
148 
108.  Norwood 2016 Indiana Practice PDMP Intervention study 
Integration of PDMPs in pharmacy practice may improve a 
pharmacist's ability to make informed clinical decisions and 
use professional judgment to prevent drug abuse. 
149 
109.  Olivia 2017 US Policy Naloxone Descriptive The program was successful as part of a health care system. 150 
110.  Owen 2014 US Policy Roles Commentary - 151 
111.  Palmer 2017 Kentucky Policy Naloxone Intervention study 
The swift organization of the training program to a wide 
variety of pharmacists resulted in a considerable number of 
naloxone-certified pharmacists. 
152 
112.  Pankonin  2008 Vietnam Attitude 
Needle/Syri
nge 
Exchange 
Interview 
Pharmacies contributed a significant proportion of the total 
syringe supply to patients. They could be an effective vehicle 
for increasing harm reduction services with enough support. 
153 
  
50 
113.  Parsons 2009 US Policy 
Needle/Syri
nge 
Exchange 
Summary - 154 
114.  Penm 2017 Ohio Policy General Intervention study 
Pharmacists were recognized as a vital component of the state 
strategy to addressing SUD by promoting responsible 
prescribing and adopting prevention practices. 
155 
115.  Peterson 2007 Australia Attitude 
Harm 
minimizatio
n 
Mailed 
survey 
Improving the number and expertise of health professionals, 
and providing adequate support for them, would address some 
of the problems of harm minimization strategies. 
156 
116.  Peterson 1999 Australia Policy Roles Commentary - 157 
117.  Philbin 2009 Mexico Attitude 
Needle/Syri
nge 
Exchange 
Interview 
Only half of the pharmacists believed these could be feasibly 
implemented, citing barriers involving religion, police, and 
lack of political will, public awareness, and funding. 
158 
118.  Price 2017 US Policy Roles Commentary - 159 
119.  Pricolo 2017 Australia Attitude Naloxone Summary - 160 
120.  Raisch 2005 US Attitude Naloxone Survey, interview 
The majority of pharmacists voiced positive attitudes and 
perceptions regarding patients treated for SUD. 
161 
121.  Rich 2002 Rhode Island Attitude 
Needle/Syri
nge 
Exchange 
Survey 
There was high level of support for nonprescription syringe 
sales to patients. The correlation between the willingness to 
sell non-prescription syringes to patients and their beliefs 
suggested that educational interventions might encourage 
pharmacists to participate in these programs. 
162 
122.  Rivera 2010 New York City Practice 
Needle/Syri
nge 
Exchange 
Survey 
Pharmacists were a frequent source of nonprescription 
counseling for their patients They may be amenable to 
providing relevant counseling services to patients. 
163 
123.  Roberts 2007 Glasgow Attitude 
Needle/Syri
nge 
Exchange 
Mailed 
survey 
Pharmacists were willing to participate in the program due to 
recognition of an acute clinical need, rather than potential 
financial gain. 
164 
124.  Roberts 1998 Glasgow Policy Roles Summary - 165 
125.  Robertson 2015 Scotland Policy Roles Mailed survey 
Pharmacist care for SUD patients has evolved from 
medication supply to a more clinical approach that included 
actively monitoring patients, managing their minor ailments 
and being engaged with the wider care team. 
166 
126.  Rose 2014 San Francisco 
Attitude 
& Practice 
Needle/Syri
nge 
Exchange 
Interview 
Pharmacists wanted the opportunity to broaden their role as 
critical partners in public health matters related to injection 
drug use through these programs. 
167 
  
51 
127.  Rose 2010 San Francisco Attitude Roles 
Survey, 
interview 
Pharmacies were selling nonprescription syringes to 
individuals perceived to be IDUs with no major problems. 
168 
128.  Saldana 2017 US Policy General Commentary - 169 
129.  Samitca 2007 Switzerland Practice 
Needle/Syri
nge 
Exchange 
Survey 
Pharmacists do not feel integrated enough in the network of 
care to drug misusers and ask for more training and better 
recognition of their role. 
170 
130.  Shafer 2017 US Policy General Descriptive 
The accessibility of naloxone dispensing at pharmacies, 
patient education, and safe drug disposal kiosks are crucial 
prevention initiatives to address the opioid epidemic and 
reduce the burden of opioid overdose. 
171 
131.  Shepherd 2014 US Policy General Descriptive 
A national controlled substance dispensing reporting system 
that uses existing PBM networks would be considerably more 
effective than the existing options. 
172 
132.  Sheridan 1997 London Attitude & Practice General 
Mailed 
survey 
Service provision was positively associated with confidence 
in both, knowledge about HIV and counseling patients 
regarding drug misuse. 
173 
133.  Sheridan 1994 UK Attitude  Students Questionnaire 
Attending the course had the effect of increasing knowledge 
of HIV/AIDS and increasing confidence in counselling SUD 
patients. 
174 
134.  Sheridan 1997 England, Wales 
Attitude 
& Practice 
Needle/Syri
nge 
Exchange 
Mailed 
survey 
More communication between providers and the community 
pharmacists, further training, new forms of service provision, 
and greater value of their role were suggested. 
175 
135.  Sheridan 2007 England Attitude & Practice General 
Mailed 
survey 
Community pharmacy play an important role in delivering 
treatment, including prescribing services, to SUD patients. 
There is unexploited capacity and moderate support for newer 
roles of pharmacists. 
176 
136.  Sheridan 2011 New Zealand Attitude PDMP Interview 
PDMP can be an issue for pharmacists and it can cause 
disruption to their work. 
177 
137.  Shimane 2015 Japan Attitude & Practice General 
Mailed 
survey 
Pharmacists who had insufficient confidence in 
communication with prescribers and who were fearful of 
problems with a prescriber, reported that they rarely referred 
to a prescriber. 
178 
138.  Snoswell 2016 Australia 
Attitude 
& 
Knowledg
e 
Students Questionnaire 
Students would be more comfortable providing opioid 
substitution treatment if greater education and training were 
available. 
179 
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139.  Stopka 2017 Massachusetts Practice 
Naloxone & 
Needle/Syri
nge 
Exchange 
Telephone 
survey 
Access to sterile syringes through nonprescription sales was 
strong. Although almost half of the pharmacists reported 
stocking and selling naloxone to prevent opioid overdose 
deaths, there is much room for improvement in access and 
training among pharmacy staff members. 
180 
140.  Taussig 2002 Atlanta Attitude 
Needle/Syri
nge 
Exchange 
Interview 
Patients’ access to sterile syringes from pharmacies would be 
increased by providing pharmacists with professional 
education programs and removing or modifying the restrictive 
Board of Pharmacy regulation governing syringe sales. 
181 
141.  Thornton 2017 West Virginia Attitude Naloxone Questionnaire 
Tailored educational material can help in regulating the 
pharmacists' fear and strengthen the benefits of over-the-
counter naloxone use. 
182 
142.  Uosukainen 2014 Finland Attitude & Practice General Descriptive 
Pharmacist who had patient experience were more positive 
about dispensing treatment and less worried about safety, 
diversion and patients’ impact on the pharmacy’s public 
image. 
183 
143.  Vorobjov 2009 Estonia Attitude Harm reduction Focus group 
There were no formal or legislative obstacles for providing 
harm reduction services at pharmacies. Addressing negative 
attitudes through educational courses involving pharmacists 
willing to be public health educators can increase access. 
184 
144.  Walters 2012 New Zealand 
Knowledg
e General Questionnaire 
Online training is an appropriate and economical method of 
improving pharmacists' clinical skills  
185 
145.  Watson 2012 US Attitude & Practice 
Harm 
reduction Summary 
Community pharmacists are very accessible and in an ideal 
position to provide services to SUD patients. However, 
pharmacists require additional support in the form of better 
health system integration, as well as remuneration models. 
186 
146.  Wazaify 2006 Ireland Policy Evaluation Interview 
Some problems were encountered in implementing the harm 
minimization model, but these may be alleviated by further 
training and greater collaborative working by pharmacists. 
187 
147.  Wenthur 2013 Indiana Attitude Education Questionnaire 
Pharmacists and pharmacy student respondents 
overwhelmingly felt that educational preparation in this area 
is important and lacking in some areas. 
188 
148.  Wickramatilake  2017 US Policy General Questionnaire 
US state alcohol and drug agencies demonstrated a robust 
response to the opioid crisis. They have followed and 
expanded on a range of evidence-based initiatives aimed at 
the opioid crisis. 
189 
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149.  Winstock 2010 Australia Attitude Roles Questionnaire 
Particular attention should be focused upon considering 
number of clients per pharmacy and improving professional 
communication between pharmacists and prescribers. 
190 
150.  Wright-DeAguero 1998 
Connectic
ut Practice 
Needle/Syri
nge 
Exchange 
Mailed 
survey 
Policies to incorporate pharmacists as active partners in HIV 
prevention should promote the sale of syringes without a 
prescription to patients as an acceptable public health practice. 
191 
151.  Zaller 2012 Rhode Island Attitude 
Needle/Syri
nge 
Exchange 
Interview 
Individual experiences of pharmacists influenced overall 
perceptions, pharmacists differentiated between SUD patients 
and others, some pharmacists demonstrated an understanding 
of the importance of sterile syringes.  
192 
152.  Zaller 2013 Rhode Island Attitude Naloxone Interview 
Most pharmacists supported the idea of a pharmacy-based 
naloxone intervention. But several barriers were identified, 
including misinformation about naloxone, interpersonal 
relationships with patients, and costs of such an intervention. 
193 
153.  Zaller 2010 Rhode Island Attitude 
Needle/Syri
nge 
Exchange 
Electronic 
survey 
Health systems should build upon the willingness of 
pharmacists in order to address the health needs of SUD 
patients. 
194 
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IV] Attitudes 
1) General 
Of the 153 papers included for qualitative synthesis, 57 (37.2%) papers discussed 
only attitudes of pharmacists towards SUD. Almost half of them (25; 13.7% of total) 
discussed general attitudes towards SUD and patients misusing or abusing drugs. Overall 
positive attitudes were reported in all papers but 20% or less of every sample had 
negative attitudes such as perceiving patients as exhibiting illegal behaviors, stigma, fear 
and discrimination, or unfavorable opinion of harm minimization strategies in each study. 
Generally, pharmacists saw themselves as both medical and legal gatekeepers when 
treating patients and made decisions accordingly, which would ultimately have 
consequences on the treatment provided to the patient.66 Pharmacists in turn saw patients 
as ‘over users’ or ‘abusers’ and had more favorable attitudes towards providing treatment 
or harm reduction strategies to ‘over users’.58 However, a study by Chaar et al noted that 
“positive attitudes, functional relationships with patients/stakeholders, professional 
satisfaction and financial rewards were found to motivate pharmacists to provide services 
for these patients.”63(p426) Also, pharmacists perceived the prevalence of SUD to be much 
higher than prescribers suggesting a more serious attitude towards the problem, even 
though their perceived self-efficacy to provide treatment to this population was low.104 
Familiarity with the patient, ease of access to medical history information and to the 
prescribing physician were related to better attitudes and greater perceived self-
efficacy.128 A study conducted in Scotland also reported that pharmacists are motivated to 
provide services to this population by being conscious of the needs of the community, 
having a desire to reduce the extent of diseases like HIV and hepatitis C infection, and to 
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expand their professional services.136 Another study conducted by the same authors 
reported that attitudes were associated with the practice site, gender, and number of years 
registered as a pharmacist. On controlling these factors, attitude was found to be an 
independent predictor of whether needles/syringes were sold.137 A study by McKormick 
et al characterized the overall attitude of pharmacists by evaluating attitudes towards four 
principal factors that shape the general attitude, namely- “the general results of 
dispensing methadone to opioid misusers (outcomes of treatment); the effect of opioid-
dependent clients on a pharmacy (pharmacy factors); reducing harm associated with drug 
use (harm reduction); and engaging with drug users (patient interaction).”139  Attitudes 
varied based on the factor being studied. Increased education and training for pharmacists 
can be possible methods to improve attitudes towards SUD patients.188                                               
 
2) Needle exchange 
 Attitudes towards needle exchange or even non-prescription syringe sales covered 
a wide array of positive and negative in all the studies. A study conducted in 2001 by 
Clarke et al, reported that pharmacy-based needle exchange programs were appreciated 
by users and the chief source of their injecting equipment. Differences in opinions about 
such programs between pharmacists and patients were related to the extent of privacy in 
the transaction. Although pharmacists reported difficulties with these practices, 
pharmacists also showed a high level of commitment towards providing needle or syringe 
exchange.67 A study conducted in Baltimore reported that while most pharmacists (87%) 
were aware of the needle exchange program, 78.3% also embraced the program. 
However, only 67.4% supported selling non-prescription needles and syringes in 
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pharmacies, indicating more favorable attitudes towards needle/syringe exchange than 
selling them without prescriptions.99 This was also seen in a study conducted in Denver, 
where only 50% of the surveyed pharmacists supported non-prescription syringe sales but 
everyone supported syringe exchange.129 The hypothesis that attitudes towards harm 
reduction strategies would be more positive in large metropolitan areas did not hold true. 
Implementation of the Expanded Syringe Access Demonstration Program (ESAP) that 
permitted selling syringes without a prescription helped improve attitudes of pharmacists 
in studies conducted in New York.72 However, a survey conducted before 
implementation of the program reported that of the 4392 licensed pharmacies, 139 
(15.9%) indicated that they would definitely not participate in the program and 7.4% left 
this question unanswered.124  On the other hand, many pharmacies mandated proof of a 
medical condition (80% in Los Angeles[LA] and 30% in San Francisco [SF]). Some also 
refused non- prescription syringe sales if the customer was a suspected injection drug 
user (74% in LA, 33% in SF). However, the authors also reported that the odds of an 
overall positive attitude were significantly higher among pharmacists who believed 
syringe access was important for preventing HIV among patients (AOR = 2.95; 95% CI = 
1.10-7.92).74 Additionally, a proposed intervention such as offering medical or social 
service referrals during syringe sale itself to patients improved attitudes of pharmacists 
towards the practice. The improved attitudes were specific towards the negative 
community factors of this harm reduction strategy like improper syringe disposal, 
loitering, increased illegal drug use that may occur.75  A study reported that the most 
frequently quoted reason for not selling needles or syringes was fear of increasing drug 
use due to their sale. However, many pharmacists also reported that they would in fact 
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conduct a sale if the patient had a referral from an support agency or clinic.83 Other 
reported reasons were, incorrectly disposed syringes, fears about staff and customer 
safety, and corporate concerns.97 Staff safety was the foremost concern in an international 
study while remuneration was the smallest concern but pharmacists had overall positive 
attitudes.144 A study in Mexico evaluated attitudes towards needle exchange programs 
(NEPs), syringe vending machines, structural barriers, and safer injection facilities. They 
also asked for suggestions for implementation of these programs from the pharmacists. 
Of these interventions, NEPs were considered the most suitable (75%); however, only 
half the surveyed sample believed these could be practicably implemented. The 
pharmacists mentioned barriers involving religion, law enforcement agencies, lack of 
public awareness and funding sources, and lack of political resolve to implement the 
program.158 Although administrative, educational, and policy reforms may aid expansion 
of such programs, the attitudes of individual pharmacies and pharmacists are essential for 
effective implementation of harm minimization strategies like needle or syringe 
exchange.144 
 
3) Naloxone 
 Attitudes towards naloxone were generally more positive than other harm 
reduction strategies. Pharmacy standing dispensing orders for naloxone and the 
regulations regarding dispensing naloxone to friends/family of patients and first 
responders are controversial topics and studies measured attitudes of pharmacists towards 
this. One study reported that the majority of the pharmacists surveyed were of the opinion 
that the supply of naloxone to patients and their caregivers was a good policy and would 
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contribute towards decreasing deaths due to drug overdose. However, the pharmacists 
also stated that this supply should be made available only after suitable training on 
resuscitation techniques and administration of naloxone was provided to the patients and 
caregivers.112 A focus group study by Green et al regarding pharmacists attitudes towards 
naloxone reported four themes: “consumer fear of future consequences if requesting 
naloxone; pharmacists' concerns about practice logistics related to naloxone; differing 
perceptions of how opioid safety is addressed in the pharmacy; and solutions to 
addressing these barriers.”100 The study also compared the opinions of the patients across 
different pharmacies and found that they differed in awareness of naloxone and 
availability at pharmacies. However, all patients expressed support for the pharmacist's 
role in the provision of naloxone. They also preferred a universal dispensing of naloxone 
based on clear criteria.100 This shows that both pharmacists and patients have positive 
attitudes towards naloxone distribution. Studies also assessed attitudes towards take home 
naloxone (THN) kits. A study reported that of the total sample 79.8% of respondents 
(pharmacists) strongly agreed or agreed that pharmacists should be recommending THN 
kits. Pharmacists working in areas with larger populations and full-time pharmacists were 
more likely to agree with this statement. Furthermore, 60.6% of pharmacists and 
pharmacists who had work experience for less than or equal to 15 years were more 
willing to participate in the THN program. Additionally, lack of time and education about 
the program were the most commonly stated barriers to implementation of the THN 
program as perceived by the pharmacists.82 This demonstrates an overall positive attitude 
towards the THN program. Some studies however, also reported negative attitudes; for 
example, a study reported that only some (20.4%) of the surveyed community 
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pharmacists felt comfortable selling naloxone without a prescription (i.e. on the basis of a 
standing order). The authors also proposed that specialized educational materials 
designed for pharmacists can help in reducing the pharmacists' fears and stress the 
benefits of over-the-counter naloxone dispensing.182 Generally, pharmacies support 
naloxone provision to patients and care-givers using standing orders. However, there may 
be other concerns like stigma of receiving naloxone. Improving public awareness of 
naloxone and training pharmacists about naloxone and addiction may help to reduce the 
concerns that patients have to face. Pharmacists could also offer naloxone through a 
universal opt-out strategy which the patients favor. This strategy is where all patients 
meeting specific evidence-based criteria are offered naloxone and there is no place for 
discrimination, leading to decreased chances of pharmacist attitudes affecting the service. 
Targeted or opt-in strategies where only patients assumed to be high risk or patients who 
request it are offered naloxone have a greater chance of patients being refused naloxone 
or unaware patients never benefitting from its use.100 
 
4) Others 
 Attitudes towards treatment for SUD were also reviewed. A study evaluating 
attitudes of pharmacists towards medications reported that most pharmacists (77.5%) 
were not highly concerned about theft or break-ins, which could be a barrier to store and 
dispense medications. Most pharmacists (70%) also stated that they would be willing to 
partake in opioid dependence treatment as the medications become available 
commercially, indicating an overall positive attitude towards SUD patients and treatment. 
The majority of respondents (85%) stated that SUD patients did not cause problems at 
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their pharmacies. When asked about buprenorphine/naloxone (Suboxone®) specifically, 
most respondents did not express increased concern regarding prescription forgery (75%) 
or diversion (80%) of buprenorphine/naloxone as compared to their experiences in 
administering other narcotic medications. Most pharmacists thus expressed positive 
attitudes regarding buprenorphine/naloxone and the patients treated for SUD.161 Another 
study discussing methadone maintenance treatment (MMT) reported some pharmacist-
related barriers to providing MMT services which could be barriers towards providing 
other treatments as well. These barriers included an increased workload leading to longer 
operating hours, concerns about safety due to burglary, apprehensions about community 
resistance, and availability of methadone training programs.92 
 Of the two studies that evaluated stigma specifically, one was a qualitative study 
conducted in Tajikistan where main themes included the following: “the significance of 
religion in defining attitudes towards drug use; labelling of patients, negative stereotypes 
(SUD patients are prone to crime, violence, and irrational aggression; inflict harm to 
families and society; are able to control drug use), emotions triggered by patients (fear, 
sympathy) and discrimination against patients (rejection, isolation, ostracism, limiting 
resources to patients).”115 The other study reported  definite behavioral discrimination 
based on stigmatizing attitudes towards patients and concluded that increased 
acquaintance with these patients may have a de-stigmatizing effect.131 It did not, 
however, evaluate the practice characteristics of pharmacists to be able to conclude that 
experience was a predictor of stigma. Although these studies do point towards a possible 
relationship between greater years of experience in treating patients and lesser 
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stigmatizing attitudes, further research is necessary to comprehensively establish this 
relationship.  
 
V] Knowledge 
Only one study assessed exclusively knowledge of pharmacists and was an 
evaluation of a training program on opioid substitution treatment. It reported 
enhancements in the confidence and skills of pharmacists after the training program 
which was established through both the quantitative and qualitative analyses.185 Thus, the 
study truly evaluated the knowledge of SUD treatments or the disorder in general among 
pharmacists. 
 
VI] Attitudes and Knowledge 
Six studies looked at both attitudes and knowledge among pharmacists but the 
focus of studies ranged from educational program evaluation, policy, naloxone or student 
populations. One study evaluated the effect of an educational program and reported 
minimal change in attitude towards methadone programs, substance abuse in general, and 
knowledge of methadone among pharmacists after a structured educational training 
program in this area.118 This finding points towards a need to include training as part of 
the curriculum in pharmacy schools itself, since attitudes and knowledge are more easily 
affected at a younger age. Subsequent training programs like these would then act as add-
on to the basic education. Another study evaluated attitudes towards and knowledge of 
policies in SUD treatments and harm minimization strategies among pharmacists and 
found that not all pharmacists knew what constitutes legitimate dispensing practices for 
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controlled substances under federal or state regulations, especially in emergencies or for 
patients with terminal illnesses like cancer. Also, many were unaware of the important 
differences among addiction, physical dependence, and tolerance. Moreover, many 
pharmacists did not view chronic prescribing or dispensing of opioids for longer periods 
to chronic pain patients as a lawful and acceptable medical practice. This was particularly 
true when the patient had a history of opioid use disorder, pointing towards a stigmatizing 
attitude by pharmacists towards SUD patients that would affect their practice.121 A study 
that assessed attitudes and knowledge of naloxone among pharmacists reported that they 
were willing to receive training about naloxone (n = 479, 80.5%) and provide naloxone 
with a prescription (n = 537, 90.3%) but fewer (n = 234, 40.8%) were willing to supply 
naloxone without the prescription, negating the use of harm reduction strategy of 
standing orders. Also, positive attitudes towards harm reduction in general were related to 
a higher disposition to supply naloxone with a prescription (OR = 1.15, 95% CI = 1.11-
1.19) as well as over-the-counter (OR = 1.13, 95% CI = 1.09-1.17). Moreover, 
pharmacists were rarely confident that they could identify patients with SUD (n = 203, 
34.1%) and counsel them on overdose and naloxone use (n = 190, 31.9%), indicating low 
perceived self-efficacy. On evaluating their knowledge, pharmacists seemed to fare 
poorly with mean naloxone knowledge scores of 1.8 out of 5. The study also asked the 
pharmacists for their negative attitudes towards naloxone provision and more than half of 
the sample identified lack of time, training, reimbursement, and especially lack of 
knowledge, thus establishing a relationship between attitudes and knowledge.146 Two of 
the three studies assessing student knowledge were related to evaluation of the 
curriculum and an educational workshop.54,142 The third study assessed student 
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knowledge regarding opioid substitution therapy (OST) and reported that the average 
scores on the knowledge questions were 3.7, 4.2 and 4.2 out of 8 for inexperienced, 
indirectly experienced (worked at a site that provided OST but did not practice 
themselves) and directly experienced students respectively. Overall, respondents showed 
a positive attitude towards the OST program, but only 33% of respondents said they 
would be comfortable providing OST as a new graduate.179 This indicates that providing 
training as part of the curriculum does not completely enable new pharmacists to practice 
in SUD treatment; further experience or experiential education may be necessary. 
Overall, only one of the studies evaluated the relationship between attitudes and 
knowledge levels and if one predicted the other. Further research in this area is necessary. 
 
VII] Practices 
 Papers  assessed pharmacist practices relating to naloxone, PDMP programs, 
MTM services, and general roles. A study found that 33% of the sampled pharmacists 
dispense naloxone in a community-pharmacy setting, and 67% within an outpatient 
clinic-based location, signifying that the majority (90%) of the sampled pharmacists 
dispense naloxone. 49 The main barriers to not dispensing naloxone were identified as 
out-of-pocket costs for patients; time constraints for pharmacists; and insufficient 
reimbursement for pharmacists. On the other hand, the study also identified the main 
facilitators as increased awareness among patients and family members about the need 
for naloxone, amplified consciousness of the general public, and additional training for 
pharmacists on how to counsel high-risk patients about naloxone.50  With respect to 
MTM services, a survey reported that pharmacists were not only comfortable in 
  64
providing MTM services, but were also likely to use services that aid in the development 
of MTM services and disease-state management. Moreover, they had a positive view of 
the value of such services to patients, but reported that lack of time tended to be a barrier 
to providing these services.53 With regards to syringe/needle exchange a study conducted 
in a Swiss region reported that pharmacists do not feel sufficiently assimilated in the 
network of care that is available to SUD patients like physicians, treatment clinics, and 
other facilities. The pharmacists identified a need for additional training and improved 
recognition of their role within this network.170 Another study reported that factors 
associated with non-prescription sales of syringes or needles included the resulting long 
hours of operation, the level of experience with and interest in harm reduction activities, 
and the geographical location of the practice site (presence in areas with high SUD 
prevalence). Interestingly, although access to non-prescription sale of sterile syringes was 
easy due to availability of sites in most geographical areas, access to naloxone was 
limited. The surveyed pharmacists expressed interest in naloxone education to understand 
the benefits, applications as well as the needs for effective distribution.180 This shows that 
although, barriers to practice exist, the pharmacists are motivated to improve their roles 
in distributing naloxone as a harm reduction strategy. In general, a study evaluating how 
pharmacists treat SUD patients concluded that community pharmacists were less 
confident in their ability to communicate with patients about SUD as compared to non- 
SUD scenarios.107 This is an important finding as it points towards a barrier that exists 
when dealing with SUD patients in general and not just a specific treatment or harm 
minimization strategy. Therefore, increasing their comfort level and confidence to treat 
SUD patients would help improve their practices which can be achieved by increasing 
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their knowledge and improving their attitudes towards SUD and patients with SUD. 
Additional research is required to definitely demonstrate a relationship between these 
factors. 
 
VIII] Attitudes and Practices 
Some studies discussed both attitudes and practices and evaluated a relationship 
between them. Specific practices like screening, counseling, syringe exchange and MTM 
services were discussed. One study reported that pharmacists, who expressed interest in 
being directly involved in screening and in projects that developed brief interventions for 
patients with SUD were most likely to report current screening. Pharmacists who 
reported currently screening for SUD and who reported wanting to improve the health 
and quality of life of patients who misuse or abuse prescription opioids were most likely 
to currently counsel patients while screening them.70 A study evaluated the pharmacist’s 
attitude towards and use of a PDMP program and awareness of prescription drug abuse in 
general and found that they used the PDMP program more if they were highly concerned 
about the high SUD prevalence in the community.148 A study evaluating counseling and 
PDMP roles of pharmacists concluded that older pharmacists with a BS in Pharmacy 
degree may be more disposed to provide counseling to patients with SUD, probably due 
to their longer work experience and additional CE related to SUD that they might have 
received over the years.89 In contrast, another study reported that there was evidence that 
the longer the respondent had been a community pharmacist, the greater the negatively 
stigmatizing attitudes towards patients with SUD. However, those providing services to 
these patients had more positive attitudes towards persons with HIV and drug misusers in 
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general when compared to non-providers.173 This suggests that experience with treating 
patients with SUD and not necessarily the number of years of community pharmacy 
experience is a predictor of positive attitudes towards patients with SUD. Another long-
term study that included surveying pharmacists at four different time points across a 
twenty-year period, evaluated attitudes using a scale, and its relationship to offering of 
clinical services. They found that the attitude score was consistently a significant 
predictor in all four years for SUD treatment and providing needle exchange.135 They also 
found that attitudes improved over time with more experience and in turn improved their 
practice indicating a symbiotic relationship between the two factors. 
 
IX] Attitudes, Knowledge and Practices 
 There were only two studies that assessed all three factors, one of which was 
conducted in the United States. This study evaluated a relationship between knowledge 
and practices, while relating their knowledge levels back to their education. They found 
that pharmacists (67.5%) described partaking in two hours or less of SUD education in 
pharmacy school while 29.2% reported having received no SUD education whatsoever. It 
was also reported that pharmacists who had greater amounts of SUD specific education 
were more likely to correctly answer questions relating to the science of addiction and 
substance abuse counseling. Furthermore, pharmacists who reported more education were 
more confident about counseling and counseled patients more commonly. Surprisingly, 
majority of pharmacists (53.7%) reported that they had never referred a patient to a 
physician, a treatment clinic or other services throughout their career.125 Although, the 
paper assessed knowledge and practices, attitudes towards SUD were not sufficiently 
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evaluated. The only item that appeared to address attitudes asked respondents how they 
perceived patients and their role in treating SUD. The largest number (48.9%) believed 
their role was both (healthcare provider and police) followed by pharmacists who 
reported that they perceived themselves as healthcare providers (44.1%). Very few 
(6.4%) perceived themselves only as police. Moreover, pharmacists were also asked how 
patients should be treated; as patients with brain disorders, as people with illegal 
behaviors, or as both. The majority of the pharmacists (71.3%) answered as both.125 This 
indicates a conflicted attitude towards patients with SUD and may lead to further 
stigmatizing behaviors. 
 The second study was focused on attitudes and knowledge towards a single role: 
opioid substitution treatment in a sample of Australian pharmacists. Pharmacists showed 
high levels of support for the program and most (98%) intended to provide and continue 
to provide the treatment. Sixty-four per cent of all pharmacists indicated that they were 
willing to handle additional clients. This finding was significantly higher (90%) among 
rural pharmacists. However, no other roles of the pharmacist were evaluated.126 
 
X] Policy 
 Papers mostly discussed general policy changes, with naloxone and syringe 
exchange being the focus of most studies, followed by policies concerning specific roles 
of the pharmacist like screening, MTM services, and PDMP programs. A study 
discussing implementation of a take home naloxone program identified many issues that 
need to be addressed including selecting the appropriate product for the patient, 
implementing collaborative practice agreements, providing training materials to 
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pharmacists, handling both patient and provider expectations seamlessly, increasing 
partnerships among different stakeholders, and finally the perception of the entire 
community with regards to the program.43 Another study evaluating online naloxone 
training materials for pharmacists following standing orders found that the materials had 
limited content on how to communicate with patients and caregivers.61 This demonstrates 
that policy changes need follow-up to ensure that pharmacists are provided with adequate 
support for effective implementation of the policy. Policy changes at the individual 
pharmacy level can also help improve SUD treatment. One study evaluated 
implementation of a pain management program by pharmacists for SUD patients which 
effectively addressed patient's needs while also succeeding in modifying drug-seeking 
behaviors of the patients. A significant decrease in drug usage was noted during the 
program's pilot testing period and this change was also persistent over time.46 Another 
study evaluated the development of a screening framework called the ADAPT-ITT model 
(a model for adapting evidence-based behavioral interventions to new populations in 
varied settings) that incorporated screening, intervention, prevention, and referral to 
treatment. The authors concluded that screening efforts in the model benefit most from 
pharmacists' knowledge of treatment medications. It was also noted that screening as a 
practice was most efficient when it was multidimensional (including all healthcare 
providers and in depth screening for all types of SUD) and enabled patient-centered 
interventions.71 
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XI] Summary of Review 
 Overall, the systematic literature review identified large gaps in the research 
conducted with the community pharmacist and substance use disorders. Although, 
attitudes were sufficiently evaluated, attitudes towards treatment like buprenorphine and 
naltrexone were not adequately assessed. Stigma, which is the biggest factor of overall 
attitude, was not evaluated adequately. There was a significant lack in studies assessing 
knowledge of the pharmacists. Practices were evaluated in some studies but important 
roles like screening and patient monitoring were not measured. Very few studies 
evaluated more than one of the three factors and even fewer established a relationship 
between the two factors. Only one US study evaluated all factors but only descriptively. 
This review indicates a need for a study that assesses attitudes, especially stigma, in depth 
knowledge of treatments and their practice in terms of all possible roles of the 
pharmacist. There is also a need to assess the relationship between the factors and 
evaluate the predictors of these factors. 
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Chapter 3 
METHODOLOGY 
This chapter describes the design of the study, population, the survey instrument in detail, 
data collection and data analysis. Relevant appendices are attached at the end of this 
document. 
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I] Study Design 
The study was a cross-sectional descriptive study utilizing electronic survey 
questionnaire methodology.  
 
II] Study Population 
The study population included a non-probability sample of n = 960 community 
pharmacists from the tristate area (Pennsylvania, Ohio and West Virginia) who were 
either part of the Giant Eagle Pharmacy chain (n = 910) or the alumni network of 
Duquesne University School of Pharmacy (n = 50). The email with link was sent to 
personal contacts at both sites who then sent it out to all pharmacists on their respective 
email lists. 
 
III] Instrument 
The questionnaire (Appendix 1) included mostly closed-ended questions with one 
open-ended question, with a mixture of items from a standardized instrument195 as well as 
investigator-designed items. Questions designed to collect respondent demographics were 
included.  The standardized instrument included in the survey and adapted for the study 
goals was a generalized measure of stigma regarding SUD, which is available in the 
public domain. The investigator-designed portion of the survey included items regarding 
pharmacist knowledge, attitudes towards harm reduction strategies and practices 
specifically for the screening of SUD as well as provision of medication therapy 
management and clinical services for SUD. The open-ended question was designed to 
collect information on views of the pharmacist regarding the current opioid epidemic 
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which was included at the end of the survey. The questionnaire was divided into four 
sections (followed by the open-ended question) as described in detail below: 
 
1) Background Information 
a) Demographics 
Items regarding respondent age, gender, race, pharmacy degree and other degree 
attainment (e.g. masters or PhD) with their respective year of graduation and board 
certifications were included in this sub-section. 
b) Practice Characteristics 
This sub-section included items on number of years worked in the pharmacy, 
average number of hours worked per week, number of pharmacists per shift, and 
prescriptions filled per week. Items also included how often respondents dispense SUD 
medication and the most frequently dispensed medication. Moreover, the sub-section 
consisted of questions regarding practice location, patient socioeconomic class and 
respondent position in the pharmacy (e.g. manager, owner). More than one choice could 
be selected for pharmacy position. 
c) Education 
This sub-section was focused on the SUD related education/training of 
respondents. Items asked respondents if they received SUD education in pharmacy 
school. The pharmacists who reported that they received SUD education were asked if 
the education they received was adequate to treat patients on a Likert scale from strongly 
disagree to strongly agree. Pharmacists were also asked to report if they had CE by 
marking CE in SUD and/or CE in naloxone. Finally, an item assessing their personal 
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experience with SUD was included, framed to determine if their friends, family or they 
had SUD, in order to reduce social desirability bias to an extent. 
 
2) Knowledge 
The second section on the questionnaire assessed responder knowledge on SUD 
medication, with respect to their pharmacology, regulations, dispensing, and side effects. 
The individual items (8) were developed using a medical newsletter196 and expert 
opinion. Items were designed as multiple choice or true/false questions. A personal 
response item evaluating responders’ opinion on their current knowledge of SUD 
medication was included in this section. To discourage respondents from looking up the 
answers to the questions, instructions for this section also stated that it was not a test of 
their individual knowledge but an aggregate assessment of pharmacist knowledge. 
 
3) Practice 
a) Services provided 
This sub-section assessed several possible roles that pharmacists can provide in 
the treatment of SUD patients. Primarily, an item asking respondents if they play any role 
in providing services to SUD patients and if so, which particular duties were performed, 
was included. The item evaluated roles such as dispensing medication, counseling, 
private space provision, patient monitoring, providing information on side effects, 
recommending therapy changes and referring patients to practitioners. Additionally, 
items regarding frequency of provision of MTM services and clinical services for SUD 
were included. 
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b) Screening 
Of all the services provided by pharmacists, the study aimed to focus on screening 
for SUD. Therefore, items assessing the importance of screening for SUD in the 
pharmacists’ opinion were developed. The individual items (9) were developed based on 
the ‘red flags’197 released by the CDC. Each item had a Likert scale response set 
consisting of: not important, somewhat important, very important and extremely 
important. 
 
4) Attitudes 
a) Stigma 
The standardized stigma scale called the Perceived Stigma of Substance Abuse 
Scale (PSAS)195 was utilized after minor changes for our study objective. The editing 
consisted of changing the statements from ‘Most people…’ to ‘Most pharmacists…’ and 
only six of the eight original items were incorporated in the questionnaire. The items had 
a response set of a Likert scale ranging from strongly disagree to strongly agree. 
b) Harm reduction 
The final sub-section consisted of items (4) assessing attitudes towards different 
harm reduction strategies, such as non-prescription needle dispensing, naloxone, 
suboxone and naltrexone dispensing. The items were designed as general statements 
regarding pharmacists to establish social distance and reduce social desirability bias.  
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5) Qualitative 
The survey concluded with an open-ended question asking pharmacists’ views on 
the current opioid epidemic. The question was designed to be general so as to illicit a 
wide variety of responses and views that might not have been captured in the survey, and 
also gave the opportunity to pharmacists to discuss issues that were not addressed in the 
survey but might have been important. 
 
IV] Data Collection 
1) IRB Approval and Informed Consent 
The study was approved by the Institutional Review Board (IRB) of Duquesne 
University. The proposed study acquired an “exempt” according to the category reserved 
for ‘Anonymous Surveys - No risk’ from the IRB on 03/02/2018.  Along with the 
questionnaire, the recruiting email (Appendix 2) was also submitted to the IRB for 
verification. It was used to inform respondents of the IRB approval, the anonymous, 
voluntary, and temporal (approximately 10-15 minutes) nature of the survey. As it was an 
online survey, submission of the survey was considered as consent to participate in the 
study and participants were informed of the same. No personal identifiers were collected 
or stored and the survey data was password protected. To provide an incentive to 
participate in the study the respondents were asked to provide their email in their 
responses for an opportunity to win one of twenty Amazon gift certificates ($30 value) 
based on a random drawing of all respondents. 
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2) Pilot testing 
The questionnaire was pilot tested by five community pharmacists for face and 
content validity as well as any other expertise-based suggestions. The specific questions 
used for pilot testing are included in Appendix 3. All relevant edits and comments were 
included in the survey that was sent out. 
 
3) Survey administration 
The survey was administered using Qualtrics© (Provo, UT) via an email link. The 
link was active from 03/09/2018 to 07/09/2018. The body of the email contained a brief 
description of the survey and incentive information followed by the link to the survey. 
The questionnaire was sent out in three different stages. Initially, the survey was 
distributed to a subset of pharmacists who were Giant Eagle community pharmacists 
(n=100) on 03/12/2018. This was followed by distribution of the link among Duquesne 
alumni (n =50) on 03/14/2018. Finally, the email was sent out to the complete list of 
Giant Eagle community pharmacists (n = 810) on 04/19/2018. Reminders were sent out 
on 05/03/2018 and 06/22/2018. 
 
V] Data analysis 
1) Quantitative 
The data from this study was analyzed using SPSS Statistics 21 (IBM Corp; 
Armonk, NY). Descriptive statistics was generated to assess participant demographic, 
practice, and educational characteristics, knowledge, practices, screening services, stigma 
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and attitudes. Frequencies as number and percentage or means and standard deviations 
are reported as applicable.  
The knowledge questions (8) were also used as a scale with each correct response 
receiving one point. Therefore, the highest knowledge scores a respondent may receive is 
8. To assess the reliability of the scale, a Kuder-Richardson 20 (KR-20) correlation 
coefficient was used as binary variables (1= correct, 0 = incorrect) were used in the scale 
and the questions had varying difficulty levels. 
Apart from frequencies of each duty performed in the practice question, a practice 
scale was also developed. The pharmacists scored one point for each duty that they did 
perform for a highest possible total of seven. To assess the reliability of the scale, a KR-
20 coefficient was used because of the presence of all binary variables in the scale (1 = if 
they perform the duty, 0 = if they don’t perform the duty) and the duties had varying 
importance in practice. 
For the screening sub-section individual frequencies of all possible responses of 
every item was assessed and a scale was developed as well. The scale was scored as 1= 
not important, 2 = somewhat important, 3 = very important and 4 = extremely important. 
The mean score and standard deviations of all items were assessed and a total mean and 
standard deviation of all pharmacists on all items were calculated. 
Individual frequencies of all possible responses of every item on the standardized 
stigma scale were assessed. The stigma scale was developed where 1 = strongly disagree, 
2 = disagree, 3 = agree and 4 = strongly agree. Mean responses with standard deviations 
of all items were calculated.  Finally, the mean score of all pharmacists on the stigma 
scale from one to four where 1= highest stigma and 4 = least stigma was also reported. 
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One item ‘most pharmacists think less...’ was reverse coded so that all items are 
directionally aligned for this calculation. Reliability statistics were performed using the 
response set of strongly disagree to strongly agree as a continuous scale. 
With regards to the attitude statements, frequencies of every possible response on 
each item were reported. An attitude scale was developed where 1= strongly disagree, 2 = 
disagree, 3 = agree and 4 = strongly agree. Mean scores and standard deviations of 
individual items were also reported. Finally, the mean score of all pharmacists on the 
overall attitude scale is reported which could therefore range from one to four, where 1 
was negative and 4 was positive attitude. The questions regarding buprenorphine and 
naltrexone were reverse coded for this calculation. Reliability statistics were performed 
using the response set of strongly disagree to strongly agree as a continuous scale. 
Differences in knowledge, stigma and practice scores were stratified by specific 
demographic variables such as, age (≥40 and <40), gender, degree attained (PharmD and 
BS in Pharmacy), whether or not they had SUD education as part of their curriculum, and 
personal experience with SUD. Pharmacists who did not wish to disclose whether or not 
they had personal experience were not included in the analysis. Independent sample t 
tests were performed at the 0.05 (α) significance level. The mean stigma scores and 
standard deviations of each group were reported along with the t-values and 
corresponding significance.  
The following were calculated: mean differences in knowledge, stigma and 
practice scores among pharmacy location groups (rural, suburban and urban), patient 
socioeconomic levels (impoverished, low, middle and high income), frequency of MTM 
services and clinical services, and their responses on the attitude questions. One-way 
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ANOVA tests were performed. The mean practice scores and standard deviations of each 
group were reported along with the F-values and corresponding significance.  
 Factors like knowledge, stigma and practice scores were correlated to practice 
variables like number of years worked, number of hours worked per week, SUD 
prescriptions dispensed per week, adequacy of SUD education and screening score. 
Bivariate correlations were performed. Analysis also included building four regression 
models to predict (1) knowledge levels specific to SUD, (2) engagement of pharmacists 
in clinical services for SUD, (3) engagement of pharmacists in assessment for potential 
prescription drug abuse (screening), and (4) level of stigma towards the patient. 
 A multiple linear regression analysis was conducted to predict knowledge scores. 
The predictors planned to be included in the model were age, degree attained, SUD 
education, personal experience, CE in SUD, gender, CE on naloxone, number of years 
worked, SUD medication dispensing frequency and stigma mean scores. The VIF statistic 
was used to check for multi-collinearity. Due to high correlations between the planned 
predictor variables, age, degree attained and SUD education, these variables were 
removed from the model. The assumptions for linear regression were evaluated before 
running the model. Independence of observations was assessed using the Durbin-Watson 
statistic. Normality of the model was evaluated by using the residual histogram and the 
normal predicted probability (P-P) plot. Homoscedasticity of the model was observed by 
using the scatterplot of the residuals. Linearity of data would be thus implied, if the above 
assumptions were met.  
 An ordinal regression was carried out to predict practice or the frequency of 
pharmacists offering clinical services to SUD patients. The variables included in the 
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model were stigma mean scores, knowledge mean scores, attitude mean scores, practice 
scores, gender and personal experience. The assumptions of ordinal regression were 
evaluated before conducting the analysis. Multi-collinearity was checked for by running a 
multiple linear regression, following which age, degree attained, and SUD education 
were removed from the model due to high correlations. Occurrence of proportional odds 
was evaluated by the test of parallel lines. 
 A multiple linear regression model was planned to predict screening scores. The 
predictors included in the model were age, degree attained, SUD education, personal 
experience, gender, knowledge, number of years worked and stigma mean scores. The 
VIF statistic was used to check for multi-collinearity. Due to significant correlations 
between the originally planned predictor variables, age, degree attained, and SUD 
education, these variables were removed from the model. The assumptions for linear 
regression were evaluated before running the model. Independence of observations was 
assessed using the Durbin-Watson statistic. Normality of the model was evaluated by 
looking at the residual histogram and the normal predicted probability (P-P) plot. The 
dependent variable or screening mean score was converted to its square root form 
because it failed to meet this assumption. Homoscedasticity of the model was evaluated 
by looking at the scatterplot of the residuals. Linearity of data would be thus implied, if 
the model met the above assumptions.  
 A multiple linear regression model was planned to predict stigma scores. 
However, the model failed the tests of assumptions of regression. As transformations did 
not help produce a valid model, a new stigma scale was developed. In this scale only sum 
of the individual responses was used instead of the means. From the questionnaire, the 
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response scale was 1 = strongly disagree, 2 = disagree, 3 = agree and 4 = strongly agree 
and there were six items in the stigma section. Therefore, stigma scores could range from 
6 to 24, with 6 being highest stigma and 24 being least stigma. One item was recoded for 
this calculation. Based on the frequency distribution of these scores three categories of 
stigma (high, medium and low) were developed. Subsequently, an ordinal regression was 
carried out to predict stigma scores. However, the originally planned predictor 
combination failed the tests for parallel lines. Therefore, the research question was 
changed with predictors like MTM services and screening scores added based on 
previously found significant correlations. Based on literature, where pharmacy factors 
like location site and patient socioeconomic class were found to be significantly 
correlated with stigma, these were added to the model as well. Multi-collinearity was 
checked by running a multiple linear regression, following which age, degree attained, 
pharmacy location, knowledge scores and SUD education were removed from the model 
due to high correlations. The variables finally included in the model were screening 
scores, practice scores, patient socioeconomic class, MTM services, and CE in SUD. The 
assumptions of ordinal regression were evaluated before conducting the analysis. 
Occurrence of proportional odds was evaluated by the test of parallel lines. 
 
2) Qualitative 
 Content analysis including axial analysis198 on the obtained responses was 
performed. Codes were developed based on an iterative process. The codebook 
(Appendix 4) contained twenty codes that included themes such as overprescribing, 
policy recommendations, education, and stigma. This was followed by axial analysis of 
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protocols that established relationships between the codes. Axial analysis consisted of 
identifying relationships between the identified themes and picking the most frequently 
occurring relationships. These themes were then assessed to look at the corresponding 
intervening codes, codes that are consequences of the theme, intervening codes and codes 
that appear to be action strategies.  
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Chapter 4 
RESULTS 
This chapter includes description of the response rate and tables consisting of the results 
of the data analysis (Table 3 to Table 32). All tables are preceded by a short description 
in which significant results have been mentioned and explained. 
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I] Response rate 
 The survey was sent out to 960 community pharmacists and received 134 
responses (partial and complete) leading to a response rate of 13.96% for the quantitative 
survey. Of the 134 pharmacists who responded to the survey, 52 (38.81%) answered the 
open-ended question. Fifty responses were usable and were included in the qualitative 
analysis. Forty-three (32.08%) responses were received from the initial cohort of 100 
Giant Eagle and 50 Duquesne University pharmacists. A total of 82 (61.19%) responses 
were received after the email was sent out to the final list. The number of responses 
received after the two reminders were 6 (4.47%) and 3 (2.24%) respectively.  
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II] Descriptive 
Table 3 presents self- reported demographic data. The average age of the respondents 
was 38.3 years (SD = 10.69) with almost 62% of the respondents below 40 years of age. 
The majorly of the respondents were female and Caucasian and had obtained the Pharm 
D (vs the BS) degree. Only 20 (14.92%) respondents reported that they had obtained 
other degrees apart from their pharmacy degrees, primarily consisting of Bachelor 
degrees in various fields.  
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Table 3: Demographics (n = 134) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
# Age categories were arbitrary 
^ Questions the responders viewed but chose not to answer. 
  
Variable Number (Percentage) Mean (Standard deviation) 
   
Age (years)  38.30 (10.69) 
Less than 40# 83 (61.9)  
40 and greater 49 (36.6)  
Not answered^ 2 (1.5)  
   
Gender   
Male 50 (37.3)  
Female 82 (61.2)  
Not answered^ 2 (1.5)  
   
Race   
Caucasian 121 (90.3)  
African American 3 (2.2)  
Asian 5 (3.7)  
American Indian 0 (0.0)  
Hispanic 1 (0.7)  
Pacific Islander 0 (0.0)  
Other 2 (1.5)  
   
Degree attained   
Pharm D 87 (64.9)  
BS Pharmacy 44 (32.8)   
Not answered^ 3 (2.2)  
   
Other degrees   
Masters 3 (2.2)  
PhD 2 (1.5)  
Other 15 (11.2)  
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Table 4 presents data regarding self - reported practice characteristics of the pharmacists. 
About 88% of the pharmacists answered the question regarding their work experience 
and on average had worked for about 15 years. The same pharmacists reported that they 
worked for about 37 hours per week and on average two to three pharmacists worked per 
shift at their pharmacies. The number of prescriptions filled per week varied from as low 
as 75 to as high 10,000 resulting in a mean of 2105.17 and a large standard deviation of 
1262.24. This was due to the presence of a few outliers in the case of part-time workers 
and one respondent with the high response, who probably worked in a large organization. 
Invalid responses were from pharmacists who stated they work in call centers or float 
among different pharmacies and responded “varies” or “not applicable”. Buprenorphine-
naloxone (Suboxone®) was the most commonly dispensed SUD medication. The majority 
of pharmacists reported that they dispensed SUD prescriptions ‘sometimes’ in any given 
week. Practice location was primarily sub-urban and patients belonged to low and 
middle-income socioeconomic classes according to the pharmacists. Respondents were 
mostly full-time pharmacists and pharmacy managers.  
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Table 4: Practice Characteristics (n = 134) 
Variable Number (Percentage) Mean Standard Deviation 
    
Number of years worked  15.06 9.82 
Responded 118 (88.06)   
Not answered^ 2 (1.5)   
Missing$ 14 (10.4)   
    
Number of hours/week  37.13 9.49 
Responded 118 (88.06)   
Not answered^ 2 (1.5)   
Missing$ 14 (10.4)   
    
Pharmacists/shift  2.26 3.00 
Responded 118 (88.06)   
Not answered^ 2 (1.5)   
Missing$ 14 (10.4)   
    
Prescriptions filled /week  2105.17 1262.24 
Valid responses 116 (86.57)   
Not answered^ 2 (1.5)   
Missing$ 14 (10.4)   
Not applicable 2 (1.5)   
    
SUD prescriptions/week  3.08# 0.97 
Never 9 (6.7)   
Rarely 23 (17.2)   
Sometimes 35 (26.1)   
Frequently 51 (38.1)   
Not answered^ 2 (1.5)   
Missing$ 14 (10.4)   
    
SUD Medication    
Buprenorphine-naloxone 55 (41.0)   
Buprenorphine 33 (24.6)   
Naloxone 12 (9.0)   
Naltrexone 6 (4.5)   
Other 3 (2.2)   
Not applicable 2 (1.5)   
Not answered^ 9 (6.7)   
Missing$ 14 (10.4)   
    
Practice Location    
Urban 26 (19.4)   
Sub-urban 71 (53.0)   
Rural 21 (15.7)   
Not answered^ 2 (1.5)   
Missing$ 14 (10.4)   
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Patient Socioeconomic 
Class 
   
Impoverished 7 (5.2)   
Low 51 (38.1)   
Middle 51 (38.1)   
High 6 (4.5)   
Not answered^ 5 (9.7)   
Missing$ 14 (10.4)   
    
Pharmacy Position@    
Full time staff pharmacist 56 (41.8)   
Part time staff pharmacist 21 (15.7)   
Pharmacy Manager 40 (29.9)   
Pharmacy Owner 3 (2.2)   
Not answered^ 5 (3.7)   
Missing$ 12 (9.0)   
    
#  Mean of all responses measured on a scale from 1 to 4 (where 1= Never, 2= Rarely, 3= Sometimes and 4= 
Frequently) 
^ Questions the responders viewed but chose not to answer. 
$ Questions the responders did not view. 
@ More than one choice could be selected for pharmacy position and so the frequencies do not add up to 134. 
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Table 5 presents educational characteristics of pharmacists. A total of 71 pharmacists 
(53%) reported that they received SUD education as part of their curriculum. The 
majority (59.2%) of these pharmacists agreed that this education was adequate to treat 
patients. With regards to CE, 73 (54.5%) and 91(67.9%) pharmacists reported that they 
have had CE in SUD and naloxone respectively. Since, there was no option to choose if 
they hadn’t received CE, no conclusion can be drawn on the responders who did not 
choose either CE. Although a majority (64.2%) of pharmacists reported that they have no 
personal experience with SUD, 22.4% reported that they did. 
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Table 5: Educational Characteristics (n=134) 
Variables Number 
(Percentage) 
Mean Standard Deviation 
    
SUD Education    
Yes 71 (53.0)   
No 48 (35.8)   
Not answered^ 1 (0.7)   
Missing$ 14 (10.4)   
    
Adequacy of SUD education (n =71) 71 (53.0) 2.63# 0.59 
Strongly disagree 2 (2.8)   
Disagree 24 (33.8)   
Agree 42 (59.2)   
Strongly agree 2 (2.8)   
Not answered^ 1 (1.4)   
    
Continuous education     
SUD 73 (54.5)   
Naloxone 91 (67.9)   
    
Personal experience    
Yes 30 (22.4)   
No 86 (64.2)   
Prefer not to disclose 2 (1.5)   
Not answered^ 1 (0.7)   
Missing$ 15 (11.2)   
    
#   Mean of all responses measured on a scale from 1 to 4 (where 1 = Strongly disagree, 2 = Disagree, 3 = Agree and 
4 = Strongly agree). 
^ Questions the responders viewed but chose not to answer. 
$ Questions the responders did not view. 
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Table 6 presents data on the questions in the knowledge section. Questions are listed 
individually with frequencies of each possible response reported. Only three items did not 
have a clear majority, namely- ‘-- is an opioid receptor antagonist’, ‘buprenorphine 
potentiates opioids’ and ‘naltrexone started within 7 days…’ This shows that there wasn’t 
consensus on these items unlike other items that were easier to answer. 
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Table 6: Knowledge (Individual items) (n=134) 
Item and responses Number (Percentage) 
  
--- is a Schedule III controlled substance.  
Naloxone 4 (3.0) 
Buprenorphine# 100 (74.6) 
Naltrexone 2 (1.5) 
Not sure 2 (1.5) 
Not answered^ 1 (0.7) 
Missing$ 25 (18.7) 
  
--- is an opioid receptor antagonist and can reduce tolerance to opioids.  
Naloxone 26 (19.4) 
Buprenorphine 11 (8.2) 
Naltrexone# 61 (45.5) 
Not sure 9 (6.7) 
Not answered^ 2 (1.5) 
Missing$ 25 (18.7) 
  
-- is the drug of choice for emergency treatment of opioid overdose.  
Naloxone# 102 (76.1) 
Buprenorphine 0 (0.0) 
Naltrexone 6 (4.5) 
Not sure 0 (0.0) 
Not answered^ 1 (0.7) 
Missing$ 25 (18.7) 
  
Is a prescription required for dispensing naloxone in your state?  
Yes 16 (11.9) 
No# 90 (67.2) 
Not sure 2 (1.5) 
Not answered^ 1 (0.7) 
Missing$ 25 (18.7) 
  
Buprenorphine can be used to potentiate opioids.  
True 50 (37.3) 
False# 33 (24.6) 
Not sure 25 (28.7) 
Not answered^ 1 (0.7) 
Missing$ 25 (18.7) 
  
Naloxone can be administered orally.  
True 22 (16.4) 
False# 83 (61.9) 
Not sure 3 (2.2) 
Not answered^ 1 (0.7) 
Missing$ 25 (18.7) 
  
Opioid administration to a patient on naltrexone is an effective pain management 
strategy. 
 
True 2 (1.5) 
False# 99 (73.9) 
Not sure 7 (5.2) 
Not answered^ 1 (0.7) 
Missing$ 25 (18.7) 
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Naltrexone can be started within 7 days of last opioid therapy  
True 44 (32.8) 
False# 23 (17.2) 
Not sure 41 (30.6) 
Not answered^ 1 (0.7) 
Missing$ 25 (18.7) 
  
^ Questions the responders viewed but chose not to answer. 
$ Questions the responders did not view. 
# Correct answers 
 
  
  95
Table 7 presents the knowledge questions as a scale with frequencies of correct answers. 
The total mean is the mean of all responders’ scores. ‘—is drug of choice for emergency…’ 
and ‘—is schedule III…’ were the questions with the highest frequency of correct answers 
(76.1% and 74.6% respectively). In contrast, pharmacists fared poorly on naltrexone can 
be started…’ and ‘buprenorphine can potentiate…’ with only 17.2% and 24.6% of correct 
answers respectively. On the item assessing responders’ opinion on their current 
knowledge level regarding SUD medication therapy, most pharmacists agreed that they 
had good current knowledge. 
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Table 7: Knowledge Scale (n = 134) 
Item Correct 
Number 
(Percentage) 
Mean  Standard 
Deviation 
    
I have good current knowledge on medication therapy for SUD  2.93# 0.59 
Strongly disagree 3 (2.2)   
Disagree 14 (10.4)   
Agree 79 (59.0)   
Strongly agree 12 (9.0)   
Not answered^ 1(0.7)   
Missing$ 25 (18.7)   
    
Q1. --- is a Schedule III controlled substance. 100 (74.6)   
    
Q2. --- is an opioid receptor antagonist and can reduce tolerance to 
opioids. 
61 (45.5)   
    
Q3. -- is the drug of choice for emergency treatment of opioid 
overdose. 
102 (76.1)   
    
Q4.  Is a prescription required for dispensing naloxone in your state? 90 (67.2)   
    
Q5.  Buprenorphine can be used to potentiate opioids. 33 (24.6)   
    
Q6.  Naloxone can be administered orally. 83 (61.9)   
    
Q7. Opioid administration to a patient on naltrexone is an effective 
pain management strategy. 
99 (73.9)   
    
Q8. Naltrexone can be started within 7 days of last opioid therapy. 23 (17.2)   
 
Total  5.52@ 1.20 
    
# Mean of all responses measured on a scale from 1 to 4 (where 1 = Strongly disagree, 2 = Disagree, 3 = Agree and 4 
= Strongly agree) 
@ Mean knowledge score of all pharmacists on a scale of 0 to 8. 
^ Questions the responders viewed but chose not to answer. 
$ Questions the responders did not view. 
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Table 8 presents reliability statistics of the knowledge scale. The KR-20 coefficient was 
high (0.84) indicating that it is a reliable scale for this population. This result occurred 
despite varying correlations from low (0.104) to high (0.759) among the individual items
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Table 8: Reliability Statistics of Knowledge Scale: Inter-correlation matrix (n =134) 
 
 Q1 Q2 Q3 Q4 Q5 Q6 Q7 Q8 
Q1 1.000 .464 .759 .615 .293 .567 .746 .174 
Q2 .464 1.000 .477 .352 .104 .470 .441 .180 
Q3 .759 .477 1.000 .615 .280 .606 .743 .162 
Q4 .615 .352 .615 1.000 .141 .467 .633 .192 
Q5 .293 .104 .280 .141 1.000 .234 .261 .153 
Q6 .567 .470 .606 .467 .234 1.000 .514 .153 
Q7 .746 .441 .743 .633 .261 .514 1.000 .226 
Q8 .174 .180 .162 .192 .153 .153 .226 1.000 
Standardized KR-20 coefficient: 0.84
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Table 9 presents results of the practice section. There was almost an equal distribution 
between respondents who played a role in SUD services and those who didn’t. The 56 
(41.8%) pharmacists who played a role in SUD services were asked to specify which 
duties they perform on the practice scale. The mean score on the practice scale (3.53) was 
low. The table also reported how often pharmacists performed MTM services in general 
and clinical services for SUD patients. On average, pharmacists reported that they rarely 
performed both these services.  
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Table 9: SUD related practice (n= 134) 
Variable Number 
(Percentage) 
Mean Standard Deviation 
    
Role in SUD services    
Yes 56 (41.8)   
No 52 (38.8)   
Not answered^ 1 (0.7)   
Missing$ 25 (18.7)   
    
Duties/ Practice Scale  56 (41.8) 3.53@ 1.76 
Dispensing medication 46 (34.3)   
Counseling patients 41 (30.6)   
Provision of private space 30 (22.4)   
Patient monitoring/assisting self-monitoring 13 (9.7)   
Advising about side effects 28 (20.9)   
Recommending/advocating therapy changes 19 (14.2)   
Referring patients to practitioners 9 (6.7)   
Not answered^ 1 (0.7)   
Missing$ 3 (2.2)   
    
MTM services  2.31# 1.08 
Never 31 (23.1)   
Rarely 25 (18.7)   
Sometimes 29 (21.6)   
Frequently 17 (12.7)   
Not answered^ 1 (0.7)   
Missing$ 31 (23.1)   
    
Clinical services  1.85# 0.73 
Never 33 (24.6)   
Rarely 52 (38.8)   
Sometimes 14 (10.4)   
Frequently 2 (1.5)   
Not answered^ 2 (1.5)   
Missing$ 31 (23.1)   
    
@ Mean practice score of all pharmacists on a scale of 0 to 7. 
# Mean of all responses measured on a scale from 1 to 4 (where 1= Never, 2= Rarely, 3= Sometimes and 4= 
Frequently) 
^ Questions the responders viewed but chose not to answer. 
$ Questions the responders did not view. 
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Table 10 presents reliability statistics of the practice scale.  The overall reliability of the 
scale was not extremely high (KR-20 = 0.66). This was probably due to the negative 
correlation of patient monitoring with dispensing and counseling duties.
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Table 10: Reliability Statistics of Practice Scale: Inter correlation matrix (n = 56) 
 
 Dispensing 
medication 
Counseling 
patients 
Provision of 
private space 
Patient 
monitoring/assisting 
self-monitoring 
Advising about 
side effects 
Recommending/
advocating 
therapy changes 
Referring 
patients to 
practitioners 
Dispensing 
medication 
 
1.000 .625 .108 -.037 .078 .059 .176 
Counseling patients 
 
.625 1.000 .303 -.033 .262 .286 .231 
Provision of private 
space 
.108 .303 1.000 .234 .393 .178 .193 
Patient 
monitoring/assisting 
self-monitoring 
-.037 -.033 .234 1.000 .275 .214 .326 
Advising about side 
effects 
.078 .262 .393 .275 1.000 .312 .025 
Recommending/adv
ocating therapy 
changes 
.059 .286 .178 .214 .312 1.000 .291 
Referring patients 
to practitioners 
.176 .231 .193 .326 .025 .291 1.000 
Standardized KR-20 coefficient = 0.66
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Table 11 reports the results on the screening scale. Of the pharmacists who responded to 
this section, most pharmacists reported that all the red flags were ‘extremely important’. 
However, due to missing data the average response on all items individually tended 
towards ‘very important’. Finally, the mean score of all pharmacists on the overall 
screening scale (3.40) indicated that pharmacists are of the opinion that screening is very 
important. 
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Table 11: Screening scale (n =134) 
Red Flag (RF) Number 
(Percentage) 
Mean Standard 
Deviation 
    
RF 1. Repeatedly receiving "cocktailed" prescriptions  3.43# 0.66 
Not important 0 (0.0)   
Somewhat important 9 (6.7)   
Very important 38 (28.4)   
Extremely important 51 (38.1)   
Not answered^ 5 (3.7)   
Missing$ 31 (23.1)   
    
RF 2. Failure of prescribers to individualize dosing strategies for patients  3.07# 0.82 
Not important 3 (2.2)   
Somewhat important 20 (14.9)   
Very important 42 (31.3)   
Extremely important 33 (24.6)   
Not answered^ 5 (3.7)   
Missing$ 31 (23.1)   
    
RF 3. Receiving multiple prescriptions for the strongest/most addiction-prone 
formulations 
 3.44# 0.66 
Not important 0 (0.0)   
Somewhat important 9 (6.7)   
Very important 37 (27.6)   
Extremely important 52 (38.8)   
Not answered^ 5 (3.7)   
Missing$ 31 (23.1)   
    
RF 4. Requests for early refills from patients  3.50# 0.65 
Not important 1 (0.7)   
Somewhat important 5 (3.7)   
Very important 36 (26.9)    
Extremely important 56 (41.8)   
Not answered^ 5 (3.7)   
Missing$ 31 (23.1)   
    
RF 5. Prescribers located far away from pharmacy sending prescription 
requests 
 3.50# 0.72 
Not important 1 (0.7)   
Somewhat important 10 (7.5)   
Very important 26 (19.4)   
Extremely important 61 (45.5)   
Not answered^ 5 (3.7)   
Missing$ 31 (23.1)   
    
RF 6. Receiving a large volume of prescriptions for controlled substances by 
one particular physician 
 3.43# 0.76 
Not important 1 (0.7)   
Somewhat important 13 (9.7)   
Very important 27 (20.1)   
Extremely important 57 (42.5)   
Not answered^ 5 (3.7)   
Missing$ 31 (23.1)   
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RF 7. Patients travelling in groups to the pharmacy to pick up controlled 
substances 
 3.59# 0.68 
Not important 1 (0.7)   
Somewhat important 7 (5.2)   
Very important 22 (16.4)   
Extremely important 65 (48.5)   
Not answered^ 8 (6.0)   
Missing$ 31 (23.1)   
    
RF 8. Receiving requests for controlled substance prescriptions to be paid for 
with cash 
 3.48# 0.65 
Not important 0 (0.0)   
Somewhat important 8 (6.0)   
Very important 35 (26.1)   
Extremely important 55 (41.0)   
Not answered^ 5 (3.7)   
Missing$ 31 (23.1)   
    
RF 9. Prescribers verifying prescriptions as legitimate when contacted, but 
without explanation other than their own directive 
 3.36# 0.84 
Not important 3 (2.2)   
Somewhat important 14 (10.4)   
Very important 26 (19.4)   
Extremely important 55 (41.0)   
Not answered^ 5 (3.7)   
Missing$ 31 (23.1)   
    
Total  3.40@ 0.49 
    
^Not answered were questions the responders viewed but chose not to answer. 
$ Missing were questions the responders did not view. 
# Mean of all responses measured on a scale from 1 to 4 (where 1= Not important, 2= Somewhat important, 3= Very important 
and 4= Extremely important) 
@ Mean screening score of all pharmacists on a scale of 1 to 4 (where 1= Not important, 2= Somewhat important, 3= Very 
important and 4= Extremely important) 
 
  
  106
Table 12 presents reliability statistics of the screening scale. The scale proved to be 
extremely reliable in this population with a reliability coefficient of 0.99.  This was 
probably because only one item was not strongly correlated with the others (RF 7 or 
‘patients traveling in groups…’) with high correlations between other red flags.
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Table 12: Reliability statistics of Screening Scale: Inter correlation matrix (n =103) 
 
 RF 1 RF 2 RF 3 RF 4 RF 5 RF 6 RF 7 RF 8 RF 9 
RF 1 1.000 .999 1.000 1.000 .999 .99 .777 .999 .999 
RF 2 .999 1.000 .999 .999 .999 .999 .778 .999 .999 
RF 3 1.000 .999 1.000 1.000 1.000 .999 .780 .999 .999 
RF 4 1.000 .999 1.000 1.000 1.000 .999 .779 .999 .999 
RF 5 .999 .999 1.000 1.000 1.000 .999 .777 1.000 .999 
RF 6 .999 .999 .999 .999 .999 1.000 .777 .999 .999 
RF 7 .777 .778 .780 .779 .777 .777 1.000 .777 .775 
RF 8 .999 .999 .999 .999 1.000 .999 .777 1.000 .999 
RF 9 .999 .999 .999 .999 .999 .999 .775 .999 1.000 
Standardized Cronbach’s Apha = 0.99 
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Table 13 presents the results of the stigma scale. Most pharmacists disagreed on all 
statements, indicating a stigmatizing attitude on all statements except the ‘Most 
pharmacists think less...’ statement. The mean scores on each item were less than three 
which proved the same result. On average, pharmacists scored a total of 2.19 out of 4 on 
the stigma scale indicating prevalence of stigmatizing attitudes.   
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Table 13: Stigma scale (n = 134) 
Item Number 
(Percentage) 
Mean Standard 
Deviation 
    
Most pharmacists would willingly accept someone who has 
been treated for substance use as a close friend. 
 2.39# 0.64 
Strongly disagree 5 (3.7)   
Disagree 50 (37.3)   
Agree 35 (26.1)   
Strongly agree 3 (2.2)   
Not answered^ 1 (0.7)   
Missing$ 40 (29.9)   
    
Most pharmacists believe that someone who has been treated 
for substance use is just as trustworthy as the average citizen. 
 2.26# 0.59 
Strongly disagree 6 (4.5)   
Disagree 59 (44.0)   
Agree 28 (20.1)   
Strongly agree 1 (0.7)   
Not answered^ 0 (0.0)   
Missing$ 40 (29.9)   
    
Most pharmacists would accept someone who has been treated 
for substance use as a teacher of young children in a public 
school. 
 2.51# 0.53 
Strongly disagree 7 (5.2)   
Disagree 65 (48.5)   
Agree 21 (15.7)   
Strongly agree 0 (0.0)   
Not answered^ 1 (0.7)   
Missing$ 40 (29.9)   
    
Most pharmacists would hire someone who has been treated 
for substance use to take care of their children. 
 1.70# 0.60 
Strongly disagree 35 (26.1)   
Disagree 52 (38.8)   
Agree 7 (5.2)   
Strongly agree 0 (0.0)   
Not answered^ 0 (0.0)   
Missing$ 40 (29.9)   
    
Most pharmacists think less of a person who has been in 
treatment for substance use.& 
 2.38# 0.62 
Strongly disagree 4 (3.0)   
Disagree 53 (39.6)   
Agree 33 (24.6)   
Strongly agree 3 (2.2)   
Not answered^ 1 (0.7)   
Missing$ 40 (29.9)   
    
Most pharmacists would be willing to date someone who has 
been treated for substance use. 
 2.09# 0.70 
Strongly disagree 19 (14.2)   
Disagree 48 (35.8)   
Agree 27 (20.1)   
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Strongly agree 0 (0.0)   
Not answered^ 0 (0.0)   
Missing$ 40 (29.9)   
    
Total  2.19@ 0.43 
    
 ^ Questions the responders viewed but chose not to answer. 
$ Questions the responders did not view. 
# Mean of all responses measured on a scale from 1 to 4 (where 1 = Strongly disagree, 2 = Disagree, 3 = Agree and 4 
= Strongly agree) 
& Item is reverse coded for mean calculations. 
@ Mean stigma score of all pharmacists on a scale from 1 to 4(where 1 = Strongly disagree, 2 = Disagree, 3 = Agree 
and 4 = Strongly agree) and (where 1 = Highest stigma and 4 = Lowest stigma) 
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Table 14 presents reliability statistics of the stigma scale. The stigma scale demonstrated 
limited reliability in this sample as the standardized and non-standardized correlation 
coefficient was 0.63 was 0.50 respectively. This could be due to the particular sample or 
due to the elimination of two items from the original scale which reduced the overall 
reliability of the scale.
  
112 
Table 14: Reliability statistics of stigma scale: Inter correlation matrix (n =94) 
 … as a 
close 
friend. 
… is just as 
trustworthy as 
the average 
citizen. 
… as a teacher of 
young children 
in a public 
school. 
…hire someone who 
has been treated for 
substance use to take 
care of their 
children. 
…think less of a 
person who has 
been in 
treatment for 
substance use. 
… willing to date 
someone who has 
been treated for 
substance use. 
… as a close 
friend. 
1.000 .071 .998 .136 .000 .180 
… is just as 
trustworthy as the 
average citizen. 
.071 1.000 .071 .401 .052 .367 
… as a teacher of 
young children in 
a public school. 
.998 .071 1.000 .151 -.002 .183 
… hire someone 
who has been 
treated for 
substance use to 
take care of their 
children. 
.136 .401 .151 1.000 .131 .445 
… think less of a 
person who has 
been in treatment 
for substance use. 
.000 .052 -.002 .131 1.000 .180 
…willing to date 
someone who has 
been treated for 
substance use. 
.180 .367 .183 .445 .180 1.000 
Standardized Cronbach’s alpha = 0.63
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Table 15 presents the results of the attitude scale. With respect to frequencies of 
responses on individual items and average attitude score on individual items, pharmacists 
showed a moderate positive attitude. However, the mean score of all pharmacists on the 
attitude scale showed was slightly negative (2.25 out of 4). 
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Table 15: Attitude Scale (n =134) 
Item Number 
(Percentage) 
Mean Standard 
Deviation 
    
Pharmacists dispensing needles without prescriptions (or a 
demonstrated legitimate medical need) leads to an increase 
in frequency of substance abuse. 
 2.29# 0.89 
Strongly disagree 16 (11.9)   
Disagree 46 (34.3)   
Agree 21 (15.7)   
Strongly agree 11 (8.2)   
Not answered^ 0 (0.0)   
Missing$ 40 (29.9)   
    
Pharmacists dispensing naloxone acts as a safety net 
leading to an increase (or encouragement) in substance 
abuse.& 
 2.22# 0.72 
Strongly disagree 14 (10.4)   
Disagree 47 (35.1)   
Agree 31 (23.1)   
Strongly agree 2 (1.5)   
Not answered^ 0 (0.0)   
Missing$ 40 (29.9)   
    
Dispensing buprenorphine/naloxone (Suboxone®) is an 
effective way for pharmacists to assist in the overall 
treatment of SUD.& 
 2.74# 0.62 
Strongly disagree 2 (1.5)   
Disagree 27 (20.1)   
Agree 57 (42.5)   
Strongly agree 7 (5.2)   
Not answered^ 1 (0.7)   
Missing$ 40 (29.9)   
    
Pharmacists dispensing oral/long acting naltrexone is an 
effective method to treat SUD. 
 2.73# 0.64 
Strongly disagree 3 (2.2)   
Disagree 26 (19,4)   
Agree 58 (43.3)   
Strongly agree 7 (5.2)   
Not answered^ 0 (0.0)   
Missing$ 40 (29.9)   
    
Total  2.25@ 0.47 
    
^ Questions the responders viewed but chose not to answer. 
$ Questions the responders did not view. 
# Mean of all responses measured on a scale from 1 to 4 (where 1 = Strongly disagree, 2 = Disagree, 3 = Agree and 4 
= Strongly agree). 
& Item reverse coded for mean calculations. 
@ Mean score of all pharmacists on the attitude scale. 
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Table 16 presents reliability statistics of the attitude scale. The reliability of the scale was 
extremely low (0.24). This was probably because the scale measured attitudes towards 
two distinct topics:- harm minimization and SUD treatment.
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  Table 16: Correlation coefficient: Inter correlation matrix (n = 94) 
 
 Pharmacists dispensing 
needles without 
prescriptions leads to an 
increase in frequency of 
substance abuse. 
Pharmacists dispensing 
naloxone acts as a 
safety net leading to an 
increase (or 
encouragement) in 
substance abuse. 
Dispensing 
buprenorphine/naloxone 
(Suboxone®) is an effective way 
for pharmacists to assist in the 
overall treatment of SUD. 
Pharmacists dispensing 
oral/long acting naltrexone is 
an effective method to treat 
SUD. 
Pharmacists dispensing 
needles without 
prescriptions leads to an 
increase in frequency of 
substance abuse. 
1.000 .302 -.193 .280 
Pharmacists dispensing 
naloxone acts as a safety 
net leading to an increase 
(or encouragement) in 
substance abuse. 
.302 1.000 -.104 .079 
Dispensing 
buprenorphine/naloxone 
(Suboxone®) is an 
effective way for 
pharmacists to assist in the 
overall treatment of SUD. 
-.193 -.104 1.000 .081 
Pharmacists dispensing 
oral/long acting naltrexone 
is an effective method to 
treat SUD. 
.280 .079 .081 1.000 
 Standardized Cronbach’s alpha= 0.24
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III] Mean differences  
Table 17 presents the results of the t-tests performed to assess mean differences in the 
knowledge scores among descriptive variables. No significant results were obtained. 
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Table 17: Mean differences in knowledge scores (t tests) 
α= 0.05 
^ Mean knowledge scores on a scale of 0 to 8. 
 
 
 
 
 
 
 
 
 
  
Variables n Mean^ Standard 
Deviation 
t df Significance 
(2 tailed) 
       
Age    0.99 105 0.33 
Less than 40 67 5.61 1.29    
40 and greater 40 5.38 1.03    
       
Gender    1.45 105 0.152 
Male 39 5.74 1.19    
Female 68 5.40 1.20    
       
Degree    0.74 105 0.46 
Pharm D 72 5.58 1.26    
B S Pharmacy 35 5.40 1.06    
       
SUD Education    0.82 105 0.41 
Yes 65 5.60 1.21    
No 42 5.40 1.09    
       
Personal experience    0.94 103 0.35 
Yes 27 5.70 1.17    
No 78 5.45 1.22    
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Table 18 presents the results of the ANOVA conducted to analyze mean differences in 
knowledge scores among practice characteristics and responses to attitude statements. No 
significant results were obtained.  
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Table 18: Mean differences in knowledge scores (ANOVA) 
Variables n Mean^ Standard 
Deviation 
F Significance  
(2 tailed) 
      
Pharmacy location 106 5.55 1.18 0.61 0.55 
Rural 21 5.48 1.17   
Suburban 59 5.47 1.14   
Urban 26 5.77 1.31   
      
Income 104 5.56 1.19 0.56 0.65 
Impoverished 7 5.00 1.53   
Low 46 5.61 1.29   
Middle 45 5.58 1.03   
High 6 5.67 1.21   
      
MTM Services 101 5.51 1.20 1.28 0.29 
Never 31 5.42 1.18   
Rarely 24 5.21 1.29   
Sometimes 29 5.83 1.23   
Frequently 17 5.59 1.00   
      
Clinical services 101 5.46 1.32 2.64 0.05 
Never 52 5.33 1.32   
Rarely 14 5.38 1.37   
Sometimes 2 6.21 0.70   
Frequently 33 4.00 1.41   
      
Attitudes       
1. Pharmacists dispensing needles without 
prescriptions 
93 5.53 1.19 0.61 0.61 
Strongly disagree 16 5.44 1.41   
Disagree 45 5.69 1.20   
Agree 21 5.29 1.00   
Strongly agree 11 5.45 1.13   
      
2. Pharmacists dispensing naloxone acts as a safety net 93 5.53 1.19 0.89 0.45 
Strongly disagree 14 5.29 1.44   
Disagree 47 5.64 1.26   
Agree 30 5.40 0.93   
Strongly agree 2 6.50 0.70   
      
3. Dispensing buprenorphine is an effective strategy 92 5.52 1.19 0.12 0.95 
Strongly disagree 2 6.00 0.00   
Disagree 26 5.50 1.24   
Agree 57 5.53 1.14   
Strongly agree 7 5.43 1.72   
      
4. Pharmacists dispensing naltrexone 93 5.53 1.19 1.52 0.22 
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α= 0.05 
^ Mean knowledge scores on a scale of 0 to 8. 
Strongly disagree 3 6.00 1.00   
Disagree 26 5.15 1.12   
Agree 57 5.61 1.10   
Strongly agree 7 6.00 1.92   
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Table 19 presents the results of the t-tests conducted to assess the mean differences in the 
stigma scores among the demographic variables. No significant results were obtained. 
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Table 19: Mean differences in stigma scores (t tests) 
α= 0.05 
^ Mean stigma score on a scale from 1 to 4 (where 1 = Strongly disagree, 2 = Disagree, 3 = Agree and 4 = Strongly 
agree) and (where 1 = Highest stigma and 4 = Lowest stigma)  
 
  
Variables n Mean^ Standard 
Deviation 
t df Significance  
(2 tailed) 
       
Age    1.30 92 0.20 
Less than 40 58 2.23 0.42    
40 and greater 36 2.12 0.43    
       
Gender    -0.06 92 0.95 
Male 37 2.18 0.42    
Female 57 2.19 0.43    
       
Degree    1.91 92 0.06 
Pharm D 63 2.25 0.42    
B S Pharmacy 31 2.07 0.42    
       
SUD Education    1.56 92 0.12 
Yes 57 2.24 0.42    
No 37 2.10 0.42    
       
Personal 
experience 
   0.14 90 0.89 
Yes 23 2.20 0.33    
No 69 2.18 0.46    
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Table 20 presents the results of the ANOVA performed to assess mean differences in 
stigma scores among practice characteristics and responses on the attitude questions. The 
ANOVA was significant on comparing mean stigma scores with MTM services [ F (3, 
90) = 2.99, p = 0.03] and on comparing clinical services [ F (3,89) = 2.98, P = 0.04]. 
Scheffe’s post-hoc test revealed that there was a significant difference between the mean 
stigma scores of pharmacists who never performed MTM services and those who 
frequently performed MTM services (p = 0.04). However, post-hoc tests could not be 
performed for clinical services as the ‘frequently’ group had only one case. 
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Table 20: Mean differences in stigma scores (ANOVA) 
*Significant at p < 0.05 
Variables n Mean^ Standard 
Deviation 
F Significance  
(2 tailed) 
      
Pharmacy location 94 2.19 0.43 2.54 0.09 
Rural 20 2.20 0.43   
Suburban 51 2.11 0.40   
Urban 23 2.35 0.45   
      
Income 92 2.18 0.42 0.23 0.88 
Impoverished 7 2.14 0.59   
Low 42 2.15 0.38   
Middle 39 2.22 0.44   
High 4 2.13 0.42   
      
MTM Services 94 2.19 0.43 2.99 0.03* 
Never 28 2.07 0.47   
Rarely 22 2.14 0.41   
Sometimes 27 2.19 0.37   
Frequently 17 2.44 0.37   
Never vs frequently$     0.04* 
      
Clinical services 93 2.19 0.42 2.98 0.04* 
Never 31 2.06 0.39   
Rarely 48 2.23 0.44   
Sometimes 13 2.33 0.35   
Frequently 1 3.00 .   
      
Attitude       
Pharmacists dispensing needles without prescriptions 94 2.19 0.43 1.63 0.18 
Strongly disagree 16 2.13 0.45   
Disagree 46 2.28 0.34   
Agree 21 2.11 0.53   
Strongly agree 11 2.03 0.45   
      
Pharmacists dispensing naloxone acts as a safety net 94 2.19 0.43 1.73 0.17 
Strongly disagree 14 2.35 0.30   
Disagree 47 2.23 0.40   
Agree 31 2.07 0.50   
Strongly agree 2 2.00 0.24   
      
Dispensing buprenorphine is an effective strategy 93 2.20 0.42 0.85 0.47 
Strongly disagree 2 2.00 0.24   
Disagree 27 2.28 0.42   
Agree 57 2.15 0.43   
Strongly agree 7 2.29 0.38   
      
Pharmacists dispensing naltrexone is effective 94 2.19 0.43 0.66 0.58 
Strongly disagree 3 2.17 0.17   
Disagree 26 2.28 0.46   
Agree 58 2.17 0.42   
Strongly agree 7 2.05 0.47   
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^ Mean stigma score of all pharmacists on a scale from 1 to 4(where 1 = Strongly disagree, 2 = Disagree, 3 = Agree 
and 4 = Strongly agree) and (where 1 = Highest stigma and 4 = Lowest stigma) 
$ Scheffe’s post hoc test 
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Figure 2  is the graphical representation of the mean stigma scores of pharmacists 
grouped according to their frequency of performing MTM services. A clear increase in 
stigma scores is visible from pharmacists who never perform MTM services to those 
frequently perform them. A higher stigma score corresponds to lesser stigmatizing 
attititudes.  
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Figure 2: Mean differences in stigma scores with MTM services 
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Figure 3  is the graphical representation of the mean stigma scores of pharmacists 
grouped according to their frequency of performing clincal servicces. A clear increase in 
stigma scores is visible from pharmacists who never perform clinical services to those 
frequently perform them. A higher stigma score corresponds to lesser stigmatizing 
attititudes.  
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Figure 3: Mean differences in stigma scores with clinical services 
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Table 21 presents the results of the t tests assessing mean differences in practice scores 
among demographic variables. No significant results were obtained.  
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Table 21: Mean differences in practice scores (t tests) 
α= 0.05 
^ Mean practice score of pharmacists on a scale of 0 to 7. 
 
 
 
 
 
 
 
 
 
 
  
Variables n Mean^ Standard 
Deviation 
t df Significance  
(2 tailed) 
       
Age    -0.19 51 0.85 
Less than 40 38 3.5 1.83    
40 and greater 15 3.6 1.64    
       
Gender    -1.20 51 0.23 
Male 15 3.07 1.58    
Female 38 3.71 1.81    
       
Degree    -1.00 51 0.32 
Pharm D 42 3.40 1.80    
B S Pharmacy 11 4.00 1.61    
       
SUD Education    -0.78 51 0.44 
Yes 32 3.38 1.76    
No 21 3.76 1.79    
       
Personal 
experience 
   0.30 49 0.76 
Yes 14 3.57 1.74    
No 37 3.41 1.74    
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Table 22 presents results of the ANOVA assessing mean differences in practice scores 
among practice characteristics and responses on the attitude questions. No significant 
results were obtained.  
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Table 22: Mean differences in practice scores (ANOVA) 
α= 0.05 
^ Mean practice score of pharmacists on a scale of 0 to 7. 
 
Variables n Mean^ Standard 
Deviation 
F Significance  
(2 tailed) 
      
Pharmacy location 53 3.53 1.76 1.04 0.36 
Rural 12 3.83 1.70   
Suburban 25 3.16 1.72   
Urban 16 3.88 1.86   
      
Income 52 3.50 1.77 1.67 0.19 
Impoverished 2 6.00 0.00   
Low 29 3.38 1.52   
Middle 18 3.56 2.12   
High 3 2.67 1.15   
      
MTM Services 50 3.74 1.58 0.21 0.89 
Never 12 3.42 1.51   
Rarely 13 3.85 1.46   
Sometimes 15 3.87 1.69   
Frequently 10 3.80 1.81   
      
Clinical services 49 3.76 1.59 1.15 0.34 
Never 26 3.08 1.51   
Rarely 10 3.88 1.66   
Sometimes 1 4.10 1.45   
Frequently 12 5.00 .   
      
Attitude       
Pharmacists dispensing needles without prescriptions 47 3.77 1.55 0.33 0.81 
Strongly disagree 9 3.56 1.51   
Disagree 23 3.74 1.51   
Agree 10 3.70 1.77   
Strongly agree 5 4.40 1.67   
      
Pharmacists dispensing naloxone acts as a safety net 47 3.77 1.55 1.21 0.32 
Strongly disagree 7 3.86 1.46   
Disagree 24 3.71 1.37   
Agree 15 4.00 1.81   
Strongly agree 1 1.00 -   
      
Dispensing buprenorphine is an effective strategy 47 3.77 1.55 0.21 0.81 
Strongly disagree 0 - -   
Disagree 15 3.73 1.44   
Agree 27 3.70 1.64   
Strongly agree 5 4.20 1.64   
      
Pharmacists dispensing naltrexone 47 3.77 1.55 0.57 0.64 
Strongly disagree 1 3.00 -   
Disagree 12 4.00 1.60   
Agree 28 3.57 1.55   
Strongly agree 6 4.33 1.63   
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IV] Bivariate Correlations 
Table 23 presents correlations between knowledge scores and practice variables. None of 
the bivariate correlations were significant.  
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Table 23: Correlations between knowledge scores and practice variables 
 
Variable n Pearson Correlation Significance (two-tailed) (p value) 
    
Number of years worked 106 -0.09 0.35 
    
Number of hours worked/week 106 -0.04 0.72 
    
SUD prescriptions/week 106 0.12 0.21 
    
Adequacy of SUD education 65 0.12 0.36 
    
Screening score 98 0.04 0.72 
    
α= 0.05 
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Table 24 presents correlations between stigma scores and practice variables. None of the 
bivariate correlations were significant except screening scores. Interestingly, there was a 
negative correlation (-0.25) and higher stigma scores meant lesser stigma. Therefore, 
there was a relationship between having high stigma and regarding screening as an 
important practice.  
  138
Table 24: Correlations between stigma scores and practice variables 
 
Variable n Pearson Correlation Significance (two-tailed) (p value) 
    
Number of years worked 94 -0.18 0.08 
    
Number of hours worked/week 94 -0.04 0.73 
    
SUD prescriptions/week 94 0.01 0.90 
    
Adequacy of SUD education 57 -0.13 0.34 
    
Screening 92 -0.25 0.01* 
    
*Significant difference at p < 0.05 
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Table 25 presents correlations between practice scores and practice variables. None of 
the bivariate correlations were significant except screening scores. There was a positive 
correlation (0.31) indicating a relationship between performing more interventions for 
SUD patients and regarding screening as an important practice.
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Table 25: Correlations between practice scores and practice variables 
 
Variable n Pearson Correlation Significance (two-tailed) (p value) 
    
Number of years worked 53 0.13 0.37 
    
Number of hours worked/week 53 -0.15 0.27 
    
SUD prescriptions/week 53 0.17 0.23 
    
Adequacy of SUD education 32 -0.10 0.58 
    
Screening score 50 0.31 0.03* 
    
*Significant difference at p < 0.05  
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V] Regression Models 
 
1) Knowledge 
A multiple linear regression analysis was conducted to predict knowledge scores. The 
predictors included in the model were personal experience with SUD, CE in SUD, 
gender, CE on naloxone, number of years worked, SUD medication dispensing frequency 
and stigma mean scores. The assumptions for linear regression were met. Independence 
of observations was confirmed by the Durbin-Watson statistic (1.26). The residual 
histogram was normal and the predicted probability (P-P) plot was mostly linear, thereby 
establishing normality of the model. The scatterplot of the residuals was spread evenly on 
both sides of the origin, proving homoscedasticity of the model. Linearity of data was 
thus implied. The linear combination of the included variables significantly predicted 
knowledge scores [F (8, 85) = 3.83, p < 0.01] with an R2 and adjusted R2 of 0.27 and 0.20 
respectively. The regression coefficient was: 
Knowledge score = 3.41 + 0.11 (CE SUD) + 0.07 (Personal experience: yes) + 0.01 
(Personal experience: not disclosed) -0.21(Years worked) + 0.11 (SUD medication 
dispensing frequency) + 0.34 (CE Naloxone) – 0.05 (Stigma score) 
The individual relative strengths of the predictors are reported in Table 26. Gender, 
number of years worked and CE in naloxone were significant predictors individually as 
well.  This also meant that with an increase of one year of work experience, knowledge 
score would decrease by 0.21 on average and pharmacists who have had CE in naloxone 
had on average a knowledge score higher by 0.34 than those who did not.  
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a) Normality assumption 
 
 
 
 
 
 
Figure 4: Histogram of residuals of knowledge regression model 
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Figure 5: Normal Predicted Probability plot of knowledge regression model 
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b) Homoscedasticity assumption 
 
 
Figure 6: Scatterplot of residuals Vs predicted values for knowledge regression model 
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Table 26: Regression model of Knowledge scores (n = 94) 
 
 Unstandardized 
Coefficients 
Standardized 
Coefficient 
t Significance 
 B Std. Error Beta   
      
Constant 3.41 1.58  2.15 0.03* 
      
CE SUD 0.56 0.52 0.11 1.07 0.29 
      
Personal experience (yes) 0.40 0.57 0.07 0.70 0.49 
      
Personal experience (not disclosed) 0.26 1.93 0.01 0.13 0.89 
      
Number of years worked -0.05 0.03 -0.21 -2.14 0.04* 
      
SUD medication dispensing 
frequency 
0.28 0.24 0.11 1.13 0.26 
      
Gender 0.04 0.02 0.17 1.80 0.08 
      
CE Naloxone 1.78 0.56 0.34 3.21 0.00* 
      
Stigma score -0.28 0.55 -0.05 -0.52 0.61 
      
*Significant difference at p<0.05  
  146
2) Practice 
An ordinal regression was carried out to predict the frequency of pharmacists offering 
clinical services to SUD patients. The variables included in the model were stigma mean 
scores, knowledge mean scores, attitude mean score, gender and personal experience with 
SUD. The assumptions of ordinal regression were met. Occurrence of proportional odds 
was confirmed by the test of parallel lines [χ2 = 18.00 (p = 0.12)]. The model fit proved to 
be significant [χ2 = 17.25 (p = 0.01)] and had a pseudo R2 of 0.37 (Nagelkerke). In this 
model, all threshold values were significant. The individual estimates or regression 
coefficients of the predictors are reported in Table 27. Stigma was the only significant 
predictor individually. This meant that an increase in stigma scores by one point meant an 
increase of 3.18 units of ordered log odds of the pharmacist ‘frequently’ offering clinical 
services instead of ‘sometimes’, ‘sometimes instead of ‘rarely’ and ‘rarely’ instead of 
‘never’. In other words, increase in stigma scores or reduced stigma was correlated with 
an increase in the odds of the pharmacist offering clinical services. 
  
  147
Table 27: Regression model of clinical services (n = 101) 
Variable Estimate Std. Error Wald Statistic df Significance 
      
Clinical services 
Threshold^      
1 11.59 4.07 8.11 1 0.00* 
2 14.90 4.38 11.56 1 0.00* 
3 17.53 4.55 14.89 1 0.00* 
      
Stigma Score 3.18 1.00 10.14 1 0.00* 
      
Knowledge Score 0.36 0.30 1.44 1 0.23 
      
Attitude Score 1.20 0.84 2.03 1 0.15 
      
Practice Score 0.28 0.22 1.60 1 0.46 
      
Gender       
Female 0.55 0.74 0.55 1 0.46 
Male 0   0  
      
Personal experience      
Yes -0.58 0.72 0.65 1 0.42 
No 0   0  
      
*Significant difference at p <0.05 
^ Threshold 1 = cutoff value between never and rarely offering clinical services 
    2 = cutoff value between rarely and sometimes offering clinical services 
   3 = cutoff value between sometimes and frequently offering clinical services 
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3) Screening 
A multiple linear regression model was created to predict screening scores. The 
predictors included in the model were personal experience, gender, knowledge, number of 
years worked, and stigma mean scores. The assumptions for linear regression were met. 
Independence of observations was confirmed using the Durbin-Watson statistic (1.46). The 
transformation of the dependent variable produced a normal plot as reported below. 
Homoscedasticity of the model was observed by looking at the evenly spread out 
scatterplot of the residuals, as reported below. Linearity of data was thus implied. The 
linear combination of the included variables significantly predicted screening scores [F (6, 
84) = 2.50, p = 0.03] with an R2 and adjusted R2 of 0.15 and 0.09 respectively. The 
regression equation was: 
Square root of screening score = 1.92 – 0.15(Gender) – 0.22(Stigma score) + 
0.07(Knowledge score) + 0.08(Personal experience: yes) + 0.18(Personal 
experience: not disclosed) + 0.22(years worked) 
The individual relative strengths of the predictors are also reported in Table 28. 
Stigma scores and work experience were significant predictors individually. This meant 
that increase in stigma score by one point meant a decrease in the square root of the 
screening score and an increase in the years worked by one year meant an increase in the 
square root of screening score, both by 0.22.  
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a) Normality assumption 
 
 
 
 
 
 
Figure 7: Histogram of residuals of screening regression model. 
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Figure 8: Normal predicted probability plot of screening regression model 
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b) Homoscedasticity assumption 
 
 
Figure 9: Scatterplot of residuals Vs predicted values of screening regression model 
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Table 28: Regression model of screening scores (n = 91) 
 
 
 Unstandardized 
Coefficients 
Standardized 
Coefficient 
t Significance 
 B Std. Error Beta   
      
Constant 1.92 0.09  22.09 0.00* 
      
Gender -0.00 0.00 -0.15 -1.47 0.15 
      
Stigma score -0.07 0.03 -0.22 -2.14 0.04* 
      
Knowledge score 0.00 0.01 0.07 0.70 0.49 
      
Personal experience (yes) 0.03 0.03 0.08 0.77 0.40 
      
Personal experience (prefer not to 
disclose) 
0.20 0.12 0.18 1.72 0.09 
      
Number of years worked 0.00 0.00 0.22 2.03 0.045* 
      
*Significant difference at p < 0.05  
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4) Stigma 
Table 29 presents the frequency distribution of the stigma total scores. As evident the 
stigma scores 12, 13, and 14 have very high frequencies compared to scores before 12 
and after 14. Therefore, three categories of stigma were based on this distribution with 
low stigma = 1 (stigma scores 15 to 18), medium stigma = 2 (stigma scores 12 to 14) and 
high stigma = 3 (stigma scores from 6 to 11). 
Subsequently, the results of the ordinal regression are presented. The variables 
included in the model were screening scores, practice scores, patient socioeconomic 
class, MTM services, and CE in SUD. The assumptions of ordinal regression were met. 
Occurrence of proportional odds was confirmed by the test of parallel lines [χ2 = 5.21 (p 
= 0.82)]. The model fit proved to be significant [χ2 = 18.77 (p = 0.03)] and had a pseudo 
R2 of 0.40 (Nagelkerke). Both threshold values were significant, meaning there was a 
significant difference between pharmacists who had low and medium as well as medium 
and high stigma scores. The individual estimates or regression coefficients of the 
predictors are reported in Table 30. Of all the predictors in the model, screening scores 
and ‘never’ and ‘rarely’ performing MTM services were found to be significant 
individually. The result indicated that an increase in screening scores by one point meant 
an increase of 1.98 units of ordered log odds of the pharmacist falling in the medium 
stigma category instead of low and being in the high stigma group instead of medium. 
Pharmacists who never performed MTM services were 3.03 times more likely to have 
high stigma as compared to medium and medium stigma as compared to low stigma than 
those who frequently performed MTM services. Pharmacists who rarely performed MTM 
services as compared to those who frequently performed MTM services were 2.30 times 
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more likely to fall in the high stigma group than medium and medium stigma group than 
low stigma. 
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Table 29: Frequency distribution of stigma total scores 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
low stigma = 1 (stigma total scores from15 to 18),  
medium stigma = 2 (stigma total scores from 12 to 14),  
high stigma = 3 (stigma total scores from 6 to 11). 
(Categories based on frequency distribution) 
Stigma total score Number Percentage 
   
6.00 1 0.7 
   
7.00 2 1.5 
   
8.00 2 1.5 
   
9.00 1 0.7 
   
10.00 6 4.4 
   
11.00 8 5.9 
   
12.00 15 11.1 
   
13.00 23 17.0 
   
14.00 12 8.9 
   
15.00 6 4.4 
   
16.00 8 5.9 
   
17.00 4 3.0 
   
18.00 6 4.4 
   
Total 94 69.6 
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Figure 10: Histogram of frequency distribution of stigma total scores 
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Table 30: Regression model of stigma total scores (n = 94) 
*Significant difference at p <0.05 
^ Threshold 1 = cutoff value between low stigma and medium stigma 
    2 = cutoff value between medium stigma and high stigma 
   
  
Variable Estimate Std. Error Wald Statistic df Significance 
      
Stigma scores 
Threshold^ 
     
1 7.21 3.19 5.10 1 0.02* 
2 11.22 3.57 9.87 1 0.00* 
      
Screening score 1.98 0.86 5.30 1 0.02* 
      
Practice Score -0.43 0.25 2.82 1 0.09 
      
Patient socioeconomic 
class 
     
Impoverished 3.84 2.42 2.52 1 0.11 
Low 1.84 1.70 1.18 1 0.28 
Middle 1.69 1.77 0.91 1 0.34 
High 0 . . 0 . 
      
MTM services      
Never 3.03 1.11 7.51 1 0.01* 
Rarely 2.30 1.08 4.59 1 0.03* 
Sometimes 1.64 0.99 2.73 1 0.10 
Frequently 0 . . 0 . 
      
CE in SUD 1.23 0.76 2.67 1 0.10 
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VI] Qualitative Results 
 
Table 31 presents the frequency distribution of all 20 codes in the protocols listed in 
descending order of frequency. Overprescribing and scale or severity of the epidemic 
were the most frequent themes while  
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Table 31: Frequency distribution of qualitative codes (n = 50) 
Codes Number Percentage 
   
Overprescribing opioids 16 14.95 
   
Scale and severity of the epidemic 13 12.15 
   
Policy recommendations 9 8.41 
   
Contributor accountability 7 6.54 
   
Negative aspects of Suboxone 7 6.54 
   
Attitude towards naloxone 7 6.54 
   
Prescriber pharmacist relationship 7 6.54 
   
Personal experience 5 4.67 
   
Barriers to practice 4 3.74 
   
PDMP 4 3.74 
   
Access to opioids 4 3.74 
   
Stigma 4 3.74 
   
Education 3 2.80 
   
Resources 3 2.80 
   
Frustration/Hopelessness 3 2.80 
   
Substances other than opioids 3 2.80 
   
Mental health 2 1.87 
   
Patients without formal SUD diagnosis 2 1.87 
   
Substitution of opioids 2 1.87 
   
Therapy/ Counseling 2 1.87 
   
Total 107 100.00 
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Table 32 presents the results of the axial analysis on the protocols and codes. Frequently 
occurring relationships between codes are described. Causal or associated relationships 
between codes, intervening codes, codes that occur as action strategies and codes that are 
consequences of the central code are listed.  
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     Table 32: Axial analysis of codes 
Code Causal/ 
Association 
Intervening 
codes 
Action strategies Consequences 
     
Pharmacist 
prescriber 
relationship 
Contributor 
accountability 
(lack) 
Barrier to 
practice 
- Frustration/Hope
lessness 
     
Scale and severity 
of the epidemic 
Overprescribing, 
education (lack), 
Contributor 
accountability 
(lack), stigma, 
access to opioids 
(easy) 
- Education, Policy 
recommendations, 
Resources, 
Prescriber 
pharmacist 
relationship 
Substances other 
than opioids 
(increase) 
     
Overprescribing Education (lack), 
Mental healthcare 
(lack), Contributor 
accountability 
(lack) 
Access to opioids 
(difficult) 
Resources, 
Substitution of 
opioids, Contributor 
accountability, 
policy 
recommendations 
Scale and 
severity of the 
epidemic 
     
Contributor 
accountability 
- Barriers to 
practice 
Policy 
recommendations, 
PDMP 
Overprescribing, 
prescriber 
pharmacist 
relationship 
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Chapter 5 
DISCUSSION AND CONCLUSION 
This chapter includes a discussion of the key findings of the study, categorized according 
to the descriptive data, seven objectives and qualitative data. This is followed by the 
limitations of the study, the conclusion, study implications and finally direction for future 
research. 
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I] Key Findings 
1) Descriptive 
 The pharmacists surveyed in this study were mostly young (below 40 years of 
age), female, and predominantly Caucasian. The majority had PharmD versus B.S in 
Pharmacy degrees. There was a significant correlation between degree obtained and year 
of graduation. It only became mandatory to have a Pharm D degree to obtain a license to 
practice as a pharmacist in 2000 in the US and therefore the younger pharmacists 
surveyed in the study resulted in more pharmacists having a PharmD. A total of 14.9% of 
the current study sample also had other advanced degrees. 
The survey also assessed pharmacy and professional characteristics. Pharmacists 
on average worked for 15 years and about 37 hours per week, although standard 
deviations for both were around 9 years and 9 hours/ week. This was likely due to the 
large range in the ages of pharmacists, even among younger age group which affected 
work experience. Also, some pharmacists had more than two degrees (some in unrelated 
fields), significantly reducing years of work experience as a community pharmacist. 
Moreover, the study responders were full-time or part-time community pharmacists 
which would render a variance in the number of hours worked per week. Most 
pharmacies had 2-3 pharmacists working per shift, but the amount of prescriptions filled 
per week as reported by the pharmacists varied greatly. This was because some 
pharmacists worked in tele-pharmacies (and so did not fill any prescriptions) while some 
were full-time pharmacists working in large pharmacies and reportedly filled 10,000 
prescriptions per week. However, most pharmacists reported filling approximately 2000 
prescriptions per week. With regards to SUD prescriptions, pharmacists mostly reported 
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‘frequently’ dispensing SUD medications. This is consistent with the high prevalence of 
SUD, but literature regarding SUD medication dispensing from the pharmacist’s 
perspective is limited. Most studies have assessed dispensing practices specific to 
naloxone. Studies have assessed attitudes of pharmacists and have found it was generally 
positive as discussed in the systematic literature review.161 There was an equal 
distribution of patients estimated to belong to the low and middle-income groups while 
few belonged to the impoverished and high-income groups, according to the pharmacists. 
Assuming that this holds true for the SUD patients as well, there might be a correlation 
between socioeconomic group and prevalence of SUD. This is consistent with literature, 
where frequency of SUD is less in people with high socioeconomic status as compared to 
people in lower socioeconomic status groups.199 However, these studies do not 
necessarily measure the true prevalence but may be indicating measured prevalence. With 
respect to their position in the pharmacy, the majority of respondents were full-time 
pharmacists as compared to part-time pharmacists. A significant proportion of 
pharmacists were also pharmacy managers, interspersed with a few owners. This 
strengthens the collected data because responses from different viewpoints within the 
community pharmacy system was available.  
The survey also assessed educational characteristics of the pharmacists. Only 53% 
reported that they received SUD-specific education as part of their curriculum which is 
especially concerning with the current large-scale prevalence of SUD. Moreover, of these 
53%, only 1.5% strongly agreed and 31.3% agreed that the education they received was 
adequate to treat patients, leaving two thirds of the pharmacists who received SUD 
education believing that it was not adequate to understand and treat SUD. These findings 
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are not surprising because most pharmacy programs do not provide sufficient SUD 
education or training as reported by a recent study that utilized a sample of US pharmacy 
curriculum representatives and College of Psychiatric and Neurologic Pharmacy (CPNP) 
members with teaching affiliations.25 The study reported that even though 94% of the 
programs reported teaching SUD content in their core curriculum, the average hours 
taught still fell short of the American Association of Colleges of Pharmacy (AACP) 
recommendations.200 The recommendations stated that at least four hours of SUD specific 
education concerning identifying, prevention and treatment of SUD should be provided in 
the curriculum. However, the average hours taught in this study of all US schools was 2.7 
in 2015.200 This points towards a severe gap in the basic education of pharmacists which 
needs to be rectified to improve their role in prevention and treatment of SUD. CE in 
SUD and naloxone can be used to overcome this gap in knowledge. More than half the 
sample had received CE in SUD and naloxone, indicating that pharmacists are interested 
in gaining knowledge in the area. However, this still leaves a significant portion of the 
sample (about 40%) who did not report that they have received CE. This is especially 
concerning because the use of MAT is on the rise. A surprisingly large number of 
pharmacists (22.4%), especially when accounting for social desirability bias, reported 
having personal experience with SUD. However, a study assessing substance use among 
pharmacists reported that slightly more than half the sampled pharmacists reported using 
a non-prescribed drug in their lifetime and greater proportion of pharmacists reported 
lifetime use of minor opiates as compared to other health care professionals.201 Therefore, 
social desirability bias may still be present in the result obtained in this study. However, 
this conclusion cannot be directly compared to the result obtained as the question is 
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confounded by including the pharmacists’ social network in their personal experience 
with SUD. 
 
2) Objective 1: Assessing Knowledge 
The first factor that the study aimed to measure was the knowledge of pharmacists 
with regards to SUD. The questions primarily focused on SUD medications because 
pharmacists are expected to have adequate knowledge regarding MAT for patients. One 
question however concerned a policy, specifically standing orders for naloxone. 
Together, the scale proved to be very reliable with a high reliability coefficient. The 
knowledge scores in the study sample averaged at 5.52 out of 8, meaning the pharmacists 
on average achieved 69% of the questions right. This indicates that increased education 
and knowledge regarding SUD should be further emphasized through targeted CE and 
curriculum development. The literature regarding knowledge of pharmacists in SUD 
seems to be limited with most papers only assessing their knowledge as an evaluation of 
a training program or CE rather than overall assessment. One study however, assessed 
overall knowledge and found that pharmacists were deficient in prevention and treatment 
of SUD.202 Moreover, pharmacy is a knowledge-based profession and their knowledge is 
linked to professionalism (more knowledge makes better pharmacists),203 making it 
essential for the pharmacist to have high levels of knowledge specific to SUD. Although 
the pharmacists in the sample answered majority of the questions correctly in the 
knowledge section, they did not fare equally well on all questions.  This could probably 
be attributed to the varying difficulty level of the questions. Some questions were 
straightforward and were expected to be common knowledge among pharmacists such as 
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scheduling of buprenorphine (the most commonly used treatment for SUD) or the drug of 
choice for emergency treatment of opioid overdose (with options including only 
maintenance treatments apart from naloxone). However, some questions not only tested 
basic knowledge but required a deeper understanding and experience with dispensing the 
specific treatments. For example, the question regarding starting naltrexone within seven 
days of opioid therapy was especially nuanced. Although, it may be started within seven 
days, it is highly advisable not to do so to avoid severe opioid withdrawal syndrome in 
case the patient had physiological opioid dependence. A naloxone challenge is necessary 
to be performed to confirm the absence of dependence if starting naltrexone. However, to 
avoid complications and difficulties of performing the challenge, it is generally advised 
to wait for a week before starting naltrexone. The ability of buprenorphine to potentiate 
opioids was another question where pharmacists performed poorly. This is because 
buprenorphine is in fact a partial opioid receptor agonist which may have prompted 
pharmacists to answer incorrectly. However, apart from being a partial agonist it also has 
greater affinity to the receptor than other opioids and displaces them, thereby attenuating 
their activity and not potentiating it. Other than the questions regarding medications, the 
standing order question also received mostly correct answers indicating that most 
pharmacists were aware of the newest significant policy change in the treatment of SUD. 
 
3) Objective 2: Assessing Practice 
The second factor assessed in the study was the SUD-related practice 
characteristics of the pharmacists. Contrary to the hypothesis in which it was expected 
that the majority of pharmacists would be involved in treating SUD in some way, almost 
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an equal number of pharmacists did and did not play a role in SUD treatment. This 
reduced the sample size considerably for the practice scale, which was administered only 
to the pharmacists who reported that they played a role in SUD. There were seven items 
on the practice scale, each corresponding to a specific intervention that pharmacists are 
expected to perform. However, results on the scale were skewed with a high percentage 
of pharmacists dispensing and counseling, but very few referring patients to practitioners 
or monitoring patients and assisting self- monitoring practices. The mean score on the 
scale was 3.53 (out of 7), meaning pharmacists on average performed 50% of the 
interventions listed. The practice with SUD patients in this study followed the basic 
model of dispensing with some counseling without emphasis upon monitoring and 
referral for further interventions. Opportunities need to be made for pharmacists to be 
able to monitor SUD patients and refer when necessary for further evaluation and 
treatment. This would include both more extensive education and the reduction of time 
and reimbursement barriers in community pharmacy, so that the potential of the 
community pharmacist can be realized for addressing the current epidemic. Although the 
current literature concludes that pharmacists play a key role in treatment and prevention 
of SUD and provide recommendations for new roles that can be implemented, it is hard 
to find studies that assess overall current practices of pharmacists in this area. Another 
important finding was that frequency of performing MTM services for general diseases 
had large variation with almost equal responses across the scale.  A study conducted in 
2006 reported that pharmacists are eager to provide MTM services for all the prescription 
drug plans for Medicare Part D.204 Another report by Centers for Medicare and Medicaid 
Services (CMS) stated that  pharmacists were leading provider of MTM services across 
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all MTM programs and were utilized by 99.5% of their plans.205 Outside the CMS, 
however only 68% of the respondents reported providing MTM services.205 This variance 
is replicated in these results as well but it is starkly different from treatment of SUD 
specifically. Pharmacists on average reported that they ‘rarely’ provided clinical services 
to SUD patients which points to a significant distinction between treatment of SUD 
versus other diseases. SUD maybe occur in combination with other diseases like 
cardiovascular diseases leading to higher complications, providing opportunity to treat 
both.206 Further research needs to be conducted on why this difference exists. 
 
4) Objective 3: Assessing Screening 
The third objective of the study was to evaluate the importance of screening for 
SUD in the pharmacists’ opinion. All red flags listed as part of the screening question 
were regarded as either ‘very’ or ‘extremely important’. This indicates that given an 
opportunity and adequate resources, pharmacists are extremely willing to screen for SUD 
and enhance their role in the treatment of SUD. The unanimous nature of the responses 
resulted in a high correlation coefficient, proving that this scale was very reliable in this 
sample. Although, the respondents reported that they believed screening for SUD to be 
highly important, it does not necessarily translate into practice. Screening for drug abuse 
has hurdles such as first and foremost establishing a professional belief within themselves 
and the patients that the questions are only for therapeutic concerns, removing hesitation 
on part of the patients to answer deeply personal questions without intruding in their 
lives, being sensitive, respectful and maintaining confidentiality.207 Lack of private space, 
increased work burdens, and lack of effective training add to these barriers. These 
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external barriers compound the already existing internal barriers such as stigma and 
negative attitudes. 
 
5) Objective 4: Assessing Stigma 
As part of assessing attitude, this study focused on stigma specifically by utilizing 
a standardized scale developed for SUD. Even though it was a standardized scale, the 
correlations between the items were not very high in this sample. This could be attributed 
to the omission of two items (to decrease responder burden) from the original scale, the 
small alterations made in the statements, or simply this specific sample. Pharmacists in 
general had a slightly stigmatizing attitude to all items on the scale. It is possible that the 
overall amount of stigma was underestimated due to social desirability bias. A systematic 
review of studies assessing stigma in SUD by health-care professionals stated that they 
stigmatized patients as being violent, manipulative, and poorly motivated for treatment. 
This resulted in providers being less involved or empathetic towards these patients.208 
Research shows that not only do health care providers commonly have stigmatizing 
attitudes towards patients with SUD but this also leads to sub-optimal health care for 
these patients.208  
 
6) Objective 5: Assessing Attitude 
The final factor was to assess general attitudes of pharmacists towards harm 
reduction strategies and maintenance treatments. The section was shortened to only four 
specific statements from the original intended in order to reduce responder burden. 
However, the small number of disparate items resulted poor internal consistency and 
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therefore limited reliability. But on correlating the harm reduction items and treatment 
items separately, significant correlation coefficients were obtained. Pharmacists had 
slight positive attitudes towards participating in harm reduction strategies like needle 
exchange and dispensing naloxone and had slightly positive attitudes concerning 
maintenance treatments like buprenorphine and naltrexone as well. However, attitudes 
towards both were not as positive as expected from pharmacists. The literature as 
observed in the systematic review is divided on attitudes towards harm reduction 
strategies such as prescription free needles and naloxone dispensing but there has been 
evidence of an increasingly positive attitude among pharmacists over the years. Also, it is 
important to note that attitudes might differ if the policy is needle exchange (which 
includes collecting and disposing used needles) or non-prescription needles.209  Our study 
only measured attitudes towards non-prescription needles. However, pharmacists 
unexpectedly had only slight positive attitudes towards maintenance treatments. This is 
especially surprising as studies that assessed pharmacists’ attitudes towards treatments 
like Suboxone® were quite positive.210,211 However, these studies were conducted when 
buprenorphine/naloxone was first introduced or when it became popular as a treatment 
for SUD. There is no literature measuring the current attitudes. It is possible that attitudes 
have become less positive because of limitations of the treatment or inappropriate 
prescribing/use of treatments in practice. No literature could be found that assessed 
pharmacist attitudes towards naltrexone in the US for comparison with our results.  
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7) Objective 6: Relationships between knowledge, stigma and practices with 
descriptive data 
Multiple t-tests and ANOVAs as well as correlations were carried out to complete 
this objective. Only four relationships were found to be significant. The first was the 
relationship between performing MTM services and stigma. It is possible that 
pharmacists who perform MTM have more positive professional attitudes towards SUD 
patients. However, it is important to note that MTM services were for generalized care 
and stigma was specifically evaluated for SUD.  
The relationship between frequency of performing clinical services and stigma 
scores was also significant. The literature describes the negative effects on treatment 
outcomes due to stigma in general. However, studies assessing the relationship between 
stigma and services offered in SUD are hard to find. Therefore, a relationship can be 
hypothesized based on these findings between reduction in stigma and increased 
practice/interaction with these patients, but further research is needed to definitively 
establish this relationship. On the other hand, high stigma may lead pharmacists to not be 
motivated to perform MTM or clinical services for these patients and therefore it is more 
appropriate to hypothesize associations rather than causality.  
Furthermore, stigma scores were also found to be significantly negatively 
correlated with screening scores. This result might seem counterintuitive at first, but it is 
possible that pharmacists who stigmatize SUD tend to label these patients and may also 
label patients who do not have a formal diagnosis of SUD but display addictive or violent 
behaviors. Also, it is important to note that the motivation for screening can be based 
upon catching infractions versus a genuine desire to intervene therapeutically. The 
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assessment for motivation for screening was beyond the scope of this study. These 
pharmacists may believe screening to be more important because they label patients as 
having SUD even before a diagnosis can be made. A study analyzing stigma in dual 
diagnosis patients with mental illness and SUD found that stigmatizing attitudes lead to 
improvement in their well-being because they received medical treatment.212 However, 
stigma is generally a negative factor in establishing a helping relationship and the 
literature on this hypothesis is divided. As a result, more research needs to be conducted 
to specify the relationship of stigma to practice.  
 The last correlation that was found to be significant was between screening and 
practice scores. This indicates that being highly involved in the care of SUD patients in 
the form of practicing large number of interventions lead pharmacists to screen patients 
that do not have a formal diagnosis of SUD but may show presence of red flags or vice 
versa. A study describing creation and evaluation of an opioid misuse screening tool 
describes how the motivation and commitment of pharmacists to provide better services 
to their patients prompted the creation of the screening tool.213 This indicates that positive 
attitudes and involvement in treatment of SUD can motivate pharmacists to screen as a 
treatment and prevention strategy. 
 
8) Objective 7: Predicting knowledge, practice, screening, and stigma 
 The final objective of the study was to look at the possible factors that together 
predict the scores on the individual scales. Four regression models were designed, and all 
models were found to be significant.  
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The first model was designed to predict knowledge and predictors included CE in 
SUD and naloxone, personal experience, number of years worked as a community 
pharmacist, frequency of dispensing SUD medication, gender and stigma scores. Of these 
predictors, number of years worked and CE in naloxone were significant predictors 
individually in this model. Number of years worked was the only predictor with negative 
regression coefficient, meaning that an increase of work experience by one year would 
lead to a corresponding decrease in the knowledge score. It is possible that pharmacists 
who have worked for many years have moved on to managerial positions and do not 
actively dispense medications leading to a lesser knowledge of current medications. 
Although, we asked pharmacists about their position in the pharmacy, it was possible to 
choose all applicable options, thereby making it impossible to confirm this hypothesis. 
Also, the more recent development of MAT and the recent emphasis upon the opioid 
epidemic has led to more awareness and education regarding SUD in health professions 
and pharmacy schools respectively. CE in naloxone being a significant predictor is not 
unexpected. Considering, most CE programs are designed to improve knowledge levels 
of pharmacists and the questions on the scale were specific to SUD medication including 
naloxone, CE in both would definitely help pharmacists increase their knowledge scores. 
The second model predicted how often pharmacists offered clinical services for 
SUD patients and the predictors included in the model were stigma, knowledge and 
attitude scores, practice scores, gender and personal experience. All threshold values 
were significant and stigma was the only significant predictor individually. This meant 
that an increase in stigma scores lead to an increase in the odds of the pharmacist offering 
clinical services. Since, higher stigma scores meant lower stigma, this finding indicates 
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that having lower stigma increases the odds of pharmacist regularly offering clinical 
services for SUD. This is consistent with stigma literature in general. 
The third model predicted screening scores with predictors like gender, stigma 
and knowledge scores, personal experience and number of years worked. Stigma score 
was individually a significant predictor in this model too. It had a negative regression 
coefficient, meaning lower stigma led to a decrease in the screening score. This meant 
that pharmacists who had more stigmatizing attitudes towards SUD tended to regard 
screening as more important. As discussed before, this could be because pharmacists who 
tend to label patients with SUD negatively, may screen more in order to refuse opioids. 
Stigmatizing behavior stems from believing that SUD is a behavioral problem that 
patients refuse to control instead of it being a biopsychosocial disorder. Hence, 
pharmacists who stigmatize these patients would believe that dispensing opioids is only 
contributing towards continuing this behavior. Therefore, stigmatizing attitudes may lead 
to higher screening but does not necessarily lead to treatment of SUD or improved 
outcomes for the patient. Number of years was also significant where increase in work 
experience by a year lead to a significant increase in the square root of the screening 
score. Again, this indicates that dealing and interacting with patients with SUD would 
help pharmacists to recognize red flags as well realize the importance of providing 
treatment to these patients; the first step of which is screening and receiving a formal 
diagnosis. 
The fourth model predicted total stigma scores where a combination of predictors 
like screening and practice scores, patient socioeconomic class, MTM services and CE in 
SUD were found to be significant. Both threshold values were significant, meaning there 
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was a significant difference between pharmacists who had low and medium as well as 
medium and high stigma scores. Of all the predictors in the model, screening scores and 
‘never’/ ‘rarely’ performing MTM services were found to be significant individually. The 
result indicated that an increase in screening scores meant an increase of odds of the 
pharmacist falling in the medium stigma category instead of low and being in the high 
stigma group instead of medium. As, described before, this indicates a relationship 
between high stigma and believing screening to be an important practice. Pharmacists 
who never or rarely performed MTM services were more likely have high stigma than 
those who frequently performed MTM services. Therefore, routine performance of MTM 
services could significantly predict occurrence of low stigma in pharmacists. 
 
9) Content analysis 
 Overprescribing opioids was clearly a significant issue for most pharmacists when 
discussing the opioid epidemic. They believed it to be the primary cause for the opioid 
epidemic and stated that it needed to be regulated (many believed regulation to be in 
process) to control the epidemic. The literature also shows that overprescribing and 
inappropriately prescribing opioids has indeed been the major cause of the current opioid 
epidemic.26,214 The pharmacists also believed substitution for opioids and improving 
policies and resources were some of the action strategies that could be useful. For 
example, one pharmacist stated: 
“Doctors need to stop prescribing opioids so frequently/casually and use other drugs 
which are just as effective without the abuse potential” 
Another stated: 
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“…Overprescribing of opioids is the reason why we are in this crisis, and the only way 
we can recover is to implement stricter prescribing laws (which is already happening) in 
addition to investing in drug rehabilitation…” 
Some pharmacists also believed that the current regulations made it hard for 
genuine chronic pain patients who need opioid treatments to receive opioids. A review 
conducted to look at opioid therapy for chronic pain patients suggested that physicians 
usually reject the idea of prescribing opioids, especially with recent regulations but it is 
possible to treat and monitor these patients without them developing an opioid use 
disorder.215 The ultimate goal is that the history of overprescribing opioids does not affect 
patients who are in genuine need of these medications. 
 It was not surprising that pharmacists spoke about the scale and severity of the 
epidemic considering the question had the opioid epidemic as the central theme. 
However, many pharmacists noted that it was such a severe a problem that it would need 
a multi-faceted approach. This indicates that pharmacists strongly believe in a possible 
solution but expect it to involve every contributor. Some pharmacists also believed the 
scale of the epidemic would result in increase of other substances. They state: 
“… Heroin is going to continue to grow (possibly at higher rates) as prescribers stop 
writing for opioids and insurance companies stop paying for medications. …” 
 This leads us to, contributor accountability which pharmacists seem to strongly 
advocate for. Of all contributors however, physicians seem to be the contributors that 
need to be held most accountable in the eyes of the pharmacists especially for 
inappropriately prescribing opioids. One pharmacist, however, spoke about how 
increasing physician accountability would also increase the burden of work on the 
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pharmacist and was thus a barrier to practice. This was a legitimate concern; for example 
use of PDMP programs as a method to responsibly prescribe medications resulted in 
increased work load for all providers and time constraints were a major barrier.216  
Increasing the number of community pharmacists in every shift might reduce this burden. 
PDMP was especially advocated for by the pharmacists. They believed that if physicians 
viewed the PDMP before prescribing opioids it would go a long way in deterring them 
from prescribing opioids. Research suggests use of PDMP does lead to a decrease in 
‘doctor shopping’ behavior which patients exhibit in order to procure opioids.217 One 
pharmacist states: 
“Many doctors are not taking the time to check the PDMP-although it seems to be 
helping with the number of patients drug shopping.” 
 Moreover, pharmacists discussed how a lack of contributor (physician) 
accountability would lead to problems in the prescriber-pharmacist relationship. Since, 
physicians are not held accountable for prescribing opioids unnecessarily, the onus fell on 
the pharmacists to intervene and refuse to dispense. This led to angry patients and 
pharmacists being labeled as intrusive by the physicians as reported by the pharmacists. 
One study evaluating communication between prescribers of opioids and pharmacists 
qualitatively found that these communications are only common indirectly via patients or 
voicemail. Direct communication was ineffective and these uncomfortable conversations 
were generally avoided by both providers.218 These findings point towards a serious gap 
in the physician-pharmacist relationship that needs to be addressed. 
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II] Recommendations 
Based on the gaps identified in the literature as well as the results of this study, 
policy recommendations can be made in the following areas: 
 
1) Educational recommendations 
Increasing SUD specific education (clinical and policy) in the curriculum may 
result in a decrease of stigmatizing behavior. Our study found a significant lack in 
education of pharmacists and stigmatizing attitudes. The increased knowledge and 
awareness will lead to greater willingness to offer pharmacy services to the SUD 
population. Increasing experiential education for pharmacy students in SUD may be 
effective as studies implied a relationship between experience and positive attitudes. 
Pharmacists had a general negative attitude towards treatments, especially Suboxone® 
due to how it was being prescribed and reported poor relationships with providers. 
Training programs for naloxone and MAT that involve the background/importance of 
treatments, information on all products (nasal/ kits/ injectable), business/operations tips 
and suggestions for storing and dispensing these treatments, and communication skills 
with both patients and providers may help. Increasing CE certificate programs for SUD 
may help pharmacists who are currently practicing.  
 
2) Governmental recommendations 
Below are some specific recommendations: 
1. Implementing standing orders in all states. 
  180
2.  Increasing the role of the community pharmacist in needle-exchange 
programs and screening practices for SUD through regulations. 
3. Increasing take home naloxone (THN) programs, especially in high 
prevalence areas.  
4. Needle distribution or non-prescription needles instead of needle exchange 
programs, which can increase access to sterile syringes and needles for 
patients.  
5. Many pharmacists in the study also discussed regulations such as disposal 
programs, adherence packaging, mandatory PDMP use and legalization of 
marijuana as possible strategies. 
 
3) Pharmacy practice 
Below are some practice recommendations: 
1. Offering MTM and screening services for SUD patients and at-risk 
individuals. Pharmacists in this study regarded screening as a very important 
practice. 
2. Obtaining education and training to implement MTM services effectively. 
Pharmacists in this study discussed how overprescribing of opioids was the 
primary reason for the current epidemic.  
3. Implementing a pain–management consult service, thereby decreasing 
overprescribing and incidence of SUD. 
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4. Augmenting roles in contacting providers, provision of products, education of 
patients and providers, and spreading of SUD specific information throughout 
the community. 
It is important to note that these practice recommendations may be difficult to 
implement based on the inherent structure of community pharmacies. Organizational 
policies of pharmacies and the policies of all organizations within the umbrella of health 
care may impede effective implementation of these recommendations. However, 
implementing many if not all the policy suggestions for both preventive and educational 
roles of the pharmacist, supported by governmental and educational policies will greatly 
help in improving the health care provided to patients with SUD. 
 
III] Limitations 
1) Response rate 
 The response rate of the study was nearly 14%, but was typically lower than 
survey research involving health care professionals. This may be attributed primarily to a 
lack of strong incentive. As the incentive was based on a random drawing of only twenty 
gift certificates, pharmacists may have believed the chance to win wasn’t very high, 
especially since the sample size was very high (the entire mailing list). Additionally, the 
amount of the gift certificate was $30 and may not have been sufficient to elicit 
responses. However, the survey was sent out through the director of operations of the 
pharmacy chain as a strategy to increase response. Although, Giant Eagle allowed 
pharmacists to complete the survey during work hours, this may or may not have had a 
significant effect on response rate. Moreover, the length of the survey may have been an 
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additional deterrent as some partial responses indicate. A similar study was conducted in 
mental illness and community pharmacists with a national sample and had a lesser 
response rate.219 The sample characteristics were similar, indicating that the small 
response rate might still have provided a representative sample. 
 
2) Generalizability 
The study was conducted in the local tristate area (PA, WV, OH) only and caution 
must be exercised before drawing conclusions for other states or regions. More 
importantly, the study sample was mostly comprised of pharmacists from only one 
community chain pharmacy. Practices, policies and general work atmosphere and ethic at 
this chain may have affected the responses. Responses from pharmacists working in other 
chains and maybe even dealing with different patient profiles may significantly change 
the results of the study. This study did include community pharmacists from Duquesne 
University alumni network and this may have increased generalizability due to variation 
in the pharmacists’ backgrounds. However, email lists for both groups of pharmacists 
were not available to identify which group the responses belonged to. Separation of the 
responses into the groups and subsequent comparison analysis could have helped confirm 
this hypothesis. A separate study conducted in 2012 by researchers affiliated with APhA 
as part of the Career Pathway Evaluation Program studied chain community pharmacists 
all over the country identified similar descriptive patterns.220 The only differences in the 
results was the average age of the pharmacists was slightly higher at 46 years old and 
they mostly had B.S. versus PharmD. Degrees. However, as discussed previously, the 
degree obtained and age of respondents is highly correlated. This study had very similar 
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sample characteristics as other national studies even though it was conducted only in 
Ohio, Pennsylvania and West Virginia.220,219 
 
3) Self-reported data 
 The third significant limitation (having self-reported data) tends to affect all 
survey research in some way, especially where responders’ data cannot be verified by 
other means. Self-reported data is susceptible to several biases. Firstly, social desirability 
bias may have occurred where pharmacists provide answers that are more socially 
acceptable. This bias is especially of concern in this study because of the sensitive nature 
of certain questions such as personal experience. The results although high, were still less 
than what is commonly observed in the literature, as discussed previously.201 Social 
desirability bias can also affect responses on non-sensitive questions such as screening or 
other personal response questions. The questionnaire has been designed to control for this 
bias as much as possible. Apart from the anonymous nature of the survey, questions and 
instructions were designed to reduce the effect of this bias as discussed in detail 
previously. The results indicate that there was less effect of this bias. For example, almost 
half the sample stated that they do not play any role in the practice and results indicated 
stigmatizing attitudes. Both results are socially undesirable behaviors. Similarly, a 
smaller number of correct responses on difficult questions were received and a proportion 
of the sample admitted to having personal experience with SUD. These results also point 
towards a valid response set. Some questions in particular may also be subject to recall 
bias, like number of years or hours worked or number of prescriptions filled, etc. These 
questions however are minor and not the key factors being measured. Also, results seem 
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consistent with few outliers for these variables and recall bias if any would not alter 
responses on these variables drastically. Finally, selection bias may have occurred 
because responders could choose the questions they wanted to answer. The survey 
allowed responders to skip questions without responding and a couple of pharmacists 
have skipped sections while a couple others have skipped specific questions. This reduces 
the total number of responses that can be analyzed. For regression models the sample size 
was reduced to less than 100 which may have affected results. However, Qualtrics® 
software allows downloading of the response file where responders who have viewed the 
question but not answered and those who have not viewed the question itself can be 
differentiated. All analyses have differentiated these two groups as far as possible. 
  
IV] Future Research 
Future studies must aim to eliminate the limitations of this study as much as possible 
while maintaining the quality and if possible adding to the depth of the data collected. 
Increased resources can be used to fund a large-scale project like a national survey of 
community pharmacists in chains as well as independent pharmacies. This would make 
the results of the study highly generalizable. The larger funding source could also be 
utilized to provide higher incentive to get a larger response rate. In this study, the cross-
sectional study design limited the interpretation of findings to associations and 
correlations only. Causal associations could not be made based on the data collected. 
Conducting a longitudinal study in the future would enable researchers to overcome some 
of these limitations. Using other research methods like a database study to study 
prescription practices, intervention studies where pharmacists are provided with 
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screening tools, or qualitative methods like interviews or focus groups might help remove 
the biases that may exist in this study. Future research should also incorporate important 
topics like use of PDMP as a screening tool, role of experiential education in knowledge 
and attitude as well as studying stigma in depth, both perceived and concrete stigma and 
how it affects various aspects of treatments.  It is also important to study the entire health 
care system and contributions from different sectors in treatment and of SUD. Future 
studies could incorporate health care providers, insurance, industry and other segments in 
relation to pharmacy functioning to better understand the barriers to pharmacist practice. 
 
V] Study Implications 
There were differences in stigma between pharmacists who performed MTM versus 
those who did not and frequency of providing clinical services was less in pharmacists 
with high stigma. This implied that more engagement with SUD patients is related to less 
stigma. Approximately one- third of pharmacists demonstrated negative attitudes toward 
harm reduction. Large percentage of pharmacists believed their education to be 
inadequate. This argues for mandatory curriculum and competency statements 
specifically developed for pharmacy schools. Moreover, experiential education should be 
emphasized because it encourages engagement with patients. The most common themes 
in qualitative analysis were overprescribing and the vast extent of the SUD problem 
demonstrating that pharmacists understand the nature of the public health crisis. Lack of 
prescriber accountability was also a common belief among the pharmacists.  
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VI] Conclusion 
This study was the first comprehensive survey of knowledge, attitudes and 
practices of community pharmacists in SUD conducted in recent times. The knowledge 
section of the study assessed medication and policy knowledge levels among 
pharmacists. Knowledge levels were high on average, but some specific areas had room 
for improvement. Also, the study successfully evaluated current practices of pharmacists, 
specifically screening. The findings of the study are especially relevant considering the 
increased expectation of screening for SUD to be conducted by pharmacists. A clear 
picture of current practices of pharmacists in practice can be drawn based on the results 
of the study. The study also included the attitude section that evaluated attitudes towards 
relevant treatment strategies which haven’t been studied before or attitudes that have 
changed over time (Suboxone®). As stigma was a major factor involved in overall 
attitude, the study not only evaluated stigma but also related it to other factors. The 
results indicate that stigma on the part of health care providers exists and its effects on 
treatment outcomes as well as practices of the provider have been studied. Significant 
relationships were established between these factors as well as the extensive descriptive 
information that we collected. These significant relationships can be used to conduct 
further research, help re-evaluate current practices and policies as well as assist in making 
future recommendations and policy and practice changes, both on the micro and macro 
level. Finally, the regression models recognized predictors of the factors evaluated in this 
study. These models provide evidence for the strong connection between the factors 
themselves as well as other descriptive and practice characteristics.  Moreover, the 
qualitative analysis elaborated the findings of the quantitative survey and produced 
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information that was previously not discussed. The overall study findings can be a step 
forward in improving the research conducted in the area, treatment outcomes and health 
care available to patients with SUD, ultimately improving their lives. 
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APPENDICES 
Appendix 1: Survey Instrument 
 
I. Background Information: 
This section gathers information about you and your practice. All responses will be kept 
confidential. 
 
A) Demographics: 
i. Age: ________ years 
ii. Gender: ___ Male  ___Female 
iii. Race:  ___Caucasian  ___African American  ___Asian  
 __American Indian ___Hispanic  ___Pacific Islander  Other: ________ 
iv. Pharmacy degree(s) attained:  ___B.S. Pharm.  ___Pharm.D. 
v. Year of last pharmacy degree graduation: ___________ 
vi. Other degree(s) attained:  ___Masters  ___Ph.D.  Other: __________ 
vii. Year of last other degree graduation: __________ 
viii. Please list any board certification(s) you have obtained: ______ 
 
B) Practice Characteristics: 
i. Number of years working in community pharmacy: ___________ 
ii. Average number of hours worked per week: ___________ 
iii. Primary practice site location (choose most applicable response):  
___Urban ___Rural ___Suburban 
iv. On average, how many pharmacists work at the pharmacy during a typical shift? 
___________ 
v. On average, how many prescriptions does your pharmacy fill during a typical 
week? ___________ 
vi. How often do you dispense prescriptions in a given week for SUD? (E.g. Naloxone, 
Buprenorphine, Naltrexone etc.)  
1 2                  3 4 
Never Rarely        Sometimes Frequently 
 
vii. What is the most frequent SUD medication do you dispense in your pharmacy? 
(E.g. Naloxone, Buprenorphine, Naltrexone etc.)  
______________________  
viii. In your opinion, the majority of patients visiting your pharmacy belong to which 
socioeconomic class? (Choose the most applicable option) 
___Impoverished ___Low income class ___Middle income class ___High Income 
class 
ix. Which of the following best represents your position in the pharmacy? (Please 
check all that apply). 
___Full time staff pharmacist ___Part time staff pharmacist 
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___Pharmacy manager ___ 
 
C) Education: 
i.  I received substance abuse education in pharmacy school: __Yes __No 
ii. If yes, I believe the education I received was adequate to effectively treat 
patients with substance use disorder (SUD). 
1 2                  3 4 
Strongly disagree Disagree          Agree Strongly 
agree  
 
iii. In the last 2 years, I have had: 
  a. Continuing education (CE) related to SUD: __Yes __No 
  b. Continuing education (CE) related to naloxone: __Yes __No 
 
iv. Do you have any personal experiences with SUD? (e.g. friend, family, self) 
 ___ Yes ___No ___Prefer not to disclose  
 
 
II. Knowledge:   
This section gathers information about your knowledge regarding the treatment of SUD. 
All responses will be kept confidential. 
Answer the following questions to the best of your ability. This is not a test of your 
personal knowledge, but rather an assessment in aggregate of pharmacist knowledge base 
regarding SUD. All data reported in aggregate and not identified as individual responses. 
 
i. I have good current knowledge on medication therapy for SUD. 
1   2 3 4 
Strongly disagree Disagree Agree Strongly agree 
    
    
ii. _________ is a Schedule III controlled substance. 
a) Naloxone 
b) Buprenorphine 
c) Naltrexone 
d) Not sure 
 
iii. __________ is an opioid receptor antagonist and can reduce tolerance to opioids. 
a) Naloxone 
b) Buprenorphine 
c) Naltrexone 
d) Not sure 
 
 
iv. __________ is the drug of choice for emergency treatment of opioid overdose. 
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a) Naloxone 
b) Buprenorphine 
c) Naltrexone 
d) Not sure 
 
v. Is a prescription required for dispensing naloxone in your state? ___Yes 
___No___Not sure 
 
vi. Buprenorphine can be used to potentiate opioids. ___True  ___False ____Not sure 
 
vii. Naloxone can be administered orally.___True  ___False ____Not sure 
 
viii. Opioid administration to a patient on naltrexone is an effective pain management 
strategy. 
___True ___False ____Not sure  
 
Naltrexone can be started within 7 days of last opioid use. ___True ___False 
____Not sure  
  
 
 
III. Practice: 
A) Services provided:  
This section gathers information about how you assess patients for potential substance 
use disorder. All responses will be kept confidential 
i. Do you play any role in providing services for SUD patients? __ Yes __ No 
If yes, which of these duties do you perform (Please check all that apply) 
__Dispensing medications for SUD.  
__ Counseling patients with SUD about substance use medications. 
__ Provision of a private space for counseling/medication reviews when needed. 
__ Patient monitoring or assisting patients to self-monitor for SUD medication 
efficacy and safety. 
__ Advising individuals about serious adverse effects associated with SUD 
medications (e.g. respiratory depression, seizures, etc.) 
__ Recommending/advocating for SUD therapy changes to optimize cost or 
formulation. 
__ Referring patients to trusted SUD practitioners in the community. 
__ Other: ___________ 
 
ii. How often do you perform formalized medication therapy management clinical 
services for patients in general who would benefit from it, defined as “a service or 
group of services that optimize therapeutic outcomes for individual patients”? 
1 2                  3 4 
Never Rarely        Sometimes Frequently 
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iii. How often do you provide clinical services for patients with diagnosed SUD? 
1 2                  3 4 
Never Rarely        Sometimes Frequently 
 
 
B) Screening: 
i. Please select how important the following are to further investigate the 
possibility of abuse potential for medication?  
 
___Repeatedly receiving "cocktailed" prescriptions (e.g. medications used in 
combination to enhance physical effects such as a “high”) 
1                                           2                                          3                                 4 
Not important at all         Somewhat important       Very important        Extremely 
important 
 
___Failure of prescribers to individualize dosing strategies for patients 
1                                           2                                          3                                 4 
Not important at all         Somewhat important       Very important        Extremely 
important 
 
___Receiving multiple prescriptions for the strongest/most addiction-prone formulations 
1                                           2                                          3                                 4 
Not important at all         Somewhat important       Very important        Extremely 
important 
 
___Requests for early refills from patients 
1                                           2                                          3                                 4 
Not important at all         Somewhat important       Very important        Extremely 
important 
 
___Prescribers located far away from pharmacy sending prescription requests 
1                                           2                                          3                                 4 
Not important at all         Somewhat important       Very important        Extremely 
important 
 
___Receiving a large volume of prescriptions for controlled substances by one particular 
physician 
1                                           2                                          3                                 4 
Not important at all         Somewhat important       Very important        Extremely 
important 
 
___Patients travelling in groups to the pharmacy to pick up controlled substances 
1                                           2                                          3                                 4 
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Not important at all         Somewhat important       Very important        Extremely 
important 
 
___Receiving requests for controlled substance prescriptions to be paid for with cash 
1                                           2                                          3                                 4 
Not important at all         Somewhat important       Very important        Extremely 
important 
 
___Prescribers verifying prescriptions as legitimate when contacted, but without 
explanation other than their own directive (e.g. “Fill it because I said so.”) 
1                                           2                                          3                                 4 
Not important at all         Somewhat important       Very important        Extremely 
important 
 
 
IV. Attitude: 
This section gathers information about how you assess patients for potential substance 
use disorders. All responses will be kept confidential. 
 
A) Stigma: 
 
1. For the following questions please select the response that best expresses your attitude 
and beliefs towards SUD: 
 
i. Most pharmacists would willingly accept someone who has been treated for 
substance use as a close friend. 
 
 
ii. Most pharmacists believe that someone who has been treated for substance use is 
just as trustworthy as the average citizen. 
 
1 2 3 4 
Strongly disagree Disagree Agree Strongly agree 
 
 
iii. Most pharmacists would accept someone who has been treated for substance use 
as a teacher of young children in a public school. 
 
1 2 3 4 
Strongly disagree Disagree Agree Strongly agree 
 
 
iv. Most pharmacists would hire someone who has been treated for substance use to 
take care of their children. 
1 2 3 4 
Strongly disagree Disagree Agree Strongly agree 
  209
 
1 2 3 4 
Strongly disagree Disagree Agree Strongly agree 
 
 
v. Most pharmacists think less of a person who has been in treatment for substance 
use.  
 
1 2 3 4 
Strongly disagree Disagree Agree Strongly agree 
 
 
vi. Most pharmacists would be willing to date someone who has been treated for 
substance use. 
 
1 2 3 4 
Strongly disagree Disagree Agree Strongly agree 
 
 
B) General attitude: 
 
2. For the following questions please select the response that best expresses your attitude 
and beliefs towards general strategies to address the drug abuse epidemic: 
 
i. Pharmacists dispensing needles without prescriptions (or a demonstrated 
legitimate medical need) leads to an increase in frequency of substance abuse. 
 
1 2 3 4 
Strongly disagree Disagree Agree Strongly agree 
 
 
ii. Pharmacists dispensing naloxone acts as a safety net leading to an increase (or 
encouragement) in substance abuse. 
 
1 2 3 4 
Strongly disagree Disagree Agree Strongly agree 
 
iii. Dispensing buprenorphine/naloxone (Suboxone®) is an effective way for 
pharmacists to assist in the overall treatment of SUD. 
 
1 2 3 4 
Strongly 
disagree 
Disagree Agree Strongly agree 
  
 
  210
iv. Pharmacists dispensing oral/long acting naltrexone is an effective method to treat 
SUD. 
 
1 2 3 4 
Strongly disagree Disagree Agree Strongly agree 
 
 
 
V. Qualitative 
Finally, we would be interested in your thoughts about prescription drug abuse. 
Please take a few minutes to share your thoughts with us regarding the question 
below. You may type your response in the space provided. What are your views 
regarding the current opioid prescription drug epidemic? 
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Appendix 2: Email 
 
Dear Pharmacist, 
  
This email is to invite you to participate in a research survey developed in partnership by 
pharmacists/researchers at Duquesne University School of Pharmacy in Pittsburgh, PA. 
and Giant Eagle Pharmacy. 
  
The purpose of the research study is to explore community pharmacists’ knowledge of 
and attitudes toward substance use disorder (SUD) and the services they provide. This 
survey is intended for community pharmacists. The email consists of a link to the online 
survey. The survey should take approximately 5-10 minutes of your time. Your response 
is crucial for the success of this project. The survey link can be found at: 
 
https://duq.az1.qualtrics.com/jfe/form/SV_ahsuTsWvmRFj7Ol 
  
You will be asked a series of questions regarding your thoughts and opinions regarding 
the care of patients with SUD. Your answers will help to identify barriers and stigma 
associated with SUD and its treatment. To assure confidentiality, your responses will be 
coded and your name will not appear in any data analysis or research reports. Therefore, 
we assure you of as much confidentiality as legally possible. Your participation in this 
research study is voluntary. Your completion and submission of the survey will constitute 
your consent to participate in the study. You do not need to answer all questions even 
though we would prefer that you do. A summary of the results will be supplied to you, at 
no cost, upon request. The study has been approved by the Duquesne University 
Institutional Review Board (IRB). 
  
To thank you for your time, upon submission of your survey, your email address will be 
entered in a random drawing for one of twenty $30.00 Amazon gift cards. 
  
If you have any questions regarding the research project or survey, please feel free to 
contact Dr. Giannetti at 412.396.6379, Dr. Kamal at 412.396.1926, Dr. Covvey at 
412.396.2636 or Dr. David Delmonico, Chair of the Duquesne University Institutional 
Review Board, at 412.396.1886 
  
Thank you in advance for your time and input. 
  
Regards, 
  
John De James R.Ph. 
Sr. Manager of Clinical Programs | Giant Eagle, Inc. 
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Appendix 3: Pilot test 
Pilot test: Community Pharmacist and Substance Use Disorders 
 
1. Were any of the questions or responses unclear? 
 
 
2. Did the responses appear to be complete? Are there any other categories you 
would like to add to responses in any of the questions? 
 
 
 
3. Are there any other questions that you think could improve the study? 
 
 
4. Please comment on the length of the survey and how long it took you to complete. 
Would the length be an impediment to completing the survey? 
 
 
5. Do you have any other comments you would like to add regarding the survey? 
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Appendix 4: Codebook 
1. Overprescribing opioids 
2. Scale and severity of the epidemic 
3. Policy recommendations 
4. Contributor accountability 
5. Negative aspects of Suboxone 
6. Attitude towards naloxone 
7. Prescriber pharmacist relationship 
8. Personal experience 
9. Barriers to practice 
10. PDMP 
11. Access to opioids 
12. Stigma 
13. Education 
14. Resources 
15. Frustration/Hopelessness 
16. Substances other than opioids 
17. Mental health 
18. Patients without formal SUD diagnosis 
19. Substitution of opioids 
20. Therapy/ Counseling 
